"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_CITTADELLASCIENZA",2000,17,7.05882352941176,2.41176470588235,0.352941176470588,0.294117647058824,0.352941176470588,1.10714285714286,1,1,1,0.294117647058824,0,8,2,1,4,0.47,0.12,0.06,0.24,30.24,0.666989676918421,NA,0.117647058823529,0.647058823529412,0.367,0.171,0.15,0.171,"RICCARDO ARISIO;GIUSEPPE DI CARA;MARIO PRETI;BRUNO GHIRINGHELLO;GUGLIELMO RONCO;ANNA SAPINO;LEONARDO MICHELETTI;ELENA BUTTI;R. PELLERITO;ELDA MONTANARO;VENTURELLA VANGI;LICIA PERUZZI;JAY S. WUNDER;M. NAVARRA;ANTONIO DURANDO;AGATA FIUMARA;SACCO CASAMASSIMA MG;PAULA MAGRO;P SEINERA;ROSANNA COPPO","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","M. BIANCHI;MARIO PRETI;BRUNO GHIRINGHELLO;MARCO CATALDI;GUGLIELMO RONCO;LEONARDO MICHELETTI;P SEINERA;GIUSEPPE DI CARA;CLAUDIO FARINA;TULLIA TODROS;RICCARDO ARISIO;ANNA SAPINO;ELENA BUTTI;MANUELA GALLI;ROBERTO BONATTI;S ZERBONI;M. NAVARRA;MAURI JOSÉ PIAZZA;GIUSEPPE SORTINO;G. SAETTA","0.5;0.5;0.5;0.5;0.5;0.5;0.33;0.33;0.33;0.33;0.31;0.31;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.2","GIUSEPPE DI CARA;MARIO PRETI;ANNA SAPINO;LEONARDO MICHELETTI;ANTONIO DURANDO;MICHELA CUCCORESE;D. FRANCESCHINI;P SISMONDI;D. LICATA;SERGIO SANDRUCCI;ANDREA GUALA;PAOLA SORBA CASALEGNO;M MASSOBRIO;PAOLA CASSONI;D LICATA;G BISI;D. FRANCESCHINI;RICCARDO ROAGNA;G BUSSOLATI;G ACCINELLI","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MARIO PRETI;LEONARDO MICHELETTI;GIUSEPPE DI CARA;ANNA SAPINO;D. FRANCESCHINI;D. LICATA;ANDREA GUALA;D LICATA;D. FRANCESCHINI;P. FRANCESCHINI;P FRANCESCHINI;A. GUALA;GIANNI BUSSOLATI;MICHELA CUCCORESE;PAOLA CASSONI;G BUSSOLATI;G ACCINELLI;MARIA PIERA MANO;ANTONIO DURANDO;P SISMONDI","0.5;0.5;0.33;0.31;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.05;0.05","ANNA SAPINO;RICCARDO ARISIO;ALFONSO FRIGERIO;C COLUCCIA;GIANNI BUSSOLATI;JOHANNES L. PETERSE;BRUNO GHIRINGHELLO;GUGLIELMO RONCO;LEONARDO MICHELETTI;MARIO PRETI;C FABRIS;CARLO DANI;CLAUDIO FARINA;FF RUBALTELLI;GIOVANNA BERTINI;M F REALI;P MURRU;P SEINERA;TULLIA TODROS;VENTURELLA VANGI","127;127;89;89;89;89;82;82;82;82;75;75;75;75;75;75;75;75;75;75","ANNA SAPINO;GIANNI BUSSOLATI;LEONARDO MICHELETTI;MARIO PRETI;D. FRANCESCHINI;GIUSEPPE DI CARA;ANDREA GUALA;D LICATA;P FRANCESCHINI;G ACCINELLI;G BUSSOLATI;MARIA PIERA MANO;MICHELA CUCCORESE;PAOLA CASSONI;ANTONIO DURANDO;ANTONIO MUSSA;G BISI;M MASSOBRIO;MARILENA BELLÒ;MAURIZIA GIAI","89;89;82;82;54;54;53;53;53;38;38;38;38;38;6;6;6;6;6;6","D. FRANCESCHINI;GIUSEPPE DI CARA;LEONARDO MICHELETTI;MARIO PRETI;A. GUALA;ANDREA GUALA;ANNA SAPINO;ANTONIO DURANDO;ANTONIO MUSSA;D LICATA;D. LICATA;G ACCINELLI;G BISI;G BUSSOLATI;GIANNI BUSSOLATI;M MASSOBRIO;MARIA PIERA MANO;MARILENA BELLÒ;MAURIZIA GIAI;MICHELA CUCCORESE","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;BUSINESS;CHEMISTRY;COMPUTER SCIENCE;PHYSICS","17;6;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;GASTROENTEROLOGY;PALEONTOLOGY;RADIOLOGY;ANATOMY;CARDIOLOGY;ENVIRONMENTAL HEALTH;GENETICS;OBSTETRICS;PEDIATRICS;ADVERTISING;ANESTHESIA;CANCER RESEARCH;DERMATOLOGY;FAMILY MEDICINE;GYNECOLOGY;LIBRARY SCIENCE;NUCLEAR MEDICINE;OPTICS;ORGANIC CHEMISTRY;PHARMACOLOGY","10;9;7;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARCINOMA;LYMPH NODE;STAGE (STRATIGRAPHY);BASAL CELL;BIOPSY;CONFIDENCE INTERVAL;FOREHEAD;HEART FAILURE;MACROCEPHALY;POPULATION;PREGNANCY;PROPORTIONAL HAZARDS MODEL;SYNDACTYLY;UPPER LIP;VULVA;ABDOMINAL MASS;ANGIOGENESIS;ANGIOPLASTY;ANURIA;BLUNT;CALCIFICATION;CARDIAC SURGERY;CARDIOPULMONARY BYPASS;CATHETER;CHEMOTHERAPY;COMPLICATION;CUMULATIVE DOSE;CYST;D-DIMER;DIALYSIS;DUCTUS ARTERIOSUS;ECTODERMAL DYSPLASIA;EMBOLIZATION;FLAIL CHEST;HISTOLOGY;IBUPROFEN;IN SITU;INCIDENCE (GEOMETRY);LAPAROSCOPY;LESION;LUMEN (ANATOMY);LUNG;LYMPH;MALIGNANCY;MULTIVARIATE ANALYSIS;NODAL;OSTEOSARCOMA;PANCREAS;PATHOLOGICAL;PEDIATRIC NEUROLOGY;PERCUTANEOUS;PERITONEAL DIALYSIS;PNEUMOTHORAX;SECTION (TYPOGRAPHY);STENT;THORACIC WALL;THORACOTOMY;THROMBOSIS;THROMBUS;UNIVERSITY HOSPITAL;UTERUS","7;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;METASTASIS;CAESAREAN SECTION;PHILTRUM;RELATIVE RISK;VULVAR CANCER;VULVAR CARCINOMA;VULVAR INTRAEPITHELIAL NEOPLASIA;VULVAR NEOPLASM;BENIGNITY;CARCINOMA IN SITU;CARDIOTOXICITY;CELL CYCLE;CHEST INJURY;DIALYSIS CATHETER;ECTOPIC PREGNANCY;EJECTION FRACTION;FIXATION (POPULATION GENETICS);GESTATION;GESTATIONAL AGE;HEMOTHORAX;MESENTERIC CYST;MISCARRIAGE;MUCOSITIS;MYOMA;PULMONARY EDEMA;THORACIC TRAUMA;UNIVARIATE ANALYSIS;UTERINE RUPTURE","4;4;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LYMPHOVASCULAR INVASION;MAMMARY GLAND;ANTHRACYCLINE;AXILLA;AXILLARY LYMPH NODES;BREAST CARCINOMA;DUCTAL CARCINOMA;EPIRUBICIN;GESTATIONAL SAC;INTERSTITIAL PREGNANCY;INVASIVE DUCTAL CARCINOMA;MAMMOGRAPHY;METASTATIC BREAST CANCER;ONCOGENE;PRIMARY TUMOR;SENTINEL LYMPH NODE;SENTINEL NODE;UTERINE MYOMECTOMY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST NEOPLASMS;HUMANS;FEMALE;CARCINOMA IN SITU;MIDDLE AGED;CARCINOMA, DUCTAL, BREAST;CARCINOMA, LOBULAR;CONGENITAL DISORDERS OF GLYCOSYLATION;;ADULT;CARCINOMA, SQUAMOUS CELL;FLAIL CHEST;MALE;PANCREATIC CYST;PHOSPHOTRANSFERASES (PHOSPHOMUTASES);AGED;ANTIBIOTICS, ANTINEOPLASTIC;EPIRUBICIN;FIBROBLASTS;LEUKOCYTES","14;13;11;8;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3","MOLECULAR RESEARCH ON BREAST CANCER;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CARDIOTOXICITY OF CANCER TREATMENTS;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;DIAGNOSIS AND TREATMENT OF PATENT DUCTUS ARTERIOSUS;GENETIC AND DEVELOPMENTAL STUDIES OF LIMB MALFORMATIONS;GENOMIC REARRANGEMENT DISORDERS IN SKIN DISEASES;GLYCOSYLATION IN HEALTH AND DISEASE;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;MANAGEMENT OF RIB FRACTURES IN TRAUMA PATIENTS;MEDICAL SCIENCE AND HEALTHCARE;RHABDOMYOLYSIS AND COMPARTMENT SYNDROMES;TRANSLATION OF CANINE CANCER RESEARCH TO HUMANS;TREATMENT AND MANAGEMENT OF ANAL CANCER;UTERINE CONDITIONS AND TREATMENTS","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;LYMPHOVASCULAR INVASION;MACROCEPHALY;PHILTRUM;SYNDACTYLY;TREATMENT;VULVAR CARCINOMA;VULVAR INTRAEPITHELIAL NEOPLASIA;VULVAR NEOPLASM;ABDOMINAL MASS;ANAESTHESIA;ANURIA;AXILLA;AXILLARY LYMPH NODES;BENIGNITY;BREAST CARCINOMA;BREAST TUMOURS;CAMURATI-ENGELMANN DISEASE;CANINE CANCER;CARCINOMA IN SITU","2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CELL CARCINOMA;CUTIS MARMORATA;LYMPH NODE;MARMORATA TELANGIECTATICA;RECURRENT SQUAMOUS;SQUAMOUS CELL;TELANGIECTATICA CONGENITA;ABERRANT EXPRESSION;AGENT EPIRUBICIN;BREAST CARCINOMAS;CAESAREAN SECTION;CANCER PATIENTS;CANCER STAGING;CANINE OSTEOSARCOMA;CARBOHYDRATEDEFICIENT GLYCOPROTEIN;CLOSED THORACIC;CONGENITAL CYSTS;DUCTUS ARTERIOSUS;FINAL RESULTS;FLAIL CHEST;FLUID OVERLOAD;GLYCOPROTEIN SYNDROMES;HEART SURGERY;ITALIAN EXPERIENCE;KIDNEY FAILURE;LAPAROSCOPIC MYOMECTOMY;LINE CHEMOTHERAPY;LOBULAR CARCINOMAS;MACROCEPHALY-CUTIS MARMORATA","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PEDIATRIC CLINIC;CLINIC UNIVERSITY;GLYCOPROTEIN SYNDROME;NODAL POSITIVITY;ROME ITALYSEARCH;DI ROCCO;LYMPH NODE;CATANIA ITALYSEARCH;CELL CARCINOMA;CM RR;FIGO STAGE;GASLINI INSTITUTE;GENOA ITALYSEARCH;GIANNINA GASLINI;INDEPENDENT PROGNOSTIC;INSTITUTE GENOA;INSTITUTE UNIVERSITY;LA SAPIENZA;LVSI RR;MARGINS RR;MET ONCOGENE;MILAN ITALYSEARCH;MULTIFOCALITY RR;NEUROLOGY PEDIATRIC;NODE STATUS;PEDIATRIC NEUROLOGY;PROGNOSTIC FACTORS;SAPIENZA ROME;SQUAMOUS CELL;SURGICAL MARGINS","14;10;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,18,150,3.57,0,0,8,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Italy;Switzerland","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","1;1","ATHEROSCLEROSIS;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PATIENT SAFETY;TRANSPLANTATION","1;1;1;1;1;1","CARDIOVASCULAR","1",NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2001,16,8.5,2.375,0.125,0.25,0.1875,1.03703703703704,0.666666666666667,0.8,0.75,0.25,0,7,8,0,1,0.44,0.5,0,0.06,46.06,1.00809917498015,NA,0.125,0.8125,0.121,0,0,0,"E. BIROLI;GIUSEPPE DI CARA;S. BASTONERO;ANDREA SCIARRONE;P. BASSINI;G. ERRANTE;E. VIORA;M CAMPOGRANDE;MYRIAM FOGLIETTA;GIORGIA MANGILI;ALFREDO BERRUTI;GIANNA MAZZUCCO;A. SUNO;M. VANZETTI;FABIO MALAVASI;MARIA GIUSEPPA SAROBBA;G. MANCINI;M DOGLIANI;RICCARDO ARISIO;ALESSANDRO RIVOLIN","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ROBERTO TORCHIO;MARCO PARVIS;C. GULOTTA;S. BASTONERO;ANDREA SCIARRONE;G. ERRANTE;E. VIORA;M CAMPOGRANDE;E. BIROLI;GIUSEPPE DI CARA;P. BASSINI;M. VANZETTI;ALESSANDRO RIVOLIN;DANIELA RISSO;DANIELE BOLLERO;PAOLO CASSANO;MAURIZIO STELLA;FABIO MALAVASI;RICCARDO ARISIO;MARCO MAFFIOLINI","0.33;0.33;0.33;0.29;0.29;0.29;0.29;0.29;0.25;0.25;0.25;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14","GIUSEPPE DI CARA;MYRIAM FOGLIETTA;FABIO MALAVASI;SILVIA PEOLA;MASSIMO MASSAIA;S. FRACCHIOLI;D. FRANCESCHINI;MARIO BOCCADORO;ALESSANDRO PILERI;D. LICATA;DIONYSSIOS KATSAROS;MARTA COSCIA;LUISELLA RIGHI;DANIELA RISSO;M MASSOBRIO;PAOLA CASSONI;R. PICCINNO;D LICATA;D. FRANCESCHINI;PAOLO CASSANO","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GIUSEPPE DI CARA;DANIELA RISSO;PAOLO CASSANO;MAURIZIO STELLA;FABIO MALAVASI;LUISELLA RIGHI;PAOLA CASSONI;MASSIMO BONGIOVANNI;SILVIA DEAGLIO;ANNA SAPINO;D. FRANCESCHINI;D. LICATA;D LICATA;D. FRANCESCHINI;P. FRANCESCHINI;P FRANCESCHINI;S. FRACCHIOLI;DIONYSSIOS KATSAROS;M MASSOBRIO;R. PICCINNO","0.25;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.12;0.12;0.12;0.12;0.12;0.12;0.11;0.11;0.11;0.11","E GUERCIO;F. BERNASCONI;F. MAGATTI;L. SPREAFICO;MARCO MAFFIOLINI;MICHELE MESCHÌA;P. PIFAROTTI;ANDREAS SCORILAS;DIONYSSIOS KATSAROS;ELEFTHERIOS P. DIAMANDIS;G GORDINI;GEORGE M. YOUSEF;H KIM;M MASSOBRIO;R. PICCINNO;S. FRACCHIOLI;ANTONELLA VILLA;FABIO PARAZZINI;GIORGIA MANGILI;GIORGIO BOLIS","302;302;302;302;302;302;302;142;142;142;142;142;142;142;142;142;89;89;89;89","DIONYSSIOS KATSAROS;M MASSOBRIO;R. PICCINNO;S. FRACCHIOLI;ALESSANDRO PILERI;MARIO BOCCADORO;MARTA COSCIA;MASSIMO MASSAIA;MYRIAM FOGLIETTA;SARA MARIANI;SILVIA PEOLA;ANNA SAPINO;FABIO MALAVASI;LUISELLA RIGHI;MASSIMO BONGIOVANNI;PAOLA CASSONI;SILVIA DEAGLIO;DANIELA RISSO;MAURIZIO STELLA;PAOLO CASSANO","142;142;142;142;54;54;54;54;54;54;54;49;49;49;49;49;49;23;23;23","GIUSEPPE DI CARA;ALESSANDRO PILERI;ANNA SAPINO;D LICATA;D. FRANCESCHINI;DANIELA RISSO;DIONYSSIOS KATSAROS;FABIO MALAVASI;LUISELLA RIGHI;M MASSOBRIO;MARIO BOCCADORO;MARTA COSCIA;MASSIMO BONGIOVANNI;MASSIMO MASSAIA;MAURIZIO STELLA;MYRIAM FOGLIETTA;P FRANCESCHINI;PAOLA CASSONI;PAOLO CASSANO;R. PICCINNO","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE","14;7;3;2;1","INTERNAL MEDICINE;GENETICS;PATHOLOGY;IMMUNOLOGY;ONCOLOGY;SURGERY;PEDIATRICS;RADIOLOGY;ANATOMY;BIOCHEMISTRY;DERMATOLOGY;GASTROENTEROLOGY;GYNECOLOGY;OBSTETRICS;QUANTUM MECHANICS;ACOUSTICS;ARTIFICIAL INTELLIGENCE;CANCER RESEARCH;CELL BIOLOGY;ENVIRONMENTAL HEALTH;MACHINE LEARNING;MOLECULAR BIOLOGY;NUCLEAR PHYSICS;OPTICS;ORGANIC CHEMISTRY;PHOTOCHEMISTRY;PSYCHIATRY;TRADITIONAL MEDICINE;UROLOGY;VIROLOGY","8;6;6;4;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;GENE;PREGNANCY;ULTRASOUND;ANTIBODY;DYSPLASIA;OSTEOCHONDRODYSPLASIA;PROSPECTIVE COHORT STUDY;RIB CAGE;STEM CELL;ANEMIA;ANGIOGENESIS;ARTIFICIAL NEURAL NETWORK;ASTHMA;BENZYL BENZOATE;BIOPSY;BLADDER INJURY;CELL;CURE RATE;DECOCTION;DISCONTINUATION;DISEASE;DOWN SYNDROME;ENZYME;ERYTHEMA;ETIOLOGY;FUROCOUMARINS;HADRON;HYPOESTHESIA;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;ION;ITCHING;LOTION;MULTIPLE MYELOMA;OUTBREAK;PATTERN RECOGNITION (PSYCHOLOGY);PHOTON;PIXEL;POPULATION;POWER (PHYSICS);REGIMEN;REPERTOIRE;SCABIES;SUN EXPOSURE;TOXICITY;TRANSPLANTATION;TRISOMY;UREMIA;URINE","5;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FETUS;OVARIAN CANCER;BREAST CANCER;CISPLATIN;DWARFISM;LEUKOPENIA;MONOCLONAL ANTIBODY;AZATHIOPRINE;CD31;CD34;CD44;CD8;CHROMOSOME;GESTATION;IONIZATION;KALLIKREIN;KIDNEY TRANSPLANTATION;NEPHROTOXICITY;NEUTROPENIA;PROGENITOR CELL;RELIABILITY (SEMICONDUCTOR);RENAL BIOPSY;T CELL;TACROLIMUS;URINALYSIS","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PRENATAL DIAGNOSIS;IN UTERO;ANEUPLOIDY;ANTHRACYCLINE;BK VIRUS;CARBOPLATIN;CD38;DUCTAL CARCINOMA;FEBRILE NEUTROPENIA;GASTROSCHISIS;IONIZATION CHAMBER;METASTATIC BREAST CANCER;MONOCLONAL;T-CELL RECEPTOR;TAXANE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;OVARIAN NEOPLASMS;FEMALE;ADULT;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;MIDDLE AGED;AGED;DOWN SYNDROME;BIOMARKERS, TUMOR;CARCINOMA;CARBOPLATIN;CISPLATIN;FEMUR;MULTIPLE MYELOMA;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BIOMARKERS;BURNS, CHEMICAL;CARCINOMA IN SITU","13;12;10;8;8;7;7;6;6;5;5;4;4;4;4;3;3;3;3;3","GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ECTOPARASITIC DISEASES IN HUMANS AND ANIMALS;GENETIC AND MOLECULAR STUDIES OF CONNECTIVE TISSUE DISORDERS;HEREDITARY ANGIOEDEMA: MOLECULAR MECHANISMS AND CLINICAL MANAGEMENT;MECHANISMS OF SKIN AGING AND PHOTODAMAGE;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;NEURAL NETWORK FUNDAMENTALS AND APPLICATIONS;ORIGINS AND APPLICATIONS OF ELECTRIC CIRCUITS;PELVIC FLOOR DISORDERS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;PROTEIN TYROSINE PHOSPHATASES IN HUMAN HEALTH AND DISEASE","2;2;1;1;1;1;1;1;1;1;1;1;1;1","DWARFISM;FETAL DNA ANALYSIS;LEUKOPENIA;OSTEOCHONDRODYSPLASIA;PRENATAL ULTRASOUND;TRISOMY DETECTION;AMNIOCENTESIS;ATOMIC LAYER ETCHING;BENZYL BENZOATE;BLADDER INJURY;CARBOPLATIN;CD31;CELL ADHESION;CHEMOTHERAPY;COLLAGEN DISORDERS;CURE RATE;DECOCTION;DISCONTINUATION;ENDOTHELIAL CELL BEHAVIOR;ERYTHEMA","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OVARIAN CANCER;KYPHOMELIC DYSPLASIA;PRENATAL DIAGNOSIS;ADVANCED OVARIAN;AIRWAY DISEASES;ANTHRACYCLINE-PRETREATED METASTATIC;AUTOLOGOUS PERIPHERAL;BLOOD PROGENITOR;BREAST CANCER;CANCER PATIENTS;CARBOPLATIN-SENSITIVE OVARIAN;CELL INFUSION;CISPLATIN-BASED CHEMOTHERAPY;CONSECUTIVE TRIALS;DALYSIS UNIT;DIFFERENTIATE AIRWAY;DUCTALIN SITU;ELDERLY RESULTS;EXTENSIVE DUCTALIN;FETUSES BORN;FIG LEAF;FUNCTIONAL NONINVASIVE;GENE KLK;HIGHDOSE CHEMOTHERAPY;HUMAN KALLIKREIN;HUMAN MYELOMA;II TRIAL;INCONTINENT WOMEN;INVASIVE CARCINOMAS;IONIZATION CHAMBER","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","KLK EXPRESSION;BV SUBFAMILIES;OVARIAN TISSUES;AGEMATCHED NORMAL;CLINICAL OUTCOME;EXPANDED BV;HIGHDOSE CHEMOTHERAPY;HIGHLY EXPRESSED;KALLIKREIN GENE;MM PATIENTS;NORMAL DONORS;OVARIAN CANCER;OVARIAN TUMOURS;PBPC INFUSION;PCR PRODUCT;PERIPHERAL BLOOD;TCR DIVERSITY;TCR REPERTOIRE;TCRBV REPERTOIRE;VACCINEBASED STRATEGIES;ABNORMALLY EXPANDED;ACTIVE SCANNING;AGAROSE GELS;AGGRESSIVE FORMS;ANALYSIS KLK;ANALYSIS REVEALED;ANTIGENEXPERIENCED MEMORY;ASTHMA BRONCHITIS;AVERAGE ONETHIRD;AVERAGE TIME","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1",1,0.06,3,2,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,10,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,10,105,3.7,0,0,27,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1","CANCER;CHILDHOOD LEUKEMIA;CLINICAL RESEARCH;HEMATOLOGY;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;RARE DISEASES;STEM CELL RESEARCH","1;1;1;1;1;1;1;1;1;1","CANCER","1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1","BLOOD CANCER;LEUKEMIA / LEUKAEMIA","1;1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2002,25,8.16,1.68,0.16,0.08,0.2,1,0.8,0.666666666666667,0.833333333333333,0.44,1,13,2,2,7,0.52,0.08,0.08,0.28,54.48,0.987516283957185,NA,0.12,0.52,0.219,0,0,0,"RICCARDO ARISIO;S. BASTONERO;ANDREA SCIARRONE;G. ERRANTE;E. VIORA;M CAMPOGRANDE;FRANCESCO SALA;SECONDO FASSINO;L. GARZARO;PLAMEN TERSIEV;R GRIO;GIORGIO GIARDINA;C CAMPAGNOLI;LUISA NAVINO;SERGIO CODA;G RAGONESI;A. LUPARIA;ALFREDO BERRUTI;F. PARISIO;MARCO DE ANDREA","3;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","M A LATINO;FRANCESCO SALA;S. BASTONERO;ANDREA SCIARRONE;G. ERRANTE;E. VIORA;M CAMPOGRANDE;P BRAVOSI;RICCARDO ARISIO;SECONDO FASSINO;L. GARZARO;E GUICCIARDI;CHIARA BENEDETTO;MARIO EANDI;LORENZO PRADELLI;PAOLO RAGNI;GIANCARLO PANZICA;ETTORE PICCOLI;MARIAGRAZIA BONISSONE;PLAMEN TERSIEV","1;0.83;0.57;0.57;0.57;0.57;0.57;0.5;0.48;0.37;0.37;0.33;0.33;0.33;0.33;0.33;0.25;0.25;0.25;0.21","FABIO MALAVASI;MICHELE DE BORTOLI;S. FRACCHIOLI;P SISMONDI;DIONYSSIOS KATSAROS;LUISELLA RIGHI;M MASSOBRIO;PAOLA CASSONI;ROBERTO ALBERA;SALVATORE POLIZZI;MARIO EANDI;ENRICO PIRA;LORENZO PRADELLI;ENRICA AUDERO;ILARIA CASCONE;MASSIMO BONGIOVANNI;MAURO FERRARA;SILVIA DEAGLIO;FEDERICO BUSSOLINO;IRENE A. RIGAULT DE LA LONGRAIS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MARIO EANDI;LORENZO PRADELLI;FABIO MALAVASI;LUISELLA RIGHI;PAOLA CASSONI;ROBERTO ALBERA;SALVATORE POLIZZI;ENRICO PIRA;MASSIMO BONGIOVANNI;MAURO FERRARA;SILVIA DEAGLIO;ANNA SAPINO;R BELLINO;S. FRACCHIOLI;DIONYSSIOS KATSAROS;M MASSOBRIO;IRENE A. RIGAULT DE LA LONGRAIS;M. PUOPOLO;MICHELE DE BORTOLI;P SISMONDI","0.33;0.33;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.11;0.09;0.09;0.09;0.09;0.09;0.08;0.08","ANDREA PAPALEO;ENRICO PIRA;MASSIMILIANO BUGIANI;MAURO FERRARA;ROBERTO ALBERA;S PALMI;SALVATORE POLIZZI;L. GARZARO;RICCARDO ARISIO;SECONDO FASSINO;ANNARITA DE LUCA;CHRISTIAN SFILIGOI;ENRICA AUDERO;FEDERICO BUSSOLINO;ILARIA CASCONE;LUCA FUSO;MICHELE DE BORTOLI;NICOLETTA BIGLIA;P SISMONDI;RICCARDO PONZONE","303;303;303;303;303;303;303;206;206;206;196;196;196;196;196;196;196;196;196;196","ENRICO PIRA;MAURO FERRARA;ROBERTO ALBERA;SALVATORE POLIZZI;ENRICA AUDERO;FEDERICO BUSSOLINO;ILARIA CASCONE;MICHELE DE BORTOLI;P SISMONDI;DIONYSSIOS KATSAROS;IRENE A. RIGAULT DE LA LONGRAIS;M MASSOBRIO;M. PUOPOLO;S. FRACCHIOLI;R BELLINO;ANNA SAPINO;FABIO MALAVASI;LORENZO PRADELLI;LUISELLA RIGHI;MARIO EANDI","303;303;303;303;196;196;196;196;196;77;77;77;77;77;6;0;0;0;0;0","DIONYSSIOS KATSAROS;ENRICA AUDERO;ENRICO PIRA;FEDERICO BUSSOLINO;ILARIA CASCONE;IRENE A. RIGAULT DE LA LONGRAIS;M MASSOBRIO;M. PUOPOLO;MAURO FERRARA;MICHELE DE BORTOLI;P SISMONDI;R BELLINO;ROBERTO ALBERA;S. FRACCHIOLI;SALVATORE POLIZZI;ANNA SAPINO;FABIO MALAVASI;LORENZO PRADELLI;LUISELLA RIGHI;MARIO EANDI","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;0;0;0;0;0","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHILOSOPHY;ECONOMICS;GEOLOGY;MATERIALS SCIENCE;PHYSICS;POLITICAL SCIENCE;SOCIOLOGY","22;15;4;2;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;GENETICS;ENVIRONMENTAL HEALTH;PATHOLOGY;SURGERY;ANATOMY;GYNECOLOGY;OBSTETRICS;IMMUNOLOGY;RADIOLOGY;BIOCHEMISTRY;CLINICAL PSYCHOLOGY;DEVELOPMENTAL PSYCHOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;GEOMETRY;ONCOLOGY;PSYCHIATRY;ANDROLOGY;AUDIOLOGY;BOTANY;CANCER RESEARCH;CELL BIOLOGY;COMPUTATIONAL BIOLOGY;COMPUTER VISION;DEMOGRAPHY;FAMILY MEDICINE;FOOD SCIENCE;LAW;LIBRARY SCIENCE;LINGUISTICS;MACROECONOMICS;MEDICAL EDUCATION;MEDICAL EMERGENCY;MEDICAL PHYSICS;METALLURGY;MICROBIOLOGY;MOLECULAR BIOLOGY;NEUROSCIENCE;NUCLEAR MEDICINE;OCEANOGRAPHY;PALEONTOLOGY;PHARMACOLOGY;PSYCHOANALYSIS;QUANTUM MECHANICS;SOCIAL PSYCHOLOGY;THEOLOGY;UROLOGY","12;9;8;7;6;5;5;5;4;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","POPULATION;PREGNANCY;CANCER;IMMUNOHISTOCHEMISTRY;GENE;ALTERNATIVE MEDICINE;ANTIBODY;CHLAMYDIA;CHLAMYDIA TRACHOMATIS;CONFIDENCE INTERVAL;ENZYME;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INTRAMEDULLARY ROD;MEDULLARY CAVITY;SURVIVAL ANALYSIS;ULTRASONOGRAPHY;ULTRASOUND;AGENESIS;ANAMNESIS;ANGER;ANTIGEN;ANXIETY;ASYMPTOMATIC;BACTERIAL VAGINOSIS;BIOLOGICAL SCIENCES;BLOOD TRANSFUSION;CARCINOMA;CARRIAGE;CENTRAL NERVOUS SYSTEM;CEREBRAL CORTEX;CHARACTER (MATHEMATICS);CHEMOTHERAPY;COGNITION;COMPARTMENT (SHIP);CONCORDANCE;CONGENITAL ADRENAL HYPERPLASIA;CONGENITAL DISEASE;CORTEX (ANATOMY);DECORTICATION;DECREE;DEFEROXAMINE;DEPRESSION (ECONOMICS);DIAGNOSTIC ACCURACY;DILIGENCE;DISEASE;DOPPLER ULTRASOUND;DOSIMETRY;EPIDEMIOLOGY;ESTROGEN;EXTERNAL QUALITY ASSESSMENT;HELICOBACTER PYLORI;HIPPOCAMPUS;HORMONE;INSULIN;INTERNAL FIXATION;ION;KAPPA;LYMPH NODE;MALIGNANCY;MEDICAL SCHOOL;MENINGES;MENOPAUSE;MULTIVARIATE ANALYSIS;NAIL (FASTENER);NONUNION;ORTHOPEDIC SURGERY;OXYTOCIN;PERSONALITY;PIXEL;POLYDACTYLY;PROSTAGLANDIN;PRUDENCE;PSYCHOPATHOLOGY;PSYCHOSOCIAL;RANDOMIZED CONTROLLED TRIAL;RATING SCALE;REDUCTION (MATHEMATICS);RETROSPECTIVE COHORT STUDY;RIPENING;SEROUS FLUID;SPERM;SPORE;STAGE (STRATIGRAPHY);STEM CELL;TESTOSTERONE (PATCH);THALASSEMIA;TIBIA;TOXICITY;TRANSDERMAL;VAGINITIS","8;7;6;4;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FETUS;BREAST CANCER;FIXATION (POPULATION GENETICS);INFERTILITY;METASTASIS;3D ULTRASOUND;ABORTION;ALLELE;ANDROGEN;ASCOSPORE;AUTOANTIBODY;BASAL (MEDICINE);BETA THALASSEMIA;BLOT;CERVICAL CANCER;CERVIX;CISPLATIN;CLEAR CELL CARCINOMA;COLOR DOPPLER;DEFERASIROX;DEFERIPRONE;DEMENTIA;DINOPROSTONE;DYDROGESTERONE;DYSOSTOSIS;ENDOMETRIAL CANCER;EXON;FERTILITY;GENE EXPRESSION;GENE ISOFORM;GONORRHEA;HAEMATOPOIESIS;HAZARD RATIO;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);INDUCTION OF LABOR;INFORMED CONSENT;IONIZATION;KALLIKREIN;LABOR INDUCTION;LIMBIC SYSTEM;LYASE;MUTATION;NEUROPSYCHOLOGY;NORETHISTERONE ACETATE;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;PLACEBO;POLYCLONAL ANTIBODIES;POLYMERASE CHAIN REACTION;PROGESTIN;PROGRESSIVE DISEASE;QUALITY ASSURANCE;RESEARCH METHODOLOGY;SEXUAL INTERCOURSE;SEXUALLY ACTIVE;SYPHILIS;TEMPERAMENT;UNIVARIATE ANALYSIS;VAGINAL DELIVERY","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PRENATAL DIAGNOSIS;SECOND TRIMESTER;ASCUS (BRYOZOA);BISHOP SCORE;BREAST CARCINOMA;CERVICAL INTRAEPITHELIAL NEOPLASIA;DEBULKING;DOUBLE BLIND;EPIRUBICIN;FIRST TRIMESTER;IONIZATION CHAMBER;MALE INFERTILITY;METASTATIC BREAST CANCER;MINI–MENTAL STATE EXAMINATION;MISOPROSTOL;MISSENSE MUTATION;MULTIPLEX POLYMERASE CHAIN REACTION;NORETHISTERONE;NORTHERN BLOT;SEX HORMONE-BINDING GLOBULIN;SEXUALLY TRANSMITTED DISEASE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;INFERTILITY;MALE;MIDDLE AGED;AGED;BREAST NEOPLASMS;FETAL DISEASES;TIBIAL FRACTURES;FRACTURES, UNUNITED;RNA, MESSENGER;;ADOLESCENT;AGED, 80 AND OVER;ALZHEIMER DISEASE;COGNITION DISORDERS;KALLIKREINS;NORETHINDRONE;SEXUALLY TRANSMITTED DISEASES","21;18;14;9;8;8;6;6;6;6;5;5;4;4;4;4;4;4;4;4","GLOBAL TRENDS IN INFERTILITY AND REPRODUCTIVE TECHNOLOGIES;BIOETHICS AND PATIENT RIGHTS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;EFFECTS OF HORMONES ON MENOPAUSAL WOMEN'S HEALTH;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETIC AND DEVELOPMENTAL STUDIES OF LIMB MALFORMATIONS;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;GYNECOLOGIC ONCOLOGY;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HEREDITARY ANGIOEDEMA: MOLECULAR MECHANISMS AND CLINICAL MANAGEMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;INNATE IMMUNITY TO VIRAL INFECTION;MECHANISMS OF ALUMINUM TOXICITY AND TOLERANCE IN PLANTS;MOLECULAR BIOLOGY OF STEROIDOGENESIS AND DISORDERS;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;MOLECULAR MECHANISMS OF CARDIAC DEVELOPMENT AND REGENERATION;MUSCULOSKELETAL EDUCATION IN MEDICAL TRAINING;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INFERTILITY;PRENATAL ULTRASOUND;SECOND TRIMESTER;3D ULTRASOUND;AGENESIS;ALUMINUM TOXICITY;ANAMNESIS;ANGIOGENIC SIGNALING;ASCUS (BRYOZOA);BASAL (MEDICINE);BETA THALASSEMIA;BIOLOGICAL SCIENCES;BISHOP SCORE;BONE HEALING;BREAST CANCER;BREAST CARCINOMA;CANCER THERAPY;CARRIAGE;CHLAMYDIA TRACHOMATIS;CLEAR CELL CARCINOMA","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CONTROLLED STUDY;ALZHEIMERS DISEASE;ANGER SUPPRESSION;ANGIOPOIETIN EXPRESSION;ANXIETY DEPRESSION;AUTHORS REPLY;BREAST METABOLIC;BUNDLE NAIL;BUNDLE NAILING;CANCER CORRELATES;CANCER PATIENTS;CANCER TISSUE;CENTRAL NERVOUS;CERVICO-VAGINAL INFECTIONS;CHLAMYDIA TRACHOMATIS;CLINICAL TRIAL;COMBINED Α-HYDROXYLASE-LYASE;COSTOEFFICACIA DEL;CYP GENE;DEFERIPRONE VERSUS;DEFICIENCY CAUSED;DEL DINOPROSTONE;DOUBLE-BLIND CONTROLLED;ELDERLY PATIENT;ELDERLY WOMEN;ENDOMETRIAL CARCINOMA;EXPRESSION ANALYSIS;FACTORIAL DESIGN;FERTILITY DISORDERS","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMAN KALLIKREIN;FUNCTIONAL INFERTILITY;IC TRACHOMATISI;ORGANIC INFERTILITY;ANG MRNA;BREAST CANCER;TRACHOMATISI INFECTION;CYP GENE;FREE SURVIVAL;HAZARD RATIO;HK MG;IFI EXPRESSION;INFERTILE COUPLES;LABOR INDUCTION;MG TOTAL;NG HK;PROGRESSION FREE;TOTAL PROTEIN;TUMOR CELLS;Α-HYDROXYLASE-LYASE DEFICIENCY;ANALYSIS REVEALED;ANGER EXPRESSION;ANGIOPOIETIN- ANG;CANCER PATIENTS;CELL LINES;CERVICAL RIPENING;CHROMOSOME Q-Q;COPYRIGHT ISUOG;FUNCTIONAL INFERTILE;HEMATOPOIETIC COMPARTMENT","9;7;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2003,33,8.81818181818182,1.57575757575758,0.242424242424242,0.121212121212121,0.242424242424242,1.11538461538462,1,0.8,1,0.242424242424242,0,13,9,3,7,0.39,0.27,0.09,0.21,50.85,0.960712274665338,NA,0.181818181818182,0.818181818181818,0.226,0.171,0.15,0.171,"RICCARDO ARISIO;E. VIORA;GABRIELLA RESTAGNO;M CAMPOGRANDE;ANTONIO DURANDO;FRANCESCO REA;F. PARISIO;G MONTANARI;ANGELO CAMPANOZZI;DIONYSSIOS KATSAROS;TULLIA TODROS;FEDERICO GRIGNOLO;ANTONIO MARIA FEA;M MASSOBRIO;GIOVANNI CORRAO;ANDREA CORRIAS;MASSIMO CONFORTINI;MARIO ROCCO DʼALTIGLIA;FELICE CARDILLO PICCOLINO;R LAZZARI","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RICCARDO ARISIO;M CAMPOGRANDE;M MASSOBRIO;GABRIELLA RESTAGNO;E. VIORA;R. TOCHIO;FEDERICO GRIGNOLO;ANTONIO MARIA FEA;FELICE CARDILLO PICCOLINO;N NEDICOVA;R. RIGAULT DE LA LONGRAIS;MARCO PARVIS;S RUSTICHELLI;C. GULOTTA;ELENA BERTONE;DIONYSSIOS KATSAROS;TULLIA TODROS;GIOVANNI BOTTA;P. GAGLIOTI;ANTONIO DURANDO","0.65;0.51;0.44;0.42;0.4;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.31;0.3;0.29;0.29;0.29;0.21","DIONYSSIOS KATSAROS;TULLIA TODROS;ANTONIO MARIA FEA;R. RIGAULT DE LA LONGRAIS;P. GAGLIOTI;LUIGI CATTEL;GIANNA MAZZUCCO;I. MASSARENTI;GIUSEPPE DI CARA;S. FRACCHIOLI;C. BUMMA;MAURO PORPIGLIA;MARILISA BIOLCATI;M PAGLIANO;D LICATA;D. FRANCESCHINI;CARLA MARIA ZOTTI;P FRANCESCHINI;IRENE A. RIGAULT DE LA LONGRAIS;C FABRIS","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTONIO MARIA FEA;R. RIGAULT DE LA LONGRAIS;DIONYSSIOS KATSAROS;TULLIA TODROS;P. GAGLIOTI;S. FRACCHIOLI;MAURO PORPIGLIA;I. MASSARENTI;MARILISA BIOLCATI;CARLA MARIA ZOTTI;C FABRIS;VITTORINA BUTTAFUOCO;C PERATHONER;MARIANGELA MOMBR�;AGATA LEONE;GIUSEPPE DI CARA;D LICATA;D. FRANCESCHINI;P FRANCESCHINI;MARIA ANTONIETTA CAU","0.33;0.33;0.3;0.29;0.29;0.2;0.2;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.12;0.12;0.12;0.12;0.12","ADOLF E. SCHINDLER;C CAMPAGNOLI;JOHANNES HUBER;JOS H.H. THIJSSEN;JÖRGE R. PASQUALINI;KARL-WERNER SCHWEPPE;RENÉ DRUCKMANN;E. VIORA;M CAMPOGRANDE;ANNA BELTRAME;ANTONIO FESTA;ARSENIO SPINILLO;CARLO PENNA;G OSNENGO;NICOLA BLASI;SALVATORE CORSELLO;SECONDO GUASCHINO;ANDREA CORRIAS;ANGELO CAMPANOZZI;FRANCESCO REA","708;708;708;708;708;708;708;213;198;171;171;171;171;171;171;171;171;116;116;116","P. GAGLIOTI;TULLIA TODROS;MARIA ANTONIETTA CAU;R BELLINO;I. MASSARENTI;MARILISA BIOLCATI;AGATA LEONE;C FABRIS;C PERATHONER;CARLA MARIA ZOTTI;MARIANGELA MOMBR�;VITTORINA BUTTAFUOCO;M PAGLIANO;D LICATA;D. FRANCESCHINI;GIUSEPPE DI CARA;P FRANCESCHINI;DIONYSSIOS KATSAROS;MAURO PORPIGLIA;S. FRACCHIOLI","105;105;59;52;46;46;32;32;32;32;32;32;23;13;13;13;13;10;10;10","DIONYSSIOS KATSAROS;P. GAGLIOTI;TULLIA TODROS;AGATA LEONE;C FABRIS;C PERATHONER;CARLA MARIA ZOTTI;D LICATA;D. FRANCESCHINI;GIANNA MAZZUCCO;GIUSEPPE DI CARA;I. MASSARENTI;M PAGLIANO;MARIA ANTONIETTA CAU;MARIANGELA MOMBR�;MARILISA BIOLCATI;MAURO PORPIGLIA;P FRANCESCHINI;R BELLINO;S. FRACCHIOLI","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHILOSOPHY;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;PHYSICS;ENGINEERING;SOCIOLOGY","30;16;4;3;3;2;2;1;1","INTERNAL MEDICINE;GENETICS;PATHOLOGY;SURGERY;OBSTETRICS;PEDIATRICS;GASTROENTEROLOGY;GYNECOLOGY;ENVIRONMENTAL HEALTH;LINGUISTICS;MEDICAL PHYSICS;ONCOLOGY;RADIOLOGY;ANATOMY;CANCER RESEARCH;CARDIOLOGY;COMPUTATIONAL BIOLOGY;DERMATOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;MICROBIOLOGY;NUCLEAR MEDICINE;OPTICS;PHARMACOLOGY;STATISTICS","18;12;10;8;6;6;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CANCER;PREGNANCY;DISEASE;CHEMOTHERAPY;GENE;POPULATION;BIOPSY;CARCINOMA;EPIDEMIOLOGY;HEPATOLOGY;KAPPA;LYMPHOMA;NASAL BONE;REPRODUCIBILITY;THYROID;ADVERSE EFFECT;ALTERNATIVE MEDICINE;ANTIBIOTICS;ANTIBODY;ANTIFUNGAL;ANXIETY;APOPTOSIS;ARTIFICIAL NEURAL NETWORK;ASTHMA;ATRESIA;AUTOPSY;BONE MARROW;CANDIDA ALBICANS;CLINICAL PHARMACOLOGY;CLINICAL TRIAL;COHEN'S KAPPA;COMPREHENSION;CONTEXT (ARCHAEOLOGY);CUBE (ALGEBRA);CYTOLOGY;DEPRESSION (ECONOMICS);DETECTOR;DIABETES MELLITUS;DOSIMETRY;DUCTUS ARTERIOSUS;EPITHELIUM;ETIOLOGY;EXTERNAL QUALITY ASSESSMENT;FAMILY HISTORY;FEMUR;FIBROSIS;GENETIC TESTING;HERNIA;HISTOLOGY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);HYPOPLASIA;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);INTERPRETATION (PHILOSOPHY);INTERVENTIONAL RADIOLOGY;ION;KIDNEY;LESION;LUNG;LYMPHATIC SYSTEM;MAGIC (TELESCOPE);MANAGEMENT SYSTEM;MEDICAL DIAGNOSIS;MEMBRANE;METAPLASIA;METHOTREXATE;NEPHROLOGY;ODDS RATIO;OSSIFICATION;OSTEOPOROSIS;PARENCHYMA;PATTERN RECOGNITION (PSYCHOLOGY);PECTORALIS MAJOR MUSCLE;PECTORALIS MUSCLE;PROSPECTIVE COHORT STUDY;PROSTHESIS;PSORIASIS;PSYCHOLOGICAL INTERVENTION;PULMONARY ARTERY;PULMONARY VALVE;QUALITY (PHILOSOPHY);RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;REGIMEN;RENAL FUNCTION;RESPIRATORY DISTRESS;RESPIRATORY FAILURE;RHEUMATOID ARTHRITIS;RHEUMATOLOGY;SESSION (WEB ANALYTICS);SISTER;SPORE;STENOSIS;TOXOPLASMOSIS;TRANSMISSION (TELECOMMUNICATIONS);TRISOMY;ULTRASONOGRAPHY;ULTRASOUND;VAGINAL DISCHARGE;VENTRICLE","9;9;6;4;4;4;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FETUS;BREAST CANCER;CERVICAL CANCER;CISPLATIN;GESTATION;GLUTEN FREE;OVARIAN CANCER;PEDIATRIC GASTROENTEROLOGY;THYROID DISEASE;THYROID FUNCTION;THYROID FUNCTION TESTS;ACUTE RESPIRATORY DISTRESS;ANTIBIOTIC PROPHYLAXIS;ASCOSPORE;ATOPY;AUTOSOMAL RECESSIVE INHERITANCE;BETHESDA SYSTEM;BONE MINERAL;CERVIX;CHROMOSOMAL TRANSLOCATION;CICLOSPORIN;COELIAC DISEASE;COLORECTAL CANCER;CORPUS ALBICANS;CYCLOPHOSPHAMIDE;CYSTATIN C;DIAPHRAGMATIC HERNIA;DOCETAXEL;DOXORUBICIN;GENE REARRANGEMENT;GERMLINE;GESTATIONAL AGE;IMMUNOGLOBULIN HEAVY CHAIN;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INFORMED CONSENT;INHERITANCE (GENETIC ALGORITHM);IONIZATION;LUNG BIOPSY;MARITAL STATUS;METASTASIS;MICROANGIOPATHY;MINIMAL RESIDUAL DISEASE;MUCOSITIS;MUTATION;MYCOSIS FUNGOIDES;NEPHROPATHY;NEUTROPENIA;OBSTETRICS AND GYNAECOLOGY;PACLITAXEL;PHASES OF CLINICAL RESEARCH;PHOSPHOLIPID;PI3K/AKT/MTOR PATHWAY;POLYMERASE CHAIN REACTION;PREECLAMPSIA;PROTHESIS;PULMONARY ATRESIA;PULMONARY FIBROSIS;QUALITY ASSURANCE;QUALITY MANAGEMENT;SEROCONVERSION;SPINDLE CELL CARCINOMA;SQUAMOUS CARCINOMA;SQUAMOUS METAPLASIA;THROMBOTIC MICROANGIOPATHY;VULVOVAGINAL CANDIDIASIS;X CHROMOSOME","6;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PRENATAL DIAGNOSIS;BREAST CARCINOMA;EPITHELIAL OVARIAN CANCER;ASCUS (BRYOZOA);BREAST RECONSTRUCTION;CANDIDA KRUSEI;CAPECITABINE;CARBOPLATIN;CARDIOLIPIN;CERVICAL INTRAEPITHELIAL NEOPLASIA;CERVICAL SCREENING;CORONAVIRUS DISEASE 2019 (COVID-19);CYSTATIN;DIFFUSE ALVEOLAR DAMAGE;EPIRUBICIN;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;GENE MUTATION;GERMLINE MUTATION;IONIZATION CHAMBER;MASTECTOMY;METAPLASTIC CARCINOMA;OMPHALOCELE;PAP SMEARS;PLACENTA;PRIMARY TUMOR;PTEN;SMALL FOR GESTATIONAL AGE;TWIN PREGNANCY;VINORELBINE;X-LINKED RECESSIVE INHERITANCE","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;BREAST NEOPLASMS;UTERINE CERVICAL NEOPLASMS;ADULT;MIDDLE AGED;;CARCINOMA, SQUAMOUS CELL;MALE;PREGNANCY;ULTRASONOGRAPHY, PRENATAL;ITALY;NASAL BONE;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;DOWN SYNDROME;PACLITAXEL;CARCINOMA;EPIRUBICIN;VAGINAL SMEARS","24;22;14;10;9;9;8;8;8;8;8;7;7;6;6;6;6;5;5;5","HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND TREATMENT OF CUTANEOUS LYMPHOMAS;CMOS IMAGE SENSOR TECHNOLOGY;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;DEVELOPMENTAL ORIGINS OF ADULT HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;ERRORS AND COMMUNICATION IN RADIOLOGY IMAGING;ETIOLOGY AND MANAGEMENT OF ABDOMINAL WALL DEFECTS;GLIOMAS;LYMPHOID NEOPLASMS;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;MICROSURGICAL RECONSTRUCTION TECHNIQUES;MTOR SIGNALING IN GROWTH AND DISEASE;NEURAL NETWORK FUNDAMENTALS AND APPLICATIONS;OPTIMIZATION OF ASSEMBLY LINE BALANCING PROBLEMS","3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FETAL DNA ANALYSIS;PRENATAL DIAGNOSIS;TRISOMY DETECTION;BREAST CARCINOMA;CELIAC DISEASE;FETAL LUNG DEVELOPMENT;GLUTEN FREE;INTER-RATER RELIABILITY;KAPPA;NASAL BONE;PEDIATRIC GASTROENTEROLOGY;THYROID DISEASE;;ABDOMINAL WALL DEFECTS;AIRWAY STENOSIS;ALBUMINURIA;ANTIBIOTIC THERAPY;ANTIPHOSPHOLIPID SYNDROME;ASCUS (BRYOZOA);ATOPY","4;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","BREAST CARCINOMA;AUTOIMMUNE THYROID;CELIAC DISEASE;EPITHELIAL OVARIAN;NASAL BONE;OVARIAN CANCER;THYROID DISEASE;ABSTRACT NOS;ADVANCED BREAST;ADVANCED EPITHELIAL;ADVANCED HEAVILY;AIRWAY DISEASES;ANTI-PHOSPHOLIPID SYNDROME;ANXIETY DEPRESSION;APO-E IMPLICATED;ATYPICAL SQUAMOUS;AUTOSOMAL RECESSIVE;BONE LENGTH;BONE MARROW;BREAST RECONSTRUCTION;BURKITTS LYMPHOMAS;CANCER PATIENTS;CARCINOMA PATHOLOGY;CERVICAL SMEARS;CERVIX CANCER;CHAIN REACTION;CHAMBER DETECTORS;CLINICAL OUTCOME;CNS TUMORS;COMPARISON STUDY","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NASAL BONE;BONE LENGTH;CONTROL SUBJECTS;FETAL DNA;PULMONARY STENOSIS;MATERNAL PLASMA;MEDIAN AGE;PULMONARY ATRESIA;AUTOIMMUNE THYROID;FALSEPOSITIVE RATE;GLUTEN-FREE DIET;GRADE ADVERSE;III DISEASE;STAGE III;THYROID DISEASE;TWIN PREGNANCIES;VENTRICULAR WALL;ACCEPTABLE SAFETY;ADVERSE EVENTS;AMP SONS;AUTOIMMUNE MARKERS;BONE ASSESSMENT;BREAST CARCINOMA;COMPLETE RESPONSES;COPYRIGHT ISUOG;CROWNRUMP LENGTH;DETECTION RATE;DUCTUS ARTERIOSUS;ECHOGRAPHIC PATTERN;FETAL ANEUPLOIDIES","15;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2004,33,9.6969696969697,2,0.212121212121212,0.151515151515152,0.272727272727273,1.30555555555556,1.16666666666667,1,1.125,0.272727272727273,1,16,8,1,7,0.48,0.24,0.03,0.21,31.7,0.673635192707816,NA,0.303030303030303,0.696969696969697,0.284,0.222,0.15,0.234,"CHIARA BENEDETTO;GABRIELLA RESTAGNO;E. CROVERI;ANGELO BOLOGNESI;CARLO SMIRNE;M. DONETTI;F CARNINO;S PELISSETTO;S. FRACCHIOLI;S. GIORDANENGO;TIZIANA PROCHILO;CECILIA TIBALDI;M A LATINO;E MADON;E LEOTTA;PAOLO BRUZZI;DIONYSSIOS KATSAROS;PIERGIORGIO GIANNESSI;PIERFRANCO CONTÉ;SILVIA MARINI","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","A. ANTICO;CHIARA BENEDETTO;GABRIELLA RESTAGNO;E. CROVERI;S PELISSETTO;CECILIA TIBALDI;M A LATINO;M FRATICELLI;SILVIA MARINI;MARCO DʼAMICO;M. CUOZZO;PRISCA SOZZANI;GIAN LUCA FORNI;GIULIA MASUELLI;LUCA MAROZIO;GABRIELA BECHIS;AURELIO LIMIDO;GABRIELA OROPEZA;F. FABRIZI;C. BARBERA","1;0.38;0.31;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25","CHIARA BENEDETTO;S PELISSETTO;S. FRACCHIOLI;CECILIA TIBALDI;DIONYSSIOS KATSAROS;SILVIA MARINI;ALESSANDRA COSCIA;R GRIO;PRISCA SOZZANI;ENRICO BERTINO;GIULIA MASUELLI;LUCA MAROZIO;GABRIELA BECHIS;M CAMPOGRANDE;M. PUOPOLO;C FABRIS;BOSSINI NICOLA;LUISA DE SANCTIS;ROBERTO RUSSO;VIRGINIA DE ROSE","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CHIARA BENEDETTO;S PELISSETTO;CECILIA TIBALDI;SILVIA MARINI;PRISCA SOZZANI;GIULIA MASUELLI;LUCA MAROZIO;GABRIELA BECHIS;S. FRACCHIOLI;M. PUOPOLO;ALESSANDRA COSCIA;R GRIO;ENRICO BERTINO;LUISA DE SANCTIS;DAMIANO ROMAGNOLO;L SILVESTRO;M CAMPOGRANDE;DIONYSSIOS KATSAROS;C FABRIS;ROBERTO RUSSO","0.38;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.22;0.22;0.2;0.2;0.2;0.17;0.17;0.17;0.15;0.15;0.1;0.1","JAMES J. DIAMOND;JAY GOLDBERG;LEONARDO PEREIRA;P SEINERA;RENATO SERACCHIOLI;VINCENZO BERGHELLA;ÉMILE DARAÏ;GABRIELLA RESTAGNO;M CAMPOGRANDE;ALBERTO BORIANO;C. PERONI;E MADON;E. GARELLI;EDOARDO TREVISIOL;F. BOURHALEB;F. MARCHETTO;M. DONETTI;R. CIRIO;S. AMERIO;S. GIORDANENGO","200;200;200;200;200;200;200;142;133;111;111;111;111;111;111;111;111;111;111;111","M CAMPOGRANDE;M MASSOBRIO;TULLIA TODROS;DAMIANO ROMAGNOLO;L SILVESTRO;LUISA DE SANCTIS;CECILIA TIBALDI;CHIARA BENEDETTO;GIULIA MASUELLI;LUCA MAROZIO;PRISCA SOZZANI;S PELISSETTO;SILVIA MARINI;ALBERTO PIAZZA;ANTONIO PIGA;M PAGLIANO;MANUELA GOIA;MARCO BARDESSONO;N CAPPELLO;VIRGINIA DE ROSE","107;107;107;56;56;56;37;37;37;37;37;37;37;26;26;26;26;26;26;26","ALESSANDRA COSCIA;CECILIA TIBALDI;CHIARA BENEDETTO;ENRICO BERTINO;GIULIA MASUELLI;LUCA MAROZIO;PRISCA SOZZANI;R GRIO;S PELISSETTO;SILVIA MARINI;ALBERTO PIAZZA;ANTONIO PIGA;C FABRIS;DAMIANO ROMAGNOLO;L FERRERO;L SILVESTRO;LUISA DE SANCTIS;M CAMPOGRANDE;M MASSOBRIO;M PAGLIANO","2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;MATERIALS SCIENCE;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE","33;16;4;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;SURGERY;BIOCHEMISTRY;GYNECOLOGY;OBSTETRICS;GASTROENTEROLOGY;PATHOLOGY;CANCER RESEARCH;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;ANATOMY;CARDIOLOGY;DEMOGRAPHY;NUCLEAR MEDICINE;OPTICS;ORGANIC CHEMISTRY;PEDIATRICS;QUANTUM MECHANICS;UROLOGY","25;11;6;6;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","PREGNANCY;GENE;CANCER;CHEMOTHERAPY;BACTERIA;BACTERIAL VAGINOSIS;CALCIUM;DISEASE;EPIDEMIOLOGY;IMMUNE SYSTEM;POPULATION;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;ANAMNESIS;ASTHMA;CHLAMYDIA TRACHOMATIS;DETECTOR;DOSIMETRY;ENZYME;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ION;MYCOPLASMA;REGIMEN;RISK FACTOR","7;6;5;5;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;FETUS;GESTATION;EOSINOPHIL;GENOTYPE;GRAM STAINING;IONIZATION;MISCARRIAGE;NEUTROPENIA;OVARIAN CANCER;PACLITAXEL;SEXUAL INTERCOURSE;UREAPLASMA;ABORTION;ABSORBED DOSE;ACUTE STROKE;ALKALINE PHOSPHATASE;ALLELE;AMYOTROPHIC LATERAL SCLEROSIS;ATOPY;BIRTH WEIGHT;BONE MINERAL;BRACHYDACTYLY;CALCIUM IN BIOLOGY;CALCIUM METABOLISM;CARDIOTOXICITY;CD8;CHROMOSOME;CHRONIC INFECTION;CISPLATIN;COELIAC DISEASE;CYTOTOXIC T CELL;DANTROLENE;DERMATITIS HERPETIFORMIS;DOT PITCH;EJECTION FRACTION;ENTEROPATHY;ESSENTIAL THROMBOCYTHEMIA;EXON;FLUOROURACIL;GENETIC ENHANCEMENT;GESTATIONAL AGE;GNAS COMPLEX LOCUS;GONORRHEA;GREAT ARTERIES;HAIR DYES;HEART BLOCK;INTRON;KALLIKREIN;LINEAR PARTICLE ACCELERATOR;LOW BIRTH WEIGHT;MAXILLARY NERVE;MUCOSITIS;MULTICENTER STUDY;MUTATION;MYCOPLASMA GENITALIUM;MYOGENESIS;MYOMA;PARATHYROID HORMONE;PARTICLE DETECTOR;PHENOTYPE;PLACEBO;POLYMERASE CHAIN REACTION;POLYUNSATURATED FATTY ACID;PSEUDOMONAS AERUGINOSA;RNA;RYANODINE RECEPTOR;SEXUALLY ACTIVE;SKIN BIOPSY;SYPHILIS;T CELL;T-CELL LYMPHOMA;TRICUSPID VALVE INSUFFICIENCY;UTERINE ARTERY EMBOLIZATION;Y CHROMOSOME","3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EPIRUBICIN;PRENATAL DIAGNOSIS;EOSINOPHIL CATIONIC PROTEIN;IONIZATION CHAMBER;METASTATIC BREAST CANCER;PREMATURE RUPTURE OF MEMBRANES;ABSOLUTE NEUTROPHIL COUNT;ANEUPLOIDY;ANTHRACYCLINE;CORRECTED TRANSPOSITION;CYTOGENETICS;DISCHARGE IONIZATION DETECTOR;DOCOSAHEXAENOIC ACID;EPITHELIAL OVARIAN CANCER;HELIUM IONIZATION DETECTOR;MULTILEAF COLLIMATOR;MULTIPLEX POLYMERASE CHAIN REACTION;OSTEOCALCIN;PERFORIN;PSEUDOHYPOPARATHYROIDISM;RNA SPLICING;RYR1;SEXUALLY TRANSMITTED DISEASE;SINGLE-NUCLEOTIDE POLYMORPHISM;SOD1;TESTIS DETERMINING FACTOR;UTERINE ARTERY;UTERINE MYOMECTOMY;VINORELBINE","3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;MIDDLE AGED;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;EPIRUBICIN;;RISK FACTORS;AGED;MALE;PACLITAXEL;ADOLESCENT;PREGNANCY;CHILD;CYSTIC FIBROSIS;FEMUR;HYPERSENSITIVITY, IMMEDIATE;ITALY;LUMBAR VERTEBRAE","25;18;13;12;11;10;9;8;7;6;6;6;5;5;4;4;4;4;4;4","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;VAGINAL MICROBIOME AND SEXUALLY TRANSMITTED INFECTIONS;PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES;RADIOTHERAPY PHYSICS AND TECHNOLOGY;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ASTHMA;ATOPIC DERMATITIS AND SKIN MICROBIOME;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS;EFFECTS OF BLOOD TRANSFUSION IN CLINICAL PRACTICE;ENGINEERING BACTERIA FOR CANCER TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF MAXILLOFACIAL TRAUMA;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPIDEMIOLOGY AND TREATMENT OF MICROSCOPIC COLITIS;GENOMIC IMPRINTING AND PARENTAL GENE EXPRESSION CONTROL;HEALTH EFFECTS OF SOY ISOFLAVONES AND PHYTOESTROGENS;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;HEPATITIS C INFECTION AND TREATMENT","3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;EPIRUBICIN;VAGINAL MICROBIOME;ANAMNESIS;FETAL DNA ANALYSIS;GRAM STAINING;NONINVASIVE PRENATAL TESTING;PACLITAXEL;PRETERM DELIVERY;REGIMEN;SEXUAL INTERCOURSE;TEETHING SYMPTOMS;UREAPLASMA;ABSOLUTE NEUTROPHIL COUNT;ACCURACY AND PRECISION;ACUTE STROKE;ADULT CONGENITAL HEART DISEASE;ANEUPLOIDY SCREENING;ARGUMENT (COMPLEX ANALYSIS);ATOPY","3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","METASTATIC BREAST;PRENATAL DIAGNOSIS;ATOPIC SYMPTOMS;BREAST CANCER;CANCER PATIENTS;CATIONIC PROTEIN;CERVICOVAGINAL INFECTIONS;DERMATITIS HERPETIFORMIS;EOSINOPHIL CATIONIC;EPITHELIAL OVARIAN;IONIZATION CHAMBER;JEJUNAL LESION;LESION PREDICTIVE;MICROBIOLOGICAL ASPECTS;NEONATAL SERUM;OVARIAN CANCER;PREGNANCY EPIDEMIOLOGICAL;PROTEIN LEVEL;RISK FACTOR;SERUM EOSINOPHIL;TERM PROGNOSIS;ACCESSORY INFRAORBITAL;ACIDS PUFAS;ACUTE STROKE;AERUGINOSA INFECTION;ANTHRACYCLINE-NAÏVE METASTATIC;ARTERY EMBOLIZATION;BIOLOGIC THERAPY;BIRTH WEIGHT;BONE METABOLISM","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","GLYCEROL TREATMENT;ACUTE STROKE;CF PATIENTS;IONIZATION CHAMBER;AERUGINOSA INFECTION;CENTRAL CORE;CORE DISEASE;SCHEDULED TREATMENT;BIRTH WEIGHT;COCHRANE LIBRARY;CONTROL SUBJECTS;EJECTION FRACTION;FUNCTIONAL OUTCOME;FUNGAL COLONIZATION;HUMAN MYOTUBES;INTRAVENOUS GLYCEROL;ISCHEMIC STROKE;LEFT VENTRICULAR;MONTHS CI;MUTATIONS LINKED;PERUGIA ITALY;TREATMENT PERIOD;VENTRICULAR EJECTION;VLBW NEONATES;ACQUIRING CHRONIC;ACUTE ISCHEMIC;AGE YRS;ANNA CANTISANI;BRAIN EDEMA;CANTISANI ROBERTO","6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2,6635,6.06,0,0,169,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE","2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEALTH SERVICES;INFECTIOUS DISEASES;LUNG;PEDIATRIC;PNEUMONIA;PREVENTION","1;1;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2005,45,11.9555555555556,1.48888888888889,0.0888888888888889,0.111111111111111,0.0888888888888889,1,0.8,0.833333333333333,0.8,0.288888888888889,0,21,11,3,6,0.47,0.24,0.07,0.13,35,0.661079242096897,NA,0.177777777777778,0.844444444444444,0.274,0,0.133,0,"E. VIORA;S. BASTONERO;PAOLO MANZONI;GABRIELLA RESTAGNO;ANTONIO DURANDO;MICHELA VERSARI;LUCIANA GHIO;M. DONETTI;S. GIORDANENGO;OSCAR BERTETTO;ANTONELLA GARITO;A BRICCOLI;ELENA MUNDO;MASSIMO CARDILLO;BIANCA MASTURZO;MARINA MINCIULLO;LUISA MURER;ALBERTO EDEFONTI;STEFANO CASCINU;FABRIZIO GINEVRI","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PAOLO MANZONI;G GOMIRATO;E. VIORA;S. BASTONERO;M FRATICELLI;MARCO DʼAMICO;AURELIO LIMIDO;GABRIELLA RESTAGNO;BIANCA MASTURZO;ANDREA SCIARRONE;M CAMPOGRANDE;MICHELA VERSARI;A BRICCOLI;ALESSANDRA LONGHI;FRANCA FAGIOLI;PIERO PICCI;GAETANO BACCI;ANTONELLA GARITO;ELENA MUNDO;MARINA MINCIULLO","0.78;0.67;0.54;0.39;0.33;0.33;0.33;0.33;0.31;0.31;0.31;0.29;0.29;0.29;0.29;0.29;0.29;0.29;0.29;0.29","C. PERONI;ANGELA SARDO;VIVIANA CRISTINA TULLIO;TERESA ROLLE;GIULIANA BANCHE;ANNAMARIA FERRERO;BRUNO BATTISTON;C M CRACCO;MARCO TAMIETTO;FEDERICO GRIGNOLO;C. J. SANZ FREIRE;ANTONIO MARIA FEA;L. FAZARI;ANNAMARIA CUFFINI;B. BROGLIATTI;ORNELLA CERVETTI;M PAGLIANO;VALERIA ALLIZOND;MICHELE PANZONE;DANIELA DOMPÈ","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANNAMARIA FERRERO;C M CRACCO;DANIELA DOMPÈ;EUGENIO VOLPI;MARCO TAMIETTO;M. MOSTERT;C. PERONI;ANGELA SARDO;CESARE GREGORETTI;TERESA ROLLE;FEDERICO GRIGNOLO;ANTONIO MARIA FEA;B. BROGLIATTI;ELEONORA COCCO;ADRIANO CHIÒ;AGUSTINA FORNERO;A. GOMEZ;PAOLO GHIGLIONE;L. FAZARI;M PAGLIANO","0.25;0.25;0.25;0.25;0.17;0.17;0.15;0.15;0.14;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.09;0.08","A BRICCOLI;ALESSANDRA LONGHI;GAETANO BACCI;MICHELA VERSARI;PIERO PICCI;FRANCA FAGIOLI;ALBERTO COLOMBO;ANDREA DECENSI;D. CASADEI-GIUNCHI;FRANCO DESIDERIO;FRANCO MONASTEROLO;MARCELLO PERSICO;MARCO MAGGIONI;NICOLE ROTMENSZ;PAOLA CASTELLANA;PATRICK MAISONNEUVE;SAVINO BRUNO;SONIA ROSSI;TOMMASO STROFFOLINI;UMBERTO VERONESI","267;267;267;267;267;236;217;217;217;217;217;217;217;217;217;217;217;217;217;217","CESARE GREGORETTI;M. MOSTERT;M PAGLIANO;MARCO TAMIETTO;DIANELLA SAVOIA;ALBERTO BORIANO;ANGELA SARDO;C. J. SANZ FREIRE;C. PERONI;M. PORZIO;A. GOMEZ;ADRIANO CHIÒ;ANNAMARIA FERRERO;DANIELA DOMPÈ;ELEONORA COCCO;EUGENIO VOLPI;PAOLO GHIGLIONE;ANNARITA SASSO;GRAZIA FAVATA;C M CRACCO","91;82;74;73;51;44;44;44;44;44;10;10;10;10;10;10;10;8;8;2","A. GOMEZ;ADRIANO CHIÒ;ALBERTO BORIANO;ANGELA SARDO;ANNAMARIA FERRERO;ANNARITA SASSO;C M CRACCO;C. J. SANZ FREIRE;C. PERONI;CESARE GREGORETTI;DANIELA DOMPÈ;DIANELLA SAVOIA;ELEONORA COCCO;EUGENIO VOLPI;GRAZIA FAVATA;L. FAZARI;M PAGLIANO;M. MOSTERT;M. PORZIO;MARCO TAMIETTO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;PSYCHOLOGY;ENGINEERING;POLITICAL SCIENCE","42;16;7;4;2;2;2;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;PATHOLOGY;OBSTETRICS;PEDIATRICS;RADIOLOGY;ANATOMY;PSYCHIATRY;GASTROENTEROLOGY;ONCOLOGY;ANESTHESIA;GYNECOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;MICROBIOLOGY;NUCLEAR MEDICINE;OPTICS;PALEONTOLOGY;PHARMACOLOGY;VIROLOGY","28;11;11;10;8;7;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3","CANCER;PREGNANCY;CHEMOTHERAPY;GENE;RADIATION THERAPY;ALTERNATIVE MEDICINE;ADJUVANT;DISEASE;NEONATAL INTENSIVE CARE UNIT;NEUROLOGY;REGIMEN;ADVERSE EFFECT;ANTIBODY;ANTIFUNGAL;AREA UNDER THE CURVE;AUTONOMIC NERVE;CLINICAL TRIAL;CONFIDENCE INTERVAL;ENDOMETRIOSIS;INCIDENCE (GEOMETRY);INTERVENTIONAL RADIOLOGY;LAPAROSCOPY;OSTEOSARCOMA;PHARMACOKINETICS;POPULATION;RANDOMIZED CONTROLLED TRIAL;SEPSIS;SMALL INTESTINE;STAGE (STRATIGRAPHY);STROMAL CELL;TOXICITY","8;8;6;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;FETUS;GESTATIONAL AGE;GENOTYPE;CICLOSPORIN;KIDNEY TRANSPLANTATION;NEURORADIOLOGY;PLACEBO;STROMAL TUMOR;ADJUVANT RADIOTHERAPY;ADJUVANT THERAPY;AMYOTROPHIC LATERAL SCLEROSIS;ANAPLASTIC LARGE-CELL LYMPHOMA;ANTIFUNGAL DRUGS;ANTIMETABOLITE;APOLIPOPROTEIN E;BASAL (MEDICINE);BIRTH WEIGHT;BURKHOLDERIA;CANCER INCIDENCE;CANDIDA GLABRATA;CARBAMAZEPINE;CERVICAL CANCER;CHROMOSOME;CISPLATIN;CLONE (JAVA METHOD);COLORECTAL CANCER;COOMBS TEST;CORPUS ALBICANS;DEOXYCHOLIC ACID;DOCETAXEL;ESCHERICHIA COLI;EXON;FAMCICLOVIR;FATTY LIVER;FLUOROURACIL;GESTATION;GIST;HAZARD RATIO;HEAD AND NECK CANCER;HEART BLOCK;HEART RATE;HUMAN FACTORS AND ERGONOMICS;IMMUNE TOLERANCE;IMMUNOTHERAPY;INFERTILITY;INJURY PREVENTION;INTRON;IONIZATION;ISOCENTER;LINEAR PARTICLE ACCELERATOR;LOW BIRTH WEIGHT;MALACIA;MALIGNANT PLEURAL EFFUSION;MONOCLONAL ANTIBODY;MUCOSITIS;MULTICENTER STUDY;MUTANT;MUTATION;MYCOPHENOLATE;MYCOPHENOLIC ACID;OPEN ANGLE GLAUCOMA;PACLITAXEL;PHASES OF CLINICAL RESEARCH;PREGNANCY RATE;PROGRAMMED CELL DEATH;PROSTATE;PROSTATE CANCER;PROTOCOL (SCIENCE);PSYCHOEDUCATION;PSYCHOMOTOR LEARNING;PSYCHOMOTOR RETARDATION;RADIOSURGERY;RNA;SOMNOLENCE;STRIDOR;SUICIDE PREVENTION;T-CELL LYMPHOMA;THERAPEUTIC DRUG MONITORING;TITER;TOLERABILITY;TRACHEOMALACIA;UNIVARIATE ANALYSIS;UTEROSACRAL LIGAMENT;VIRAL DISEASE;Y CHROMOSOME","5;5;5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADJUVANT CHEMOTHERAPY;PRENATAL DIAGNOSIS;PULSED-FIELD GEL ELECTROPHORESIS;ANAPLASTIC LYMPHOMA KINASE;ANEUPLOIDY;ANTIBODY TITER;BRADYCARDIA;BURKHOLDERIA CENOCEPACIA;BURKHOLDERIA CEPACIA COMPLEX;CERVICAL CANCER SCREENING;EPIRUBICIN;FETAL HEAD;FETAL HEART;FOLINIC ACID;GENE MUTATION;HEMOLYTIC DISEASE OF THE NEWBORN (ABO);HERPESVIRIDAE;INTRAVENTRICULAR HEMORRHAGE;IONIZATION CHAMBER;LARYNGOMALACIA;MAMMARY GLAND;METASTATIC BREAST CANCER;MOLECULAR EPIDEMIOLOGY;MULTILEAF COLLIMATOR;MULTILOCUS SEQUENCE TYPING;MUTATION FREQUENCY;NEOADJUVANT THERAPY;OXCARBAZEPINE;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RETINOPATHY OF PREMATURITY;RNA SPLICING;SECOND TRIMESTER;SERRATIA MARCESCENS;SINGLE-NUCLEOTIDE POLYMORPHISM;SOD1;STEATOHEPATITIS;SYSTEMIC CANDIDIASIS;TAMOXIFEN;TESTIS DETERMINING FACTOR;TRASTUZUMAB;VINORELBINE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;BONE NEOPLASMS;ITALY;;MIDDLE AGED;NEOPLASM RECURRENCE, LOCAL;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;COLORECTAL NEOPLASMS;ENDOMETRIOSIS;OSTEOSARCOMA;AGED;INFANT, NEWBORN;ANTIBODIES, MONOCLONAL;CYCLOSPORINE;GESTATIONAL AGE;PREGNANCY","34;23;18;14;12;12;11;10;10;9;8;8;8;8;7;7;6;6;6;6","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF ENDOMETRIOSIS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;KIDNEY TRANSPLANTATION;PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES;RADIOTHERAPY PHYSICS AND TECHNOLOGY;SARCOMA RESEARCH AND TREATMENT;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;COLORECTAL CANCER RESEARCH AND TREATMENT;DEMAND RESPONSE IN SMART GRIDS;DEVELOPMENT AND CARE OF INFANT SKIN;DIAGNOSIS AND TREATMENT OF RETINOPATHY OF PREMATURITY;DISEASES RELATED TO BLOOD GROUP VARIANTS;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;ESOPHAGEAL INTERVENTION TECHNIQUES;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;GLYCOSYLATION IN HEALTH AND DISEASE","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ADJUVANT CHEMOTHERAPY;REGIMEN;AUTONOMIC NERVE;CICLOSPORIN;FETAL DNA ANALYSIS;INTERVENTIONAL RADIOLOGY;INVASIVE FUNGAL INFECTIONS;METASTATIC BREAST CANCER;NEOADJUVANT THERAPY;NEONATAL SKIN;NEURORADIOLOGY;OSTEOSARCOMA;PRENATAL DIAGNOSIS;STROMAL TUMOR;ACICLOVIR;ADJUVANT RADIOTHERAPY;ADJUVANT THERAPY;ALLOIMMUNIZATION;ANAPLASTIC LARGE-CELL LYMPHOMA;ANTIBODY TITER","3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","BREAST CANCER;AUTONOMIC NERVEGANGLIONIC;CANCER PATIENTS;FUNGAL INFECTIONS;GASTROINTESTINAL STROMAL;HUGE MASS;MESENTERIC GASTROINTESTINAL;NEOADJUVANT CHEMOTHERAPY;NERVEGANGLIONIC DIFFERENTIATION;PEDIATRIC KIDNEY;PRIMITIVE MESENTERIC;STROMAL TUMOR;SYNCHRONOUS NODULES;ACETATE TOCOPHEROL;ACIDS PROGRAMMED;ADJUVANT ANTHRACYCLINES;ADJUVANT CMF;ADJUVANT SYSTEMIC;AGENTI ANTIFUNGINI;AGLI AGENTI;ALS CAUSING;ANTIFUNGINI DI;ATRESIA MORPHOLOGICAL;AUTOMATED DETECTION;BACTERIAL SEPSIS;BENIGN PROSTATIC;BILE ACIDS;BIRTH WEIGHT;BLOOD LEVELS;BONE MARROW","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FATTY LIVER;FOREIGN IMMIGRANTS;CEPACIA COMPLEX;LIVER DISEASE;NON-ALCOHOLIC FATTY;PFGE CLUSTERS;RFLP TYPE;ANTI DC;ANTIBODIES ANTI;CF CENTERS;COLONIZED PATIENTS;CONTINUOUS INFUSION;CYCLOSPORINE MICROEMULSION;DRIVING SAFETY;EPIDEMIC CLONE;IONIZATION CHAMBERS;KIDNEY-TRANSPLANT RECIPIENTS;PEDIATRIC KIDNEY-TRANSPLANT;RECA RFLP;ANTI DCE;ANTI JKA;ANTI KELL;ANTIFUNGAL AGENTS;BOX-PCR CLONES;CANCER INCIDENCE;CANDIDA ALBICANS;CERVICAL CANCER;CF PATIENTS;COMPLEX ISOLATES;CONFIDENCE INTERVAL","6;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,0,2.7,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2006,30,9.3,2.13333333333333,0.166666666666667,0.1,0.133333333333333,1.06976744186047,1,0.75,1,0.233333333333333,1,11,12,4,2,0.37,0.4,0.13,0.07,42.3,0.828141830635956,NA,0.166666666666667,0.733333333333333,0.32,0.15,0.167,0.167,"RICCARDO ARISIO;PAOLO MANZONI;SAVERIO DANESE;ANTONIO DURANDO;MARIA PIA FORNERIS;GIOVANNI GUARALDI;FABIO PARAZZINI;IRENE TARDIVO;ELIO CASTAGNOLA;GIORGIO BOLIS;MARCO FLORIDIA;EMANUELA RABAIOTTI;CECILIA TIBALDI;MICHELA DONADIO;VELJKOVIC ALEKSANDAR;GIUSEPPE ROBERTO D’AGOSTINO;GIOVANNA SCARFONE;SILVIO DANESE;SAVERIO TATEO;ENRICA TAMBURRINI","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GIARIO CONTI;R VOLANTE;GUGLIELMO RONCO;PAOLO MANZONI;PIER LUIGI CALVO;M. BALDI;ELIO CASTAGNOLA;UGO SALA;PAOLO GALLETTO;MICHAEL MOSTERT;GIOVANNA GOMIRATO;RICCARDO ARISIO;ALESSANDRO MUSSA;C. BARBERA;MARIA PIA FORNERIS;FABIO PARAZZINI;IRENE TARDIVO;GIORGIO BOLIS;EMANUELA RABAIOTTI;VELJKOVIC ALEKSANDAR","1;0.5;0.5;0.48;0.45;0.45;0.33;0.33;0.33;0.33;0.33;0.33;0.25;0.25;0.22;0.22;0.22;0.22;0.22;0.22","ANTONIO DURANDO;MARIA PIA FORNERIS;IRENE TARDIVO;CECILIA TIBALDI;VELJKOVIC ALEKSANDAR;IACOPO BAUSSANO;MARIO CASTELLO;LUCIANO ANFOSSI;MICHAEL MOSTERT;ELISABETTA BIGNAMINI;FEDERICA CAVALLO;ALFREDO BERRUTI;IRENE ALABISO;M. MESITI;ANTONELLO LEZO;S. FRACCHIOLI;ROSSAMA BELLEZZA-FONTANA;GIUSEPPE PALADINI;LORENZO SILENGO;G. GORZEGNO","2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MICHAEL MOSTERT;MARIA PIA FORNERIS;IRENE TARDIVO;VELJKOVIC ALEKSANDAR;IACOPO BAUSSANO;MARIO CASTELLO;LUCIANO ANFOSSI;ELISABETTA BIGNAMINI;CECILIA TIBALDI;ANTONIO DURANDO;S. FRACCHIOLI;DIONYSSIOS KATSAROS;FABRIZIO BOGLIATTO;IRENE A. RIGAULT DE LA LONGRAIS;M. SCOZZAFAVA;L. MICHELETTI;M. PUOPOLO;ANTONELLO LEZO;ROSSAMA BELLEZZA-FONTANA;GUIDO GIUSTETTO","0.33;0.22;0.22;0.22;0.22;0.22;0.22;0.22;0.17;0.14;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.11;0.11;0.08","B. MASSIDDA;SAVERIO DANESE;A. FINI;A. RUBAGOTTI;CHIARA BENEDETTO;D. AMADORI;FRANCESCO BOCCARDO;FRANCO BUZZI;GIUSEPPE PALADINI;M. MESITI;M. RINALDINI;MAURO PORPIGLIA;N. RESTUCCIA;P SISMONDI;PAMELA GUGLIELMINI;ROBERTO FRANCHI;SILVIA SCALI;V. DISTANTE;RICCARDO ARISIO;ANTONIO DURANDO","335;276;220;220;220;220;220;220;220;220;220;220;220;220;220;220;220;220;191;161","GIUSEPPE PALADINI;M. MESITI;M. RINALDINI;MAURO PORPIGLIA;N. RESTUCCIA;AGATA A. TINNIRELLO;BRIGITTE BISARÒ;EMILIA TURCO;FEDERICA CAVALLO;FIORELLA ALTRUDA;GUIDO FORNI;GUIDO TARONE;LORENZO SILENGO;PAOLA DEFILIPPI;PAOLA DI STEFANO;SARA CABODI;GUIDO GIUSTETTO;CECILIA TIBALDI;MICHAEL MOSTERT;ALFREDO BERRUTI","220;220;220;220;220;134;134;134;134;134;134;134;134;134;134;134;78;59;56;36","CECILIA TIBALDI;IACOPO BAUSSANO;MICHAEL MOSTERT;AGATA A. TINNIRELLO;ALFREDO BERRUTI;ANTONELLO LEZO;ANTONIO DURANDO;ANTONIO PIGA;BRIGITTE BISARÒ;DIONYSSIOS KATSAROS;ELISABETTA BIGNAMINI;EMILIA TURCO;FABRIZIO BOGLIATTO;FEDERICA CAVALLO;FIORELLA ALTRUDA;G. GORZEGNO;GIUSEPPE PALADINI;GUIDO FORNI;GUIDO GIUSTETTO;GUIDO TARONE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE","28;8;4;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;PEDIATRICS;GYNECOLOGY;PATHOLOGY;GASTROENTEROLOGY;ONCOLOGY;OPTICS;OBSTETRICS;RADIOLOGY;ANESTHESIA;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;GENERAL SURGERY;IMMUNOLOGY;CANCER RESEARCH;CARDIOLOGY;CELL BIOLOGY;CHROMATOGRAPHY;DERMATOLOGY;ECOLOGY;ELECTRICAL ENGINEERING;ENDOCRINOLOGY;FOOD SCIENCE;LAW;MECHANICAL ENGINEERING;MEDICAL EMERGENCY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;NURSING;OPERATING SYSTEM;ORGANIC CHEMISTRY;QUANTUM MECHANICS;STATISTICS","23;8;7;7;6;6;5;5;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;PREGNANCY;DISEASE;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;RANDOMIZED CONTROLLED TRIAL;REGIMEN;BACTERIA;CARCINOMA;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;CYSTIC FIBROSIS;GENE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LAPAROTOMY;NEWBORN SCREENING;ODDS RATIO;POPULATION;PROSPECTIVE COHORT STUDY;SEPSIS","10;5;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CISPLATIN;OVARIAN CANCER;CERVICAL CANCER;FETUS;PSEUDOMONAS AERUGINOSA;ADENOCARCINOMA;AIRWAY RESISTANCE;ALLELE;BETHESDA SYSTEM;BIRTH WEIGHT;BRONCHOCONSTRICTION;BRONCHODILATOR;CAESAREAN SECTION;CARCINOGENESIS;CELL CYCLE;CLINICAL ENDPOINT;COINFECTION;ELECTROSPRAY IONIZATION;GALACTOSEMIA;GESTATIONAL AGE;GLYCAN;HAZARD RATIO;HEPATITIS B VIRUS;HISTIOCYTOSIS;HYPERCALCAEMIA;INFLAMMATORY BOWEL DISEASE;IONIZATION;ISOELECTRIC FOCUSING;LANGERHANS CELL HISTIOCYTOSIS;LAPAROSCOPIC SURGERY;LINEAR PARTICLE ACCELERATOR;LOW BIRTH WEIGHT;LUNG VOLUMES;MARSUPIALIZATION;METHEMOGLOBIN;MUTANT;MUTATION;NEPHRECTOMY;NEUROTOXICITY;PACLITAXEL;PANCREATIC DISEASE;PENUMBRA;PERIPHERAL NEUROPATHY;POLYMERASE CHAIN REACTION;PRIMARY NURSING;PROTEIN KINASE B;PYROSEQUENCING;QUALITY ASSURANCE;RARE DISEASE;RESPIRATORY DISEASE;SUBCUTANEOUS FAT;TOPOTECAN;TRANSGENE;TRIGLYCERIDE;TYROSINE KINASE;UNIVARIATE ANALYSIS;UTERINE CERVIX;VAGINAL DELIVERY;VIRAL DISEASE;VIRAL LOAD;VULVAR CANCER","5;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CERVICAL INTRAEPITHELIAL NEOPLASIA;MECONIUM;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;CARBOPLATIN;CERVICAL CANCER SCREENING;CERVICAL SCREENING;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;COLPOSCOPY;DIGITAL POLYMERASE CHAIN REACTION;ENDOCERVIX;FUNCTIONAL RESIDUAL CAPACITY;GENETICALLY MODIFIED MOUSE;HYPERTRIGLYCERIDEMIA;IONIZATION CHAMBER;LAMIVUDINE;MAMMARY GLAND;METASTATIC BREAST CANCER;METHACHOLINE;MULTILEAF COLLIMATOR;ONCOGENE;PAP SMEARS;RETINOPATHY OF PREMATURITY;SURGICAL NURSING;TAMOXIFEN;TRASTUZUMAB;ZIDOVUDINE","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;BREAST NEOPLASMS;MALE;ITALY;ADENOCARCINOMA;ADULT;MIDDLE AGED;UTERINE CERVICAL NEOPLASMS;;ANTINEOPLASTIC AGENTS;INFANT;INFANT, NEWBORN;CHILD, PRESCHOOL;MAMMARY NEOPLASMS, EXPERIMENTAL;MASS SCREENING;MOUTH DISEASES;OVARIAN NEOPLASMS;TREATMENT OUTCOME;AGED","23;19;15;11;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;4","EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLYCOSYLATION IN HEALTH AND DISEASE;HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;CUTANEOUS MANIFESTATIONS OF COVID-19: A COMPREHENSIVE REVIEW;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF RETINOPATHY OF PREMATURITY;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GLOBAL MATERNAL AND CHILD HEALTH OUTCOMES;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;MANAGEMENT AND TREATMENT OF TUMOR LYSIS SYNDROME;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;PEDIATRIC URINARY TRACT INFECTIONS;PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;REGIMEN;CYSTIC FIBROSIS;CYTOLOGY SCREENING;INVASIVE INFECTIONS;MECONIUM ILEUS;ANASTROZOLE;ANTIRETROVIRAL THERAPY;BETHESDA SYSTEM;BLADDER CANCER;CANCER STEM CELLS;CANCER THERAPY;CARBOPLATIN;CERVICAL SCREENING;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;CLINICAL ENDPOINT;COLLIMATOR;CONCORDANCE;DIDANOSINE;DNA NANOTECHNOLOGY","3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OVARIAN CANCER;BREAST CANCER;ADVANCED OVARIAN;AFFECT TIME;CANCER PATIENTS;CANCER RESULTS;CONSOLIDATION THERAPY;CYSTIC FIBROSIS;EPIDOXORUBICIN VERSUS;FUNGAL INFECTION;II STUDY;INVASIVE FUNGAL;NATIONAL SURVEY;NEONATAL SCREENING;PHASE II;PREGNANT WOMEN;PRETERM NEONATES;ADVANCED BREAST;ANASTROZOLE ITA;ANASTROZOLE VERSUS;ANTIRETROVIRAL THERAPY;ASSURANCE PROGRAM;ATYPICAL GLANDULAR;BLADDER CARCINOMADISCUSSION;BONE ULTRASOUND;BOWEL DISEASE;BREAST TUMORIGENESIS;BREAST-LIKE CANCER;CANCER MITO-;CANCER PROGRESSING","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;TRASTUZUMAB-BASED THERAPY;PREVIOUSLY UNDETECTED;RESIDUAL NEUROPATHY;ADVANCED BREAST;ADVANCED OVARIAN;HER-POSITIVE ADVANCED;HIV INFECTION;MAMMARY EPITHELIAL;OVARIAN CANCER;UNDETECTED HIV;ANTIRETROVIRAL TREATMENT;CANCER INSTITUTE;CANCER PATIENTS;CANCER PROGRESSING;CHEMOTHERAPY PATIENTS;CLINICAL OUTCOME;DOUBLE-TRANSGENIC MICE;ENDOCRINE THERAPY;EPITHELIAL CELLS;FIRST-LINE CARBOPLATINPACLITAXEL;GALACTOSE UNITS;HR CI;MASS SPECTROMETRY;MONTHS RANGE;NATIONAL CANCER;NEUROLOGICAL TOXICITY;NODE-POSITIVE ER-POSITIVE;PATIENTS RECEIVED;POST-PROGRESSION TREATMENT","5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,0,2.78,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1",NA,NA,"CANCER","1","6.1 PHARMACEUTICALS","1","BREAST CANCER","1",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2007,33,12.2727272727273,2.63636363636364,0.151515151515152,0.181818181818182,0.151515151515152,1.53333333333333,1,1.5,1,0.424242424242424,0,24,3,3,2,0.73,0.09,0.09,0.06,49.36,0.935342671628434,NA,0.333333333333333,0.878787878787879,0.446,0.173,0.333,0.173,"RICCARDO ARISIO;TULLIA TODROS;V. CIRIMINNA;M. MENSA;GUGLIELMO RONCO;GIOVANNA OGGÈ;M. OBERTO;P. GAGLIOTI;VANIA VEZZOSI;ANGELIKA REINER‐CONCIN;STEN THORSTENSON;ISABEL AMENDOEIRA;THOMAS DECKER;SIMONETTA BIANCHI;GÁBOR CSERNI;MARIA PIA FOSCHINI;JANINA KULKA;BRUNO GHIRINGHELLO;M. DRIJKONINGEN;ANNA SAPINO","5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","GUGLIELMO RONCO;VALENTINA ROVEI;ALESSANDRA GRAZIOTTIN;TULLIA TODROS;V. CIRIMINNA;M. MENSA;GIOVANNA OGGÈ;M. OBERTO;P. GAGLIOTI;PAMELA GIUBILATO;RICCARDO ARISIO;M CAMPOGRANDE;R VOLANTE;S. BASTONERO;ANDREA SCIARRONE;S. STILLAVATO;G. ERRANTE;E. VIORA;BRUNO GHIRINGHELLO;GABRIELE CENTINI","0.55;0.5;0.5;0.43;0.43;0.43;0.43;0.43;0.43;0.4;0.36;0.34;0.33;0.29;0.29;0.29;0.29;0.29;0.22;0.2","RICCARDO ARISIO;TULLIA TODROS;V. CIRIMINNA;M. MENSA;GIOVANNA OGGÈ;M. OBERTO;P. GAGLIOTI;ANNA SAPINO;G ROSSETTI;ENRICO BERTINO;ISABELLA CASTELLANO;C FABRIS;FRANCA DANIELLE;GIOVANNI BATTISTA FERRERO;ROBERTO GUASCHINO;FRANCO CURTI;VALENTINA ROVEI;ANTONINA SMEDILE;M. VACCHINI;FRANCO CASTAGNO","5;4;4;4;4;4;4;3;2;2;2;2;1;1;1;1;1;1;1;1","VALENTINA ROVEI;TULLIA TODROS;V. CIRIMINNA;M. MENSA;GIOVANNA OGGÈ;M. OBERTO;P. GAGLIOTI;RICCARDO ARISIO;G ROSSETTI;ENRICO BERTINO;C FABRIS;ANNA SAPINO;M. SCATÀ;D. DANELON;FRANCESCO PORTA;M MOMBRÒ;G.L. PANATTONI;GIOVANNI BATTISTA FERRERO;ISABELLA CASTELLANO;ALBERTO BORRACCINO","0.5;0.43;0.43;0.43;0.43;0.43;0.43;0.36;0.18;0.18;0.18;0.16;0.12;0.12;0.12;0.12;0.12;0.11;0.1;0.1","RICCARDO ARISIO;DANIELE FARINA;GIOVANNA GOMIRATO;PAOLO MANZONI;GUGLIELMO RONCO;C. GIOVANNOZZI;CRISTIANA MAGNANI;ELISABETTA TRIDAPALLI;FABIO MOSCA;FRANCO MERLETTI;G VETRANO;GIUSEPPINA CORONA;ILARIA STOLFI;LIDIA DECEMBRINO;LORENZA PUGNI;MAURO STRONATI;MICHAEL MOSTERT;MILENA MAULE;ROBERTO PEDICINO;BRUNO GHIRINGHELLO","477;409;409;409;343;337;337;337;337;337;337;337;337;337;337;337;337;337;337;332","FRANCO MERLETTI;MICHAEL MOSTERT;MILENA MAULE;RICCARDO ARISIO;ADRIANO CHIÒ;A. PIZZI;ANTONINA SMEDILE;CHIARA VALPREDA;DOUGLAS TESTA;FRANCA DANIELLE;FRANCO CASTAGNO;FRANCO CURTI;M. GIROTTO;M. VACCHINI;MARIA LORENA ABATE;MARIO RIZZETTO;MARION C. LANTERI;OSVALDO GIACHINO;P. GHIAZZA;PAOLA MAGISTRONI","337;337;337;337;225;105;105;105;105;105;105;105;105;105;105;105;105;105;105;105","GIOVANNA OGGÈ;M. MENSA;M. OBERTO;P. GAGLIOTI;TULLIA TODROS;V. CIRIMINNA;ANNA SAPINO;ISABELLA CASTELLANO;A. PIZZI;ADRIANO CHIÒ;ALBERTO BORRACCINO;ANTONINA SMEDILE;CHIARA VALPREDA;D. DANELON;DOUGLAS TESTA;FRANCA DANIELLE;FRANCESCO PORTA;FRANCO CASTAGNO;FRANCO CURTI;FRANCO MERLETTI","4;4;4;4;4;4;3;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY;ENGINEERING;MATERIALS SCIENCE;PHYSICS;POLITICAL SCIENCE","32;18;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;GENETICS;GYNECOLOGY;PATHOLOGY;OBSTETRICS;PEDIATRICS;RADIOLOGY;CARDIOLOGY;ONCOLOGY;INTENSIVE CARE MEDICINE;ANATOMY;SURGERY;BOTANY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;GASTROENTEROLOGY;IMMUNOLOGY;LINGUISTICS;PSYCHIATRY;STATISTICS;UROLOGY;VIROLOGY","26;16;10;10;9;8;8;5;5;4;3;3;2;2;2;2;2;2;2;2;2;2","PREGNANCY;CANCER;RANDOMIZED CONTROLLED TRIAL;BIOPSY;CHEMOTHERAPY;CONFIDENCE INTERVAL;CYTOLOGY;GENE;LYMPH NODE;ULTRASOUND;ALTERNATIVE MEDICINE;ANTIBODY;BLOOD FLOW;CONCORDANCE;LUNG;MEDICAL DIAGNOSIS;POPULATION;TRISOMY;ALLERGY;ANTIFUNGAL;ANTIGEN;ASTHMA;BASEMENT MEMBRANE;BLOOD PRESSURE;BODY MASS INDEX;BONE AGE;BONFERRONI CORRECTION;CEREBRAL BLOOD FLOW;CHARACTERIZATION (MATERIALS SCIENCE);CHEMOPROPHYLAXIS;CHINA;COHEN'S KAPPA;CONCOMITANT;CORONARY SINUS;CRANIOSYNOSTOSIS;CROSS-SECTIONAL STUDY;CZECH;DIALYSIS;DISEASE;DOWN SYNDROME;ELECTROPHYSIOLOGY;EPIDEMIOLOGY;FOLLICULAR PHASE;GENETIC TESTING;GROWTH CHART;GROWTH VELOCITY;HEMODIALYSIS;HEMODYNAMICS;HEPATITIS B;HISTOLOGY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);HUMAN SEXUALITY;HYPERPLASIA;HYSTERECTOMY;IMMUNOHISTOCHEMISTRY;INTENSIVE CARE;INTENSIVE CARE UNIT;KAPPA;LATERAL VENTRICLES;LEUKEMIA;LIBIDO;LYMPH;MITE;MULTIPLE COMPARISONS PROBLEM;NEONATAL INTENSIVE CARE UNIT;ODDS RATIO;PENICILLIUM;PERFUSION;POTASSIUM CHANNEL;PRESENTATION (OBSTETRICS);PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;PSYCHOSOCIAL;PUBLIC HEALTH;PULMONARY FUNCTION TESTING;QT INTERVAL;RECEIVER OPERATING CHARACTERISTIC;REFERENCE VALUES;REFERRAL;REPRODUCIBILITY;RESIDUAL RISK;RESPIRATORY SYSTEM;RESUSCITATION;SENSITIZATION;SEXUAL DYSFUNCTION;SEXUAL FUNCTION;SPINA BIFIDA;SPORE;STATEMENT (LOGIC);SUDDEN CARDIAC DEATH;SUDDEN DEATH;SUDDEN INFANT DEATH SYNDROME;THORAX (INSECT ANATOMY);TOXICITY;TRANSMISSION (TELECOMMUNICATIONS);TRANSPLANTATION;URINARY SYSTEM;VELOCIMETRY;VENTRICLE;VIRUS;YOUNG ADULT","13;10;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FETUS;BREAST CANCER;GESTATIONAL AGE;CERVICAL CANCER;GESTATION;BIRTH WEIGHT;LOW BIRTH WEIGHT;NEONATOLOGY;3D ULTRASOUND;ALLERGEN;AMYOTROPHIC LATERAL SCLEROSIS;ASCOSPORE;ATOPY;BETHESDA SYSTEM;CHEMOTHERAPY REGIMEN;CLADOSPORIUM;CONGENITAL MALFORMATIONS;CRANIOSYNOSTOSES;CYCLOPHOSPHAMIDE;CYTOKERATIN;FLUCONAZOLE;GENOTYPE;H&E STAIN;HAZARD RATIO;HEPATITIS B VIRUS;HERG;IMMUNOGLOBULIN E;LASER DOPPLER VELOCIMETRY;LOCUS (GENETICS);LONG QT SYNDROME;LUNG FUNCTION;LUNG VOLUMES;LUTEAL PHASE;LYMPHOBLASTIC LEUKEMIA;MELPHALAN;METASTASIS;MICROBUBBLES;MULTICENTER STUDY;NEUTROPENIA;OCCULT;PERSISTENT LEFT SUPERIOR VENA CAVA;PLACEBO;POLYMERASE CHAIN REACTION;POWER DOPPLER;PROSTATE;REPOLARIZATION;SEROLOGY;SPIROMETRY;SYPHILIS;VENOUS RETURN CURVE","9;5;5;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CERVICAL INTRAEPITHELIAL NEOPLASIA;PRENATAL DIAGNOSIS;SENTINEL LYMPH NODE;SMALL FOR GESTATIONAL AGE;CERVICAL SCREENING;COLPOSCOPY;INTRAUTERINE GROWTH RESTRICTION;LIQUID-BASED CYTOLOGY;ACUTE LYMPHOCYTIC LEUKEMIA;AIRBORNE ALLERGEN;ASCUS (BRYOZOA);AXILLA;AXILLARY LYMPH NODES;CERVICAL CARCINOMA;DIFFUSING CAPACITY;FETAL GROWTH;FETAL WEIGHT;FIRST TRIMESTER;FUNCTIONAL RESIDUAL CAPACITY;GENOTYPING;HBSAG;HOUSE DUST MITE;LOWER URINARY TRACT SYMPTOMS;LYMPH NODE METASTASIS;LYMPHEDEMA;MASTECTOMY;MECHANICAL INDEX;MICROMETASTASIS;MULTICENTER TRIAL;PLACENTA;SENTINEL NODE;SEXUALLY TRANSMITTED DISEASE;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN;UMBILICAL ARTERY;VENTRICULOMEGALY;VINCRISTINE;WINDOW PERIOD","4;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;BREAST NEOPLASMS;UTERINE CERVICAL NEOPLASMS;CERVICAL INTRAEPITHELIAL NEOPLASIA;;MALE;MIDDLE AGED;ITALY;MASS SCREENING;INFANT, PREMATURE, DISEASES;CYTOLOGICAL TECHNIQUES;HEPATITIS B;VAGINAL SMEARS;AGED;EUROPE;ADENOCARCINOMA;AGED, 80 AND OVER;ALLERGENS","23;19;15;13;13;12;10;10;10;9;9;7;6;6;6;5;5;4;4;4","HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MOLECULAR RESEARCH ON BREAST CANCER;DEVELOPMENT AND DISORDERS OF FETAL BRAIN;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ATOPIC DERMATITIS AND SKIN MICROBIOME;CANCER SURVIVORSHIP AND QUALITY OF LIFE;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND MANAGEMENT OF ECTOPIC PREGNANCY;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;EXERCISE PHYSIOLOGY AND CARDIOVASCULAR HEALTH;GENETICS AND DEVELOPMENT OF CRANIOFACIAL ABNORMALITIES;HEPATITIS B INFECTION AND TREATMENT;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PATHOGENESIS AND TREATMENT OF OSTEONECROSIS;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION","4;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CYTOLOGY SCREENING;TRISOMY DETECTION;BREAST CANCER;CERVICAL SCREENING;CONCORDANCE;FETAL DEVELOPMENT;FETAL DNA ANALYSIS;FETAL MRI;INTRAUTERINE GROWTH RESTRICTION;LIQUID-BASED CYTOLOGY;LOW BIRTH WEIGHT;MATERNAL WEIGHT GAIN;NEONATOLOGY;NEUROSONOGRAPHY;SQUAMOUS INTRAEPITHELIAL LESION;TRISOMY;3D ULTRASOUND;ABDOMINAL WALL DEFECTS;ACUTE LYMPHOCYTIC LEUKEMIA;AIRBORNE ALLERGEN","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","BREAST CANCER;LYMPH NODE;BREAST CARCINOMAS;CANCER SCREENING;CERVICAL CANCER;CONTROLLED TRIAL;NODE BIOPSY;NODE INVOLVEMENT;PRETERM NEONATES;SENTINEL LYMPH;SMALL-FOR-GESTATIONAL AGE;ABSTRACT ELECTROCARDIOGRAPHIC;ACUTE LYMPHOBLASTIC;ADJUVANT CHEMOTHERAPY;AGE FETUSES;AGE WEEKS;AIEOP-ALL- TRIAL;ALLERGEN EXPOSURE;AMYOTROPHIC LATERAL;AUTOMATED MOLECULAR;BASED VERSUS;BENIGN PROSTATIC;BFM-BASED CHEMOTHERAPY;BIRTH WEIGHT;BLOOD DONORS;BLOOD FLOW;BONE ALTERATIONS;BRAIN VASCULARIZATION;CANCER FINDINGS;CANCER PATIENTS","3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AOR CI;BASED CYTOLOGY;LIQUID BASED;POSITIVE PREDICTIVE;CERVICAL INTRAEPITHELIAL;CONVENTIONAL CYTOLOGY;FETAL BRAIN;GESTATIONAL AGE;INTRAEPITHELIAL NEOPLASIA;RELATIVE SENSITIVITY;BLOOD DONORS;CHORIONIC VILLUS;FEV FEV;PREGNANT WOMEN;VFI VALUES;VI FI;ADJUVANT CHEMOTHERAPY;BASEMENT MEMBRANE;BLINDLY REVIEWED;BLOOD SUPPLY;BRAIN PERFUSION;CELLSMM AOR;CERVICAL CANCER;CIN DIAGNOSES;CONFIDENCE INTERVAL;CYTOLOGIC FINDINGS;EFFECTIVE TOOL;FACILITATES INFORMED;GENITAL LESIONS;HBV INFECTION","6;6;6;5;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2008,35,9.85714285714286,1.48571428571429,0.0857142857142857,0.0857142857142857,0.0857142857142857,1.2,0.75,0.75,0.75,0.2,0,11,12,5,4,0.31,0.34,0.14,0.11,49.23,0.897154968681916,NA,0.457142857142857,0.885714285714286,0.298,0.333,0.167,0.333,"RICCARDO ARISIO;PAOLO MANZONI;DANIELE FARINA;ANTONIO DURANDO;LINA MU;CECILIA TIBALDI;DIONYSSIOS KATSAROS;HERBERT YU;LINGENG LU;MICHAEL MOSTERT;GIOVANNI AGRIESTI;VALERIA SAVASI;G. MARINO;LUCA GASTALDO;MARIO PRETI;ANDREA CALVO;CLAIRE THORNE;FEDERICA LOMBARDO;MARIA AGNESE LATINO;LUCA SBAIZ","5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","RICCARDO ARISIO;PAOLO MANZONI;DANIELE FARINA;G. MARINO;M LAUDI;PAOLO ZOLA;LORENZO CAPUSSOTTI;MICHAEL MOSTERT;LINA MU;DIONYSSIOS KATSAROS;HERBERT YU;LINGENG LU;PAOLA COPPO;EUGENIA ROTA;SÍLVIA DE PAULA LEAO COSTA;ANTONIO DURANDO;MARIO PRETI;CECILIA TIBALDI;MAURO PORPIGLIA;DAVID KAUFMAN","0.71;0.53;0.53;0.5;0.5;0.5;0.5;0.48;0.37;0.37;0.37;0.37;0.33;0.33;0.33;0.32;0.27;0.25;0.25;0.25","PAOLO MANZONI;ANTONIO DURANDO;CECILIA TIBALDI;DIONYSSIOS KATSAROS;MICHAEL MOSTERT;MARIO PRETI;ANDREA CALVO;ADRIANO CHIÒ;ROBERTO CANAPARO;ROBERTO GNAVI;MAURO PORPIGLIA;ALESSANDRA CHINAGLIA;ROBERTA PICARIELLO;CHIARA BENEDETTO;CARLOTTA CASTAGNOLI;PRISCA SOZZANI;OLGA SOCHIRCA;ANNA ORLANDO;G MILLESIMO;IRENE A. RIGAULT DE LA LONGRAIS","4;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","PAOLO MANZONI;MICHAEL MOSTERT;DIONYSSIOS KATSAROS;ANTONIO DURANDO;MARIO PRETI;CECILIA TIBALDI;MAURO PORPIGLIA;CHIARA BENEDETTO;PRISCA SOZZANI;ANDREA CALVO;ADRIANO CHIÒ;ROBERTO GNAVI;ALESSANDRA CHINAGLIA;ROBERTA PICARIELLO;ANNA ORLANDO;G MILLESIMO;GIUSEPPE STEFFENINO;CARLOTTA CASTAGNOLI;L TARENZI;OLGA SOCHIRCA","0.53;0.48;0.37;0.32;0.27;0.25;0.25;0.25;0.25;0.24;0.24;0.17;0.17;0.17;0.17;0.17;0.17;0.11;0.11;0.1","RICCARDO ARISIO;ANTONIO DURANDO;DIONYSSIOS KATSAROS;HERBERT YU;LINA MU;LINGENG LU;ANNA GILLIO‐TOS;ANNAROSA DEL MISTRO;CARLO NALDONI;D MINUCCI;FRANCESCA CAROZZI;GUGLIELMO RONCO;JACK CUZICK;MANUEL ZORZI;MARCO ZAPPA;MASSIMO CONFORTINI;NEREO SEGNAN;PAOLO GIORGI ROSSI;PAOLO PALMA;PATRIZIA SCHINCAGLIA","439;318;318;318;318;318;298;298;298;298;298;298;298;298;298;298;298;298;298;298","DIONYSSIOS KATSAROS;ANNA GILLIO‐TOS;ANTONIO DURANDO;MARIO PRETI;MICHAEL MOSTERT;PAOLO MANZONI;CARLOTTA CASTAGNOLI;CHIARA BENEDETTO;IRENE A. RIGAULT DE LA LONGRAIS;MAURO PORPIGLIA;OLGA SOCHIRCA;PRISCA SOZZANI;ADRIANO CHIÒ;ANDREA CALVO;L TARENZI;ALESSANDRA CHINAGLIA;ANNA ORLANDO;G MILLESIMO;GIUSEPPE STEFFENINO;ROBERTA PICARIELLO","318;298;289;289;94;71;37;29;29;29;29;29;21;21;21;9;9;9;9;9","DIONYSSIOS KATSAROS;ANTONIO DURANDO;MARIO PRETI;MICHAEL MOSTERT;ADRIANO CHIÒ;ALESSANDRA CHINAGLIA;ANDREA CALVO;ANNA GILLIO‐TOS;ANNA ORLANDO;CARLOTTA CASTAGNOLI;CECILIA TIBALDI;CHIARA BENEDETTO;G MILLESIMO;GIUSEPPE STEFFENINO;IRENE A. RIGAULT DE LA LONGRAIS;L TARENZI;MAURO PORPIGLIA;OLGA SOCHIRCA;PAOLO MANZONI;PRISCA SOZZANI","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;SOCIOLOGY;ENGINEERING;CHEMISTRY;GEOGRAPHY;POLITICAL SCIENCE","33;14;3;3;2;1;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;ONCOLOGY;OBSTETRICS;PATHOLOGY;PEDIATRICS;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;SURGERY;DEMOGRAPHY;GASTROENTEROLOGY;UROLOGY;VIROLOGY;BIOCHEMISTRY;CANCER RESEARCH;CARDIOLOGY;DERMATOLOGY;FAMILY MEDICINE;MICROBIOLOGY;OPTICS;PHARMACOLOGY;RADIOLOGY","26;11;9;7;6;6;6;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;DISEASE;GENE;VIRUS;POPULATION;PREGNANCY;CONFIDENCE INTERVAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);NEONATAL INTENSIVE CARE UNIT;PROPORTIONAL HAZARDS MODEL;REGIMEN;ANTIFUNGAL;ANTIGEN;COHORT;COLONIZATION;HEPATITIS C;INCIDENCE (GEOMETRY);RECEPTOR;SEPSIS;TRANSFORMING GROWTH FACTOR;UTERUS","11;6;6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;HEPATITIS B VIRUS;COLORECTAL CANCER;GENOTYPE;AMYOTROPHIC LATERAL SCLEROSIS;BLADDER CANCER;CANDIDA INFECTIONS;FLUCONAZOLE;HAZARD RATIO;HEPATITIS C VIRUS;NEONATAL SEPSIS;PHENOTYPE;ACETYLCHOLINE RECEPTOR;ANDROGEN;ANTIDEPRESSANT;CANCER ANTIGEN;CANDIDA GLABRATA;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;CHLAMYDIAL INFECTION;COINFECTION;CYTOTOXIC T CELL;DEGENERATIVE DISEASE;DENDRITIC CELL;DIENOGEST;DYDROGESTERONE;EPITOPE;FERTILITY;FETUS;GESTATION;GESTATIONAL AGE;GROWTH FACTOR;HEALTH SERVICES;HEART RATE;INFLAMMATORY BOWEL DISEASE;INFORMED CONSENT;INTERSTITIAL LUNG DISEASE;LOW BIRTH WEIGHT;MALT LYMPHOMA;MEGESTROL ACETATE;MESSENGER RNA;METASTASIS;MICRORNA;MUTANT;MUTATION;PERCUTANEOUS CORONARY INTERVENTION;PRION PROTEIN;PROGESTIN;PROSTATE CANCER;PSEUDOLYMPHOMA;RADICAL SURGERY;RARE DISEASE;RESEARCH METHODOLOGY;RESPIRATORY DISEASE;SEROLOGY;SEXUAL INTERCOURSE;ST ELEVATION;ST SEGMENT;TGF BETA SIGNALING PATHWAY;THROMBOLYSIS;TOLERABILITY;VIRAL DISEASE;VIRAL LOAD","5;4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HBSAG;CYSTECTOMY;SOD1;ACTIVIN TYPE 2 RECEPTORS;BAROREFLEX;BONE METASTASIS;BREAST DISEASE;BRONCHUS;CANDIDA KRUSEI;CD40;CERVICAL INTRAEPITHELIAL NEOPLASIA;CETUXIMAB;CHLORMADINONE ACETATE;CITALOPRAM;COLPOSCOPY;CYPROTERONE ACETATE;FAMILY PLANNING;GENOTYPE-PHENOTYPE DISTINCTION;HEPATITIS DELTA;HORMONE RECEPTOR;INFLAMMATORY BOWEL DISEASES;INSULIN-LIKE GROWTH FACTOR 2;METASTATIC BREAST CANCER;MUCOSA-ASSOCIATED LYMPHOID TISSUE;NORETHISTERONE;PAPILLOMAVIRIDAE;PENETRANCE;PRENATAL DIAGNOSIS;PRIMARY ANGIOPLASTY;PRNP;RETINOPATHY OF PREMATURITY;RIBAVIRIN;SIDA;THIOPURINE METHYLTRANSFERASE;TRASTUZUMAB","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;BREAST NEOPLASMS;MIDDLE AGED;;ADULT;AGED;HIV INFECTIONS;ITALY;MALE;PREGNANCY COMPLICATIONS, INFECTIOUS;AGED, 80 AND OVER;CANDIDIASIS;MUTATION;SUPEROXIDE DISMUTASE;EUROPE;AMYOTROPHIC LATERAL SCLEROSIS;ANTIBODIES, MONOCLONAL;BONE NEOPLASMS;DISEASE PROGRESSION","24;20;18;13;11;11;11;11;10;8;7;6;6;6;6;5;4;4;4;4","HEPATITIS B INFECTION AND TREATMENT;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;HEPATITIS C INFECTION AND TREATMENT;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATOPIC DERMATITIS AND SKIN MICROBIOME;CANCER OF UNKNOWN PRIMARY SITE;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF SJÖGREN'S SYNDROME;GENE THERAPY FOR SPINAL MUSCULAR ATROPHY;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GLYCOSYLATION IN HEALTH AND DISEASE;HER2 SIGNALING IN BREAST CANCER TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;INNATE IMMUNE RECOGNITION AND SIGNALING PATHWAYS;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;HBV INFECTION;REGIMEN;CANDIDA INFECTIONS;HEPATITIS C;HIV;HIV EPIDEMIOLOGY;IGF-1;NEONATAL SEPSIS;URINARY DIVERSION;ANTIFUNGAL RESISTANCE;ANTIGEN PRESENTATION;ANTIRETROVIRAL THERAPY;AUTISM;BONE METASTASIS;BONE PAIN;BREAST CANCER;BREAST CANCER SCREENING;BREAST DISEASE;CANCER ANTIGEN","6;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;PREGNANT WOMEN;COLON-RECTAL CANCER;SURGICAL PROCEDURES;UROLOGIC SURGICAL;UTERUS NEOPLASM;ACETYLCHOLINE RECEPTOR;ACUTE ST-ELEVATION;ADULTONSET ATAXIA;ADVANCED BREAST;AKINESIA DEFORMATION;ALENDRONATE THERAPY;ALS POPULATION;ANTIGEN EXPRESSION;BAROREFLEX SENSITIVITY;BASELINE FEATURES;BLOOD DONORS;BONE OBSERVATIONAL;BOVINE LACTOFERRIN;BOWEL DISEASE;BRONCHUS-ASSOCIATED LYMPHOID;CANCER METASTASES;CANCER OUTCOMES;CANCER PROGRESSING;CANCER SCREENING;CANDIDA SUBSPECIES;CARE UNIT;CARE UNITS;CARRYING GENOTYPE;CDSUPSUPT-CELL COUNTS","5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BLOOD PRESSURE;HBV-DNA LEVELS;HPV TESTING;RELATIVE SENSITIVITY;CHRNA CHRNB;CHRNB CHRND;CONVENTIONAL CYTOLOGY;HPV DNA;LETHAL MULTIPLE;MULTIPLE PTERYGIUM;MYASTHENIC SYNDROME;PTERYGIUM SYNDROME;WOMEN AGED;BREAST CANCER;CD T-CELL;HIV RNA;HIV-INFECTED WOMEN;INTERVENTRICULAR SEPTUM;PG MG;PREGNANT WOMEN;TT GENOTYPE;ABORTIONS FETAL;ACETYLCHOLINE RECEPTOR;ACHR COMPONENTS;ACHR SUBUNITS;AKINESIA DEFORMATION;ALTERATIONS RESULT;ANTIRETROVIRAL TREATMENT;CANCER SCREENING;CARDIAC DEFECTS","5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,11.33,487.17,28.57,2,0.33,16,0,0,1,0,3,0,0,2,0,6,0,0,0,0,0,0,0,4,2,0,6,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","6;3;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;AGING;PATIENT SAFETY;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;BIOTECHNOLOGY;BREAST CANCER;CHILDHOOD LEUKEMIA;ORPHAN DRUG;OSTEOPOROSIS;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;PREVENTION;REGENERATIVE MEDICINE","6;6;5;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","5;1","BREAST CANCER;ENDOMETRIAL CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA","1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;3.3 CHEMOPREVENTION","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2009,28,11.5,1.71428571428571,0.214285714285714,0.142857142857143,0.214285714285714,1.1,0.857142857142857,0.8,0.857142857142857,0.392857142857143,0,14,9,1,3,0.5,0.32,0.04,0.11,35.32,0.763587324845026,NA,0.25,0.857142857142857,0.347,0.278,0.15,0.278,"PAOLO MANZONI;CECILIA TIBALDI;DANIELE FARINA;MARCO FLORIDIA;ENRICA TAMBURRINI;SERENA DALZERO;M. RAVIZZA;GIANFRANCO ANZIDEI;GABRIELLA RESTAGNO;CARMELA PINNETTI;GIOVANNI GUARALDI;CLAUDIO PRIOLO;A. MOLINARI;CHIARA BENEDETTO;PAMELA GIUBILATO;GUGLIELMO RONCO;ALESSANDRA MELONI;ROBERTA GUARDIONE;BRUNELLA GUERRA;VANNA PECILE","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1","PAOLO MANZONI;DANIELE FARINA;CHIARA BENEDETTO;PAMELA GIUBILATO;GUGLIELMO RONCO;CECILIA TIBALDI;SIMONA PELISSETTO;GIOVANNI SUCCO;BRUNO BATTISTON;R VOLANTE;ERIKA CROSETTI;LEONARDO MICHELETTI;GABRIELLA RESTAGNO;MARCO FLORIDIA;ENRICA TAMBURRINI;SERENA DALZERO;M. RAVIZZA;GIANFRANCO ANZIDEI;CLAUDIO PRIOLO;ROBERTA GUARDIONE","0.67;0.53;0.5;0.4;0.4;0.4;0.33;0.33;0.33;0.33;0.33;0.33;0.27;0.23;0.23;0.23;0.23;0.23;0.22;0.22","CECILIA TIBALDI;CHIARA BENEDETTO;A. CASTELLA;M DEMAESTRI;THOMAS RUTHERFORD;BRUNO BATTISTON;ORNELLA GUARDAMAGNA;PETER E. SCHWARTZ;F. ABELLO;ELENA ALLÌA;SILVIA MARINI;ANDREA CALVO;G BUSSOLATI;N CAPPELLO;UMBERTO RICARDI;V. BARACCO;CATERINA MARCHIÒ;DAVID FERGUSON;CARLA MARIA ZOTTI;MARINELLA CLERICO","4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CHIARA BENEDETTO;CECILIA TIBALDI;BRUNO BATTISTON;A. CASTELLA;SILVIA MARINI;N CAPPELLO;CARLA MARIA ZOTTI;GIULIA MASUELLI;PAOLA SERAFINI;LORENA CHARRIER;M DEMAESTRI;MT BERTERO;ALESSANDRO MUSSA;THOMAS RUTHERFORD;PETER E. SCHWARTZ;ORNELLA GUARDAMAGNA;F. ABELLO;V. BARACCO;DAVID FERGUSON;MARINELLA CLERICO","0.5;0.4;0.33;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.12;0.1;0.1;0.09;0.09;0.09;0.08;0.08","GABRIELLA RESTAGNO;CECILIA TIBALDI;ADRIANO CHIÒ;ANDREA CALVO;BRYAN J. TRAYNOR;FABRIZIO SALVI;GABRIELE MORA;IRENE OSSOLA;JENNIFER C. SCHYMICK;JESSICA MANDRIOLI;MARIA ROSARIA MONSURRÒ;MARIO SABATELLI;MAURA BRUNETTI;ROSSELLA SPATARO;STEFANIA BATTISTINI;VINCENZO LA BELLA;ANDREA MARTINUZZI;ANNA BARTOLETTI‐STELLA;ANNA GHELLI;ANNA MARIA PORCELLI","207;167;132;132;132;132;132;132;132;132;132;132;132;132;132;132;119;119;119;119","CECILIA TIBALDI;ADRIANO CHIÒ;ANDREA CALVO;CHIARA BENEDETTO;GIULIA MASUELLI;N CAPPELLO;SILVIA MARINI;F. ABELLO;ORNELLA GUARDAMAGNA;V. BARACCO;PETER E. SCHWARTZ;THOMAS RUTHERFORD;BRUNO BATTISTON;ALESSANDRO MUSSA;ANNA SAPINO;CATERINA MARCHIÒ;ELENA ALLÌA;G BUSSOLATI;ISABELLA CASTELLANO;UMBERTO RICARDI","167;132;132;101;101;101;101;75;75;75;74;74;65;62;23;23;23;23;23;23","CECILIA TIBALDI;A. CASTELLA;ADRIANO CHIÒ;ALESSANDRO MUSSA;ANDREA CALVO;ANNA SAPINO;BRUNO BATTISTON;CARLA MARIA ZOTTI;CATERINA MARCHIÒ;CHIARA BENEDETTO;ELENA ALLÌA;F. ABELLO;G BUSSOLATI;GIULIA MASUELLI;ISABELLA CASTELLANO;LORENA CHARRIER;M DEMAESTRI;MT BERTERO;N CAPPELLO;ORNELLA GUARDAMAGNA","4;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;GEOGRAPHY;MATERIALS SCIENCE","26;19;2;2;2;2;1;1;1","INTERNAL MEDICINE;GENETICS;OBSTETRICS;PEDIATRICS;IMMUNOLOGY;PATHOLOGY;GYNECOLOGY;SURGERY;DERMATOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;ANDROLOGY;ANESTHESIA;CELL BIOLOGY;DEMOGRAPHY;MICROBIOLOGY;ONCOLOGY;OPTICS;PHYSIOLOGY;PSYCHIATRY;RADIOLOGY","16;14;8;6;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2","PREGNANCY;CANCER;GENE;POPULATION;ADVERSE EFFECT;CONFIDENCE INTERVAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);AIRWAY;ASYMPTOMATIC;CHOLESTEROL;CONTEXT (ARCHAEOLOGY);DISEASE;NEONATAL INTENSIVE CARE UNIT;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;ANTIBIOTICS;ANTIBODY;ANTIFUNGAL;ANXIETY;APOPTOSIS;BACTERIA;BACTERIAL VAGINOSIS;BORON;BREASTFEEDING;CARCINOMA;CAROTENOID;CAROTID ARTERIES;CELL;CHEMOTHERAPY;CHINA;CHLAMYDIA;CHLAMYDIA TRACHOMATIS;CHRONIC PAIN;COHORT;CONCOMITANT;CONFOUNDING;CONNECTIVE TISSUE;CORD BLOOD;CREATININE;CYSTIC FIBROSIS;DETECTOR;DISTRESS;ETIOLOGY;GRADING (ENGINEERING);GUIDELINE;HISTOLOGY;HOMEOSTASIS;HYSTERECTOMY;IMMUNOHISTOCHEMISTRY;IN SITU;INCIDENCE (GEOMETRY);INTENSIVE CARE;IRRADIATION;LOGISTIC REGRESSION;MEDICAL DIAGNOSIS;MICROTUBULE;MITOCHONDRION;MYCOPLASMA;NEUTRON;OBESITY;OBSERVATIONAL STUDY;ODDS RATIO;ORCHIOPEXY;OSTEOPLASTY;OSTEOTOMY;OXIDATIVE STRESS;PARENTERAL NUTRITION;PELVIC PAIN;PREFERENCE;PSYCHOLOGICAL INTERVENTION;RANDOMIZED CONTROLLED TRIAL;RECONSTRUCTIVE SURGERY;RESPIRATORY SYSTEM;SEPSIS;SEX ORGAN;SIBLING;SIGNIFICANT DIFFERENCE;SPERM;STAGE (STRATIGRAPHY);TEST (BIOLOGY);TRANSPLANTATION;TRICHOMONAS VAGINALIS;VAGINA;VAGINITIS;VIRUS;VULVA","10;4;4;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MUTATION;CERVICAL CANCER;FETUS;GESTATIONAL AGE;TOLERABILITY;VIRAL LOAD;ALLELE;AMIKACIN;AMPICILLIN;AMYOTROPHIC LATERAL SCLEROSIS;ANTIBIOTIC RESISTANCE;APOLIPOPROTEIN B;AUTOANTIBODY;AUTOIMMUNE DISEASE;BIRTH WEIGHT;BREAST CANCER;CAESAREAN SECTION;CANDIDA PARAPSILOSIS;CARCINOMA IN SITU;CELL SURVIVAL;CHROMOSOMAL TRANSLOCATION;CHROMOSOME;CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;EXON;FAMILIAL HYPERCHOLESTEROLEMIA;FERTILITY;FLUCONAZOLE;GENOTYPE;GESTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS B VIRUS;INFERTILITY;INTIMA-MEDIA THICKNESS;ISOTOPES OF BORON;LIPID PROFILE;LIPOPROTEIN;LOW BIRTH WEIGHT;LUPUS ERYTHEMATOSUS;LUTEIN;MITOCHONDRIAL DNA;MULTIPLE CHOICE;MUTANT;MYCOPLASMA HOMINIS;NEONATOLOGY;NEUTRON CAPTURE;NEUTRON TEMPERATURE;OVARIAN CANCER;PACLITAXEL;PAIN DISORDER;PALIVIZUMAB;PLACEBO;POST PARTUM;PROBIOTIC;PYROSEQUENCING;RESPIRATORY CHAIN;SOMATIZATION;SPERM MOTILITY;STATHMIN;STRIDOR;SYSTEMIC LUPUS ERYTHEMATOSUS;TRIGLYCERIDE;TUBULIN;UREAPLASMA UREALYTICUM;VAGINAL DISEASE;VAGINAL FLORA;VIRAL DISEASE;VULVODYNIA","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIRETROVIRAL THERAPY;CERVICAL INTRAEPITHELIAL NEOPLASIA;PRENATAL DIAGNOSIS;AMNIOTIC FLUID;BREAKPOINT;CANDIDA KRUSEI;CASPOFUNGIN;CERVICAL CARCINOMA;CERVICAL SCREENING;COLPOSCOPY;CONNECTIVE TISSUE DISEASE;CYTOGENETICS;DUCTAL CARCINOMA;IMIPENEM;KARYOTYPE;LACTOBACILLUS RHAMNOSUS;LAMIVUDINE;LARYNGOMALACIA;LDL RECEPTOR;MISSENSE MUTATION;OBSTETRIC HISTORY;RETINOPATHY OF PREMATURITY;SOD1;SOMATIZATION DISORDER;VARICOCELE;ZEAXANTHIN;ZIDOVUDINE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;ITALY;MALE;;PREGNANCY;CARCINOMA IN SITU;CERVICAL INTRAEPITHELIAL NEOPLASIA;HIV INFECTIONS;MIDDLE AGED;PREGNANCY COMPLICATIONS, INFECTIOUS;UTERINE CERVICAL NEOPLASMS;YOUNG ADULT;ADENOCARCINOMA;ADOLESCENT;HEAD AND NECK NEOPLASMS;OVARIAN NEOPLASMS;PRENATAL DIAGNOSIS;AGED","20;18;13;9;9;8;8;7;7;7;7;7;7;7;6;6;5;5;5;4","PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;BORON NEUTRON CAPTURE THERAPY;CHOLESTEROL-LOWERING TREATMENT;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF RETINOPATHY OF PREMATURITY;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;GENE THERAPY TECHNIQUES AND APPLICATIONS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;MOLECULAR RESEARCH ON BREAST CANCER;PHARMACOKINETICS OF ANTIBIOTICS IN CRITICALLY ILL PATIENTS;PREVENTION AND MANAGEMENT OF SURGICAL SITE INFECTIONS;REGULATION AND FUNCTION OF MICROTUBULES IN CELL DIVISION;STANDARDISATION AND MANAGEMENT OF COPD","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CYTOLOGY SCREENING;NEVIRAPINE;PRETERM INFANTS;TOLERABILITY;AMIKACIN;ANTIFUNGAL THERAPY;ANTIRETROVIRAL THERAPY;BONE REGENERATION;BORON NEUTRON CAPTURE THERAPY;BREAKPOINT;BREAST CANCER;CANCER CELL METABOLISM;CANCER TREATMENT;CANDIDA KRUSEI;CANDIDA PARAPSILOSIS;CARCINOMA IN SITU;CELL SURVIVAL;CERVICAL SCREENING;CFTR;CHROMOSOMAL INVERSION","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORD BLOOD;AIRWAY RESPONSIVENESS;AMERICAN ACADEMY;AMYOTROPHIC LATERAL;ANTIRETROVIRAL TREATMENT;ASYMPTOMATIC NON-PREGNANT;BACTERIAL INFECTION;BALANCED CHROMOSOME;BANK NETWORK;BLOOD BANK;BLOOD BANKING;BORON IMAGING;CAESAREAN SECTION;CANCER PATIENTS;CARDIOVASCULAR RISK;CELL HOMEOSTASIS;CELL SURVIVAL;CERVICAL SCREENING;CHILDREN TREATED;CHROMOSOME REARRANGEMENTS;CIN DIAGNOSES;COHORT STUDY;CONDUCTANCE REGULATOR;CONNECTIVE TISSUE;CYSTIC FIBROSIS;DIRECTED FAMILY;DISEASE EVOLVING;DUCTAL CARCINOMA;ENDOCERVICAL MICROORGANISMS;FAMILIAL AMYOTROPHIC","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NUCLEAR GRADE;STATHMIN EXPRESSION;DUCTAL CARCINOMA;Β IIITUBULIN;CANDIDA SPECIES;OVARIAN CANCER;RECEIVED PLATINUM;TREATMENT RESPONSE;AMNIOTIC FLUID;BACTERIAL VAGINOSIS;BLOOD SAMPLES;BREAST-CONSERVING SURGERY;CD COUNTS;CHORIONIC VILLUS;CHROMOSOME REARRANGEMENTS;CIN CIN;CONFIDENCE INTERVAL;CONNECTIVE TISSUE;DISEASE PROGRESSION;DISRUPTIVE MUTATIONS;FAMILY CARRYING;FETAL BLOOD;FLUID CHORIONIC;GRAM-POSITIVE BACTERIA;GROWTH PATTERN;HIFΑ STABILIZATION;HOMOPLASMIC DISRUPTIVE;INTERVAL CI;LOCAL RECURRENCE;MICROPAPILLARY CARCINOMA","7;6;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,7.33,483.67,10,2,0.67,10,0,0,0,0,0,0,1,2,0,1,2,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Italy","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES","3;3;1;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;ACUTE RESPIRATORY DISTRESS SYNDROME;BIOMEDICAL IMAGING;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EMERGING INFECTIOUS DISEASES;HEART DISEASE;INFECTIOUS DISEASES;INFLUENZA;LUNG;NEUROSCIENCES;PATIENT SAFETY;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;PNEUMONIA & INFLUENZA;RARE DISEASES;STROKE;TRAUMATIC BRAIN INJURY (TBI);TRAUMATIC HEAD AND SPINE INJURY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;INJURIES AND ACCIDENTS;RESPIRATORY","1;1;1","6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2010,44,9.56818181818182,1.61363636363636,0.113636363636364,0.113636363636364,0.113636363636364,1.15151515151515,0.833333333333333,1,0.833333333333333,0.409090909090909,0,27,5,4,6,0.61,0.11,0.09,0.14,37.09,0.82076613996301,NA,0.159090909090909,0.681818181818182,0.33,0.133,0.15,0.133,"MAURO STRONATI;P. CRESCENTI;PAOLO MANZONI;A. GRIPPA;F. D’AMICO;ROSARIA MANICONE;FEDERICA D’AMICO;PASQUALE MARTINELLI;E. VERCESI;CHIARA GALLETTO;M. NICOLOSI;A. OSTINELLI;ELIO CASTAGNOLA;IOLANDA MAZZUCCHELLI;T. PIPICELLA;MARCO FLORIDIA;CECILIA TIBALDI;SIMONE CESARO;CHRYSSOULA TZIALLA;OTTAVIO ZIINO","3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","A. GRIPPA;FEDERICA D’AMICO;F. D’AMICO;G LOMBARDO;F. DʼAMICO;P. CRESCENTI;FERDINANDO D’AMICO;F. CARONZOLO;E. GOLLO;VALENTINA DONVITO;FRANCESCA D’AMICO;MARIA ROSA GIOLITO;LEONARDO SACCO;ASQUALE CALABRESE;T. PIPICELLA;RICCARDO NATOLI;GUGLIELMO RONCO;G. GAGLIO;DAVIDE MARINI;MG ACCETTA","0.79;0.79;0.78;0.75;0.67;0.66;0.58;0.58;0.58;0.5;0.5;0.5;0.5;0.5;0.46;0.46;0.39;0.38;0.33;0.33","ROSARIA MANICONE;CHIARA GALLETTO;CECILIA TIBALDI;NICOLETTA BERTORELLO;ANDREA CORRIAS;FRANCESCO PORTA;ALESSANDRO MUSSA;FRANCA FAGIOLI;SILVANA LEANZA;ADA FUNARO;RICCARDO ARISIO;GIULIA NACCI;ROSSELLA PARROTTA;MARCO VOLANTE;PAOLA BOVINO;GIUSEPPE MIGLIARETTI;LILIANA VAGLIANO;DIONYSSIOS KATSAROS;MARIELLA TROVATI;ANDREA CALVO","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ROSARIA MANICONE;CHIARA GALLETTO;NICOLETTA BERTORELLO;ANDREA CORRIAS;FRANCESCO PORTA;ALESSANDRO MUSSA;FRANCA FAGIOLI;CECILIA TIBALDI;CARLA MARIA ZOTTI;LORENA CHARRIER;ANDREA CALVO;CRISTINA MOGLIA;ADRIANO CHIÒ;ELENA MARIA BRACH DEL PREVER;ADA FUNARO;RICCARDO ARISIO;GIULIA NACCI;ROSSELLA PARROTTA;MARCO VOLANTE;PAOLA BOVINO","0.32;0.25;0.25;0.25;0.25;0.25;0.25;0.17;0.17;0.17;0.1;0.1;0.1;0.08;0.08;0.08;0.08;0.08;0.08;0.08","GUGLIELMO RONCO;ANNA GILLIO‐TOS;ANNAROSA DEL MISTRO;BRUNO GHIRINGHELLO;CARLO NALDONI;FRANCESCA CAROZZI;JACK CUZICK;LAURA DE MARCO;MANUEL ZORZI;MARCO ZAPPA;MASSIMO CONFORTINI;NEREO SEGNAN;PAOLA PIEROTTI;PAOLO DALLA PALMA;PAOLO GIORGI ROSSI;PATRIZIA SCHINCAGLIA;RAFFAELLA RIZZOLO;SALVATORE GIRLANDO;DESIRÉE CASELLI;ELIO CASTAGNOLA","885;880;880;880;880;880;880;880;880;880;880;880;880;880;880;880;880;880;139;139","ANNA GILLIO‐TOS;LAURA DE MARCO;LILIANA VAGLIANO;SILVANA LEANZA;VALERIO DIMONTE;ADRIANO CHIÒ;ANDREA CALVO;CRISTINA MOGLIA;ADA FUNARO;DIONYSSIOS KATSAROS;ENZA FERRERO;ERIKA ORTOLAN;GIULIA NACCI;GIUSEPPE MIGLIARETTI;IDA RAPA;MARCO VOLANTE;NICOLA LO BUONO;PAOLA BOVINO;RICCARDO ARISIO;ROSSELLA PARROTTA","880;880;103;103;103;75;75;75;55;55;55;55;55;55;55;55;55;55;55;55","CECILIA TIBALDI;CHIARA GALLETTO;FRANCA FAGIOLI;NICOLETTA BERTORELLO;ROSARIA MANICONE;ADA FUNARO;ADRIANO CHIÒ;ALESSANDRO MUSSA;ANDREA CALVO;ANDREA CORRIAS;ANNA GILLIO‐TOS;CARLA MARIA ZOTTI;CRISTINA MOGLIA;DIONYSSIOS KATSAROS;ELENA MARIA BRACH DEL PREVER;ENZA FERRERO;ERIKA ORTOLAN;FRANCESCO PORTA;GIULIA NACCI;GIUSEPPE MIGLIARETTI","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;PHYSICS;COMPUTER SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;CHEMISTRY;ECONOMICS;MATHEMATICS","44;12;7;7;4;4;3;3;2;2;2","INTERNAL MEDICINE;PATHOLOGY;GENETICS;SURGERY;CARDIOLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;NURSING;PEDIATRICS;PHYSICAL THERAPY;OBSTETRICS;OPTICS;FAMILY MEDICINE;IMMUNOLOGY;LAW;RADIOLOGY;GYNECOLOGY;MECHANICAL ENGINEERING;MEDICAL EDUCATION;MEDICAL EMERGENCY;NUCLEAR MEDICINE;PSYCHIATRY","33;13;10;9;8;7;7;6;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3","BLOOD PRESSURE;CANCER;DIABETES MELLITUS;PREGNANCY;POPULATION;AMBULATORY;CHEMOTHERAPY;GENE;INCIDENCE (GEOMETRY);DISEASE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);QUALITY OF LIFE (HEALTHCARE);REGIMEN;STROKE (ENGINE);ANTIBIOTICS;BEDTIME;CLINICAL TRIAL;CREATININE;HEART FAILURE;LOGISTIC REGRESSION;MULTIDISCIPLINARY APPROACH;ODDS RATIO;PHYSICAL ACTIVITY;PSYCHOLOGICAL INTERVENTION;SARCOMA;TRANSMISSION (TELECOMMUNICATIONS);ULTRASOUND","10;10;6;6;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","AMBULATORY BLOOD PRESSURE;DIASTOLE;LEFT VENTRICULAR HYPERTROPHY;MUTATION;BREAST CANCER;CERVICAL CANCER;ESSENTIAL HYPERTENSION;HEART RATE;MICROALBUMINURIA;OBSTETRICS AND GYNAECOLOGY;ADENOCARCINOMA;AMYOTROPHIC LATERAL SCLEROSIS;ANTIHYPERTENSIVE DRUG;BACTEREMIA;BETA BLOCKER;BEVACIZUMAB;BLADDER CANCER;BONE DENSITY;BONE MINERAL;BRIEF PAIN INVENTORY;CENSUS;CHEMOTHERAPY REGIMEN;CLINICAL ENDPOINT;COLORECTAL CANCER;CONSTRAINT-INDUCED MOVEMENT THERAPY;COVERED STENT;DEPRESSIVE SYMPTOMS;DOSIMETER;EJECTION FRACTION;EPISIOTOMY;EUTHYROID;FETUS;GENE EXPRESSION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEMIDESMOSOME;HEPATITIS C VIRUS;HOSPITAL ANXIETY AND DEPRESSION SCALE;HYDROCHLOROTHIAZIDE;IMAGE NOISE;IMAGE QUALITY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INTERNAL CONSISTENCY;INTERNATIONAL STANDARDIZATION;INTIMA-MEDIA THICKNESS;INTRA-RATER RELIABILITY;INTRACLASS CORRELATION;LAMININ;LIPOSARCOMA;LYMPHOBLASTIC LEUKEMIA;MATERNAL MORBIDITY;METASTASIS;MUCOSITIS;MUTANT;NEBIVOLOL;NEONATAL SEPSIS;NEURORADIOLOGY;ODDS;OLMESARTAN;OPHTHALMOSCOPY;OVARIAN CANCER;OXYGEN SATURATION;PACLITAXEL;PERCHLORATE;PHASES OF CLINICAL RESEARCH;PROTOCOL (SCIENCE);PSEUDOMONAS AERUGINOSA;RELIABILITY (SEMICONDUCTOR);RENAL CAPSULE;RESEARCH METHODOLOGY;RESTENOSIS;RETINOPATHY;SAMPLING (SIGNAL PROCESSING);SCANNING LASER OPHTHALMOSCOPY;SCHISTOSOMIASIS;SEROLOGY;SOFT TISSUE SARCOMA;SPIROMETRY;TELMISARTAN;THEMATIC ANALYSIS;THYROID FUNCTION;THYROID FUNCTION TESTS;TRANSPORTER;TYPE 2 DIABETES;UNIVARIATE ANALYSIS;VENOUS THROMBOEMBOLISM;VIRAL LOAD","3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CERVICAL INTRAEPITHELIAL NEOPLASIA;CERVICAL SCREENING;COLPOSCOPY;MISSENSE MUTATION;ALIEN;CERVICAL CANCER SCREENING;CERVICAL CARCINOMA;CHILDHOOD LEUKEMIA;CONCURRENT VALIDITY;CORE BIOPSY;CORONAVIRUS DISEASE 2019 (COVID-19);DIASTOLIC HEART FAILURE;FAMILY PLANNING;GENE MUTATION;GERIATRIC DEPRESSION SCALE;GERMLINE MOSAICISM;GLYCATED HEMOGLOBIN;INFLAMMATORY BREAST CANCER;JUNCTIONAL EPIDERMOLYSIS BULLOSA (VETERINARY MEDICINE);MACULOPATHY;NEOADJUVANT THERAPY;OSTEOPENIA;OVARIAN CARCINOMA;PAPILLOMAVIRIDAE;PRENATAL DIAGNOSIS;PROBAND;SEROPREVALENCE;SOD1;SOX9;SYMPORTER;VO2 MAX","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;ADULT;ITALY;MALE;HIV INFECTIONS;INFANT, NEWBORN;MIDDLE AGED;PREGNANCY;SCHISTOSOMIASIS HAEMATOBIA;YOUNG ADULT;ANTI-RETROVIRAL AGENTS;ANTINEOPLASTIC AGENTS;CHILD;CHILD, PRESCHOOL;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INFLUENZA, HUMAN;ADOLESCENT;CAMPOMELIC DYSPLASIA","24;20;17;13;12;12;10;6;6;6;6;6;5;5;5;5;5;5;4;4","EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;SARCOMA RESEARCH AND TREATMENT;AGE-RELATED MACULAR DEGENERATION RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;BIOLOGY AND PATHOLOGY OF KERATINS AND RELATED DISORDERS;CALCINEURIN-NFAT SIGNALING IN TRANSCRIPTIONAL REGULATION;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;COLORECTAL CANCER RESEARCH AND TREATMENT;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EFFECTS OF PHYSICAL ACTIVITY ON HEALTH OUTCOMES;EMERGENCY DEPARTMENT CROWDING;EPIDEMIOLOGY AND PREVENTION OF CARDIOVASCULAR DISEASES IN RUSSIA;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;FEMOROACETABULAR IMPINGEMENT SYNDROME AND HIP PATHOLOGY;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","REGIMEN;STROKE (ENGINE);BEDTIME;CERVICAL SCREENING;ESSENTIAL HYPERTENSION;EXERCISE;HIV;HIV INFECTION;HYPERTENSION;MICROALBUMINURIA;SOFT TISSUE SARCOMA;AEROBIC EXERCISE;ANTIHYPERTENSIVE DRUG;BACTEREMIA;BETA BLOCKER;BONE MINERAL DENSITY;BRIEF PAIN INVENTORY;BRONCHOPNEUMONIA;CANCER IMAGING;CARDIOPULMONARY EXERCISE TESTING","3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","ELDERLY PEOPLE;ADAPTED PHYSICAL;COMBINED THERAPY;ELDERLY PATIENTS;ELDERLY SUBJECTS;HYPERTENSION PP;PHYSICAL ACTIVITY;PREGNANT WOMEN;STROKE PP;ABSTRACT P--;ACETILSALICILIC ACID;ACUTE LYMPHOBLASTIC;ADVANCED BREAST;AERUGINOSA INFECTION;ALIEN HAND;ALLA CONFERENZA;ANEURYSM DEVELOPMENT;ASPETTI CLINICI;ASSISTENCE NAMED;BARE STENT;BEVACIZUMAB COMBINED;BLOOD PRESSURE;BNP CONCENTRATIONS;BONE APPRAISAL;BONE ULTRASOUND;BREAST CANCER;BRONCHOPNEUMOPATHY PP;BULLOSA HERLITZ;CAMPOMELIC DYSPLASIA;CANCER INTER-OBSERVER","4;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BLOOD PRESSURE;ELDERLY SUBJECTS;ELDERLY PEOPLE;OVARIAN CANCER;CARDIOVASCULAR RISK;LEFT VENTRICULAR;STUDY INCLUDED;BP CONTROL;HORMONAL CONTRACEPTION;MVSH GRH;MVSI GRM;ANGIOTENSINE II;BP VALUES;CANCER CELLS;COMBINED THERAPY;CONTROLLED BP;DIABETES MELLITUS;II ANTAGONIST;MG DOSE;ADAPTED PHYSICAL;AMBULATORY BLOOD;ASA MG;AVERAGE AGE;CAROTID INTIMA-MEDIA;CLINIC MEASUREMENT;CRITICAL CARE;DBP MMHG;GRM MVSH;HYPERTENSIVE SUBJECTS;MEASUREMENT ABPM","25;12;11;11;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,9,1324.6,17.24,4,0.8,55.6,0,0,0,0,4,0,0,1,0,4,1,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"Italy;Canada;United States","4;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","5;3;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;TRANSPLANTATION;STEM CELL RESEARCH;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;LIVER DISEASE;LUNG;LYMPHOMA;NUTRITION;ORGAN TRANSPLANTATION;ORPHAN DRUG;PATIENT SAFETY;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","4;4;3;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;INJURIES AND ACCIDENTS","2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","3;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;MYELOMA","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",1,2963532,269412,4,11,7,1,58,67353,0.653274538624857,"AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;AZIENDA OSPEDALIERO UNIVERSITARIA SAN GIOVANNI BATTISTA;IMPERIAL COLLEGE LONDON;INSTITUT CATALÀ D'ONCOLOGIA;INSTITUT D'INVESTIGACIÓ BIOMÉDICA DE BELLVITGE;INSTITUT SCIENTIFIQUE DE SANTÉ PUBLIQUE;KAROLINSKA INSTITUTET;LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE;LUND UNIVERSITY;TAMPERE UNIVERSITY;VRIJE UNIVERSITEIT AMSTERDAM","1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2009-SINGLE-STAGE (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3215 REPRODUCTIVE MEDICINE","1;1","CANCER;CERVICAL CANCER;CLINICAL RESEARCH;COST EFFECTIVENESS RESEARCH;HEALTH SERVICES;HPV AND/OR CERVICAL CANCER VACCINES;IMMUNIZATION;INFECTIOUS DISEASES;PREVENTION;SEXUALLY TRANSMITTED INFECTIONS;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","1;1","3.4 VACCINES;4.4 POPULATION SCREENING","1;1","CERVICAL CANCER","1","6.4 COST ANALYSES AND HEALTH CARE DELIVERY","1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2011,32,11.78125,1.625,0.09375,0.0625,0.09375,1,0.75,0.666666666666667,0.75,0.375,0,15,10,4,1,0.47,0.31,0.12,0.03,30.38,0.714129756435814,NA,0.21875,0.8125,0.251,0,0,0,"PAOLO MANZONI;HUBERT MESSNER;DANIELE FARINA;NICOLA LAFORGIA;MAURO STRONATI;MATTEO RINALDI;ILARIA STOLFI;DIONYSSIOS KATSAROS;GIOVANNINO CICCONE;SILVIA CATTANI;FABIO MOSCA;MICHAEL MOSTERT;PAOLA BRIGNOLO;CARMELA PINNETTI;GIANFRANCO TROSSARELLI;LUCA FUSO;F CARNINO;VINCENZO BELCASTRO;MARCO FLORIDIA;GIUSEPPINA LIUZZI","5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","FEDERICA D’AMICO;FRANCESCA D’AMICO;T. PIPICELLA;FERDINANDO D’AMICO;G LOMBARDO;PAOLO MANZONI;DANIELE FARINA;DAVIDE MARINI;R. GRASSO;P. CRESCENTI;GIANFRANCO BUTERA;L. BITTO;RICCARDO NATOLI;SIMON T. MACDONALD;HUBERT MESSNER;M. VIVALDA;M. BORTOLIN;MARIO RAVIOLO;DAVID DE BONO;VINCENZO BELCASTRO","0.67;0.5;0.5;0.5;0.5;0.4;0.36;0.33;0.33;0.33;0.33;0.33;0.33;0.33;0.26;0.25;0.25;0.25;0.25;0.24","M. RIBEZZO;PAOLA OMEDÈ;LAURA BERGAMASCO;FRANCESCA FERRONI;DARIO FERRERO;IMAD SHEIBAN;GIUSEPPE SAGLIO;MARISA PAUTASSO;ETTORE PICCOLI;TULLIA TODROS;MANUELA SCATÀ;FEDERICA VIGNA‐TAGLIANTI;STEFANIA PIZZIMENTI;MAURO RINALDI;ELISABETTA DOLFIN;MILENA MAULE;IVANO DAL CONTE;ALESSANDRO ROLFO;BENEDETTA GUANI;GIUSEPPINA BARRERA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FEDERICA VIGNA‐TAGLIANTI;IVANO DAL CONTE;ELISABETTA DOLFIN;BENEDETTA GUANI;ALBERTO REVELLI;CRISTINA LUSSIANA;ETTORE PICCOLI;TULLIA TODROS;ALESSANDRO ROLFO;SIMONA CARDAROPOLI;ELENA VASARIO;FRANCESCO GIUSEPPE DE ROSA;MASSIMO BELLETTATO;M. OBERTO;MANUELA SCATÀ;M. RIBEZZO;LAURA BERGAMASCO;FRANCESCA FERRONI;IMAD SHEIBAN;STEFANIA PIZZIMENTI","0.2;0.2;0.17;0.17;0.17;0.17;0.1;0.1;0.1;0.1;0.1;0.09;0.09;0.08;0.07;0.07;0.07;0.07;0.07;0.07","PAOLO MANZONI;DANIELE FARINA;ELENA GALLO;HUBERT MESSNER;FABIO MOSCA;DIONYSSIOS KATSAROS;ALESSANDRO BUDA;CHIARA ROMUALDI;COSTANTINO MANGIONI;DANIELA GARAVAGLIA;DUCCIO CAVALIERI;ENRICA CALURA;GIORGIO CATTORETTI;GIOVANNA CHIORINO;GUIDO MENATO;ILARIA FUSO NERINI;LUCA BELTRAME;LUCA CLIVIO;LUCA SCARAMPI;MAURIZIO D’INCALCI","214;213;211;210;208;196;177;177;177;177;177;177;177;177;177;177;177;177;177;177","MILENA MAULE;M. OBERTO;FRANCESCO GIUSEPPE DE ROSA;ALBERTO REVELLI;BENEDETTA GUANI;CRISTINA LUSSIANA;ELISABETTA DOLFIN;ALESSANDRO ROLFO;ELENA VASARIO;ETTORE PICCOLI;SIMONA CARDAROPOLI;TULLIA TODROS;CRISTINA TOALDO;ERIC CIAMPORCERO;FRANCESCA FERRONI;GIUSEPPINA BARRERA;IMAD SHEIBAN;LAURA BERGAMASCO;M. RIBEZZO;MAURO RINALDI","151;78;53;48;48;48;48;39;39;39;39;39;20;20;20;20;20;20;20;20","ALBERTO REVELLI;ALESSANDRO ROLFO;BENEDETTA GUANI;CRISTINA LUSSIANA;CRISTINA TOALDO;DARIO FERRERO;ELENA VASARIO;ELISABETTA DOLFIN;ERIC CIAMPORCERO;ETTORE PICCOLI;FEDERICA VIGNA‐TAGLIANTI;FRANCESCA FERRONI;FRANCESCO GIUSEPPE DE ROSA;GIULIA MASUELLI;GIUSEPPE SAGLIO;GIUSEPPINA BARRERA;IMAD SHEIBAN;IVANO DAL CONTE;LAURA BERGAMASCO;M. OBERTO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;MATHEMATICS;ART;PHYSICS;ENGINEERING;ENVIRONMENTAL SCIENCE;GEOGRAPHY;POLITICAL SCIENCE","31;15;3;2;2;1;1;1;1","INTERNAL MEDICINE;GENETICS;GYNECOLOGY;OBSTETRICS;ONCOLOGY;CARDIOLOGY;IMMUNOLOGY;PATHOLOGY;PEDIATRICS;EMERGENCY MEDICINE;ENDOCRINOLOGY;GERONTOLOGY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;PSYCHIATRY;STATISTICS;SURGERY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;HUMANITIES;MICROBIOLOGY;OPTICS;PHYSICAL THERAPY;VIROLOGY","25;11;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","PREGNANCY;CANCER;RANDOMIZED CONTROLLED TRIAL;MULTIVARIATE ANALYSIS;SEPSIS;ADVERSE EFFECT;GERIATRICS;LACTOFERRIN;ALTERNATIVE MEDICINE;BACTERIA;BLOOD PRESSURE;CLINICAL TRIAL;CONFIDENCE INTERVAL;CONFOUNDING;DISEASE;GENE;GYNECOLOGIC ONCOLOGY;HEMODIALYSIS;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INCIDENCE (GEOMETRY);INFLAMMATION;MEDICAL PRESCRIPTION;ODDS RATIO;POPULATION;PROPORTIONAL HAZARDS MODEL;RECEPTOR","10;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GESTATIONAL AGE;CERVICAL CANCER;BIRTH WEIGHT;ENDOMETRIAL CANCER;FETUS;LOW BIRTH WEIGHT;PLACEBO;PREECLAMPSIA;UNIVARIATE ANALYSIS;ADENOCARCINOMA;ANTIPHOSPHOLIPID SYNDROME;AUTOANTIBODY;BACTEREMIA;BIRTH CERTIFICATE;BREAST CANCER;CERVIX;CLINICAL ENDPOINT;CORONARY ATHEROSCLEROSIS;CUMULATIVE INCIDENCE;CYCLOPHOSPHAMIDE;DEMENTIA;DIASTOLE;ECLAMPSIA;ENTERAL ADMINISTRATION;ENTEROPATHY;FLUOROURACIL;GEE;GENOTYPE;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEMOFILTRATION;HUMAN GENETICS;HYPOPLASTIC LEFT HEART SYNDROME;INJURY PREVENTION;INSULIN RESISTANCE;INTERIM ANALYSIS;INTRACLASS CORRELATION;LACTOBACILLUS;LEVOFLOXACIN;LUPUS ANTICOAGULANT;LUTEINIZING HORMONE;MACROPHAGE;MACROPHAGE MIGRATION INHIBITORY FACTOR;MICRORNA;MYELODYSPLASTIC SYNDROMES;OVARIAN CANCER;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR;PROBIOTIC;PROINFLAMMATORY CYTOKINE;PULSE (MUSIC);PULSE PRESSURE;REPRODUCTIVE MEDICINE;RESTENOSIS;SEPTIC SHOCK;SONOGRAPHER;SYPHILIS;TISSUE FACTOR;TOLERABILITY;UREMIC TOXINS;WILCOXON SIGNED-RANK TEST","4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LACTOBACILLUS RHAMNOSUS;COGNITIVE DECLINE;COLPOSCOPY;DIASTOLIC HEART FAILURE;EPITHELIAL OVARIAN CANCER;FOLLICLE-STIMULATING HORMONE;MASS-CASUALTY INCIDENT;NEOINTIMA;PARAMETRIUM;PLACENTA;PLACENTAL ABRUPTION;POLYCYSTIC OVARY;POLYMORPHISM (COMPUTER SCIENCE);PROTEIN LOSING ENTEROPATHY;TAMOXIFEN","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;;MALE;MIDDLE AGED;AGED;HIV INFECTIONS;ITALY;PRE-ECLAMPSIA;OVARIAN NEOPLASMS;PREGNANCY COMPLICATIONS, INFECTIOUS;AGED, 80 AND OVER;BREAST NEOPLASMS;CANDIDEMIA;GENITAL NEOPLASMS, FEMALE;INFANT, PREMATURE, DISEASES;PREGNANCY;UTERINE CERVICAL NEOPLASMS;BACTEREMIA","22;18;11;10;10;10;7;7;7;7;6;6;5;5;5;5;5;5;5;4","COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;GYNECOLOGIC ONCOLOGY;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;ACUTE MYELOID LEUKEMIA;BIOLOGICAL BASIS AND CLINICAL MANAGEMENT OF SYPHILIS;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;DIAGNOSIS AND TREATMENT OF PATENT DUCTUS ARTERIOSUS;DIAGNOSIS AND TREATMENT OF RETINOPATHY OF PREMATURITY;DISASTER RESPONSE AND PUBLIC HEALTH PREPAREDNESS;EMERGENCY DEPARTMENT CROWDING;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;HYPERGLYCEMIC CHOREA AND BASAL GANGLIA LESIONS;IMPACT OF GESTATIONAL DIABETES MELLITUS ON PREGNANCY;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;METABOLIC ACIDOSIS IN CHRONIC KIDNEY DISEASE;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MOLECULAR RESEARCH ON BREAST CANCER;MOYAMOYA DISEASE AND SYNDROME;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS","4;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LACTOFERRIN;UNIVARIATE ANALYSIS;BREAST CANCER SCREENING;CLINICAL PRACTICE GUIDELINES;GERIATRIC ASSESSMENT;GYNECOLOGIC ONCOLOGY;LACTOBACILLUS RHAMNOSUS;PRETERM INFANTS;ADVERSE PREGNANCY OUTCOMES;AEROBIC EXERCISE;ANTIPHOSPHOLIPID SYNDROME;ATHEROMA;BACTEREMIA;BIRTH CERTIFICATE;BLOODSTREAM INFECTION;BREASTFEEDING SUPPORT;CANCER;CARDIAC METABOLISM;CARDIAC RISK;CARDIOPULMONARY EXERCISE TESTING","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","BOVINE LACTOFERRIN;ADAPTED PHYSICAL;CANCER CENTERS;ELDERLY PEOPLE;FOLLOW-UP PRACTICE;FUNGAL INFECTIONS;GYNECOLOGICAL ONCOLOGY;INVASIVE FUNGAL;LACTOFERRIN SUPPLEMENTATION;MULTICENTER RANDOMIZED;NETWORK STUDY;ONCOLOGY FOLLOW-UP;ONCOLOGY NETWORK;PATIENT CHARACTERISTICS;PIEDMONT REGIONAL;PRACTICE ATTRIBUTABLE;PREGNANCY OUTCOMES;PRETERM VLBW;PREVENTS INVASIVE;RANDOMIZED CONTROLLED;REGIONAL ONCOLOGY;VLBW NEONATES;ACROFRONTOFACIONASAL DYSOSTOSIS;ACUTE KIDNEY;ADJUVANT CHEMOTHERAPY;ADVANCED HIV;ADVERSE PREGNANCY;AGEING PATIENTS;ALATHR POLYMORPHISM;ALLOGENEIC STEM","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","FUNCTIONAL DEPENDENCE;PREGNANT WOMEN;CDC-C WOMEN;CONCURRENT ARM;FASTING PLASMA;GESTATIONAL AGE;GLUCOSE LEVELS;INCREASE CI;PLASMA GLUCOSE;STANDARD-DOSE REGIMEN;TEST SET;TOXIC EFFECTS;TRAINING SET;TRIAGE SYSTEM;TUMOUR TISSUE;ACUTE CRITICAL;ADJUVANT CHEMOTHERAPY;ADULTS CHILDREN;ADVANCED AGE;ADVANCED HIV;ADVERSE EFFECTS;ADVERSE PERINATAL;ALLELIC VARIANTS;ANALYSIS CONFIRMED;ANTIRETROVIRAL TREATMENT;ARM PATIENTS;BREAST CANCER;CRITICAL ILLNESS;EXOGENOUS FSH;FETAL GROWTH","4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,7.43,327.29,25.81,3,0.38,81.5,0,0,3,0,2,0,0,3,0,5,2,0,0,0,0,0,0,7,1,0,7,1,0,0,0,0,0,0,0,0,"United States;Italy","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","7;5;5;1;1;1","CLINICAL RESEARCH;CANCER;RARE DISEASES;HEMATOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LYMPHOMA;ORPHAN DRUG;PEDIATRIC;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;TRANSPLANTATION;AGING;CHILDHOOD LEUKEMIA;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEALTH SERVICES;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES","7;6;6;5;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","4;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;8.1 ORGANISATION AND DELIVERY OF SERVICES","4;3;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LIVER CANCER;OVARIAN CANCER","4;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","5;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2012,66,13.8787878787879,2.40909090909091,0.227272727272727,0.181818181818182,0.257575757575758,1.18691588785047,1,1,1.0625,0.409090909090909,1,36,17,4,2,0.55,0.26,0.06,0.03,36.89,0.883299263595949,4.79423868312757,0.409090909090909,0.893939393939394,0.328,0.394,0.427,0.29,"UMBERTO VITOLO;PAOLO MANZONI;GABRIELLA RESTAGNO;ADRIANO CHIÒ;ANDREA CALVO;GIUSEPPE ROSSI;ALAN E. RENTON;MAURO STRONATI;IRENE OSSOLA;GABRIELE MORA;MARIO SABATELLI;MARCELLA ZOLLINO;MAURA PUGLIATTI;MONICA BALZAROTTI;DIONYSSIOS KATSAROS;TULLIA TODROS;BRYAN J. TRAYNOR;GIANLUCA GAÏDANO;JESSICA MANDRIOLI;DANIELE FARINA","7;7;7;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","VITO SANNA;PAOLO MANZONI;GABRIELLA AGNOLETTI;FULVIO GABBARINI;ROBERTO BORDESE;MAURO STRONATI;ROBERTA MARAGLIANO;ANDREA BELLONE;MASSIMILIANO ETTERI;TULLIA TODROS;GABRIELLA RESTAGNO;A. BORGHESI;DANIELE FARINA;UMBERTO VITOLO;MATTEO PAONESSA;LORENZA MARENGO;ANTONIO ANDREACCHIO;ROSSELLA ATTINI;GIORGINA BARBARA PICCOLI;MARTINA FERRARESI","1;0.83;0.62;0.53;0.53;0.52;0.52;0.5;0.5;0.47;0.4;0.37;0.36;0.35;0.33;0.33;0.33;0.33;0.33;0.33","UMBERTO VITOLO;GABRIELLA RESTAGNO;ADRIANO CHIÒ;ANDREA CALVO;TULLIA TODROS;ROSSELLA ATTINI;ANNALISA CHIAPPELLA;MARCO LADETTO;FEDERICA FASSIO;CRISTINA MOGLIA;MARIO BOCCADORO;GIULIA BENEVOLO;CAROLA BOCCOMINI;ANDREA EVANGELISTA;ISABELLA CASTELLANO;BARBARA BOTTO;ALESSANDRO MUSSA;ANNA SAPINO;SILVIA PARISI;MICHAEL MOSTERT","7;7;6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","TULLIA TODROS;GABRIELLA RESTAGNO;UMBERTO VITOLO;ROSSELLA ATTINI;FEDERICA FASSIO;LUCIA D’AMICO;ENRICO RUFFINI;ELISA POZZI;RICCARDO FERRACINI;ALFREDO BRUSCO;ILARIA ROATO;ADRIANO CHIÒ;SILVIA PARISI;ALESSANDRO MUSSA;ANDREA CALVO;FEDERICA TRIVELLI;C. MARMO;FRANCESCO OLIVA;FRANCESCO SAVINO;PIERMARIA FURLAN","0.47;0.4;0.35;0.33;0.31;0.25;0.25;0.25;0.25;0.25;0.25;0.24;0.22;0.21;0.18;0.17;0.17;0.17;0.17;0.17","PAOLO MANZONI;EVELYNE JACQZ‐AIGRAIN;DANIEL K. BENJAMIN;FLORENTIA KAGUELIDOU;P. BRIAN SMITH;CHRISTOPH P. HORNIK;KEVIN M. WATT;MICHAEL COHEN-WOLKOWIEZ;PREM FORT;REESE H. CLARK;GABRIELLA RESTAGNO;ADRIANO CHIÒ;ANDREA CALVO;ALAN E. RENTON;BRYAN J. TRAYNOR;ELISA MAJOUNIE;FRANCESCO MARROSU;GIUSEPPE BORGHERO;IRENE OSSOLA;MARIA ALESSANDRA SOTGIU","594;493;484;484;484;467;467;467;467;467;385;345;345;337;337;337;337;337;337;337","ADRIANO CHIÒ;ANDREA CALVO;TULLIA TODROS;ROSSELLA ATTINI;UMBERTO VITOLO;ALESSANDRO ROLFO;ANNA MARIA NUZZO;ANNALISA PIAZZESE;SILVIA PARISI;ANNA SAPINO;ISABELLA CASTELLANO;MARIO BOCCADORO;ANDREA EVANGELISTA;BARBARA BOTTO;GIULIA BENEVOLO;MICHAEL MOSTERT;CRISTINA MOGLIA;DANIELA SARDEI;MASSIMO BELLETTATO;NICOLETTA BIGLIA","284;284;174;134;128;123;123;123;123;101;101;87;85;85;85;82;81;68;68;64","UMBERTO VITOLO;ADRIANO CHIÒ;ANDREA CALVO;TULLIA TODROS;ANNA SAPINO;CAROLA BOCCOMINI;ISABELLA CASTELLANO;MARIO BOCCADORO;MICHAEL MOSTERT;ROSSELLA ATTINI;ALBERTO ROCCI;ALESSANDRA LAROCCA;ALESSANDRO MUSSA;ALESSANDRO ROLFO;ALFREDO BRUSCO;ANDREA EVANGELISTA;ANDREA ZONTA;ANNA GILLIO‐TOS;ANNA MARIA NUZZO;ANNA MONDINO","7;4;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ECONOMICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;ART;SOCIOLOGY","61;27;4;3;3;3;2;2;2;2;2;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;PEDIATRICS;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;IMMUNOLOGY;OBSTETRICS;ANESTHESIA;OPTICS;PSYCHIATRY;RADIOLOGY;CANCER RESEARCH;DERMATOLOGY;ENDOCRINOLOGY;FAMILY MEDICINE;GYNECOLOGY;NEUROSCIENCE;PALEONTOLOGY","51;23;20;12;11;11;10;7;7;5;5;5;4;4;4;4;3;3;3;3;3;3;3","GENE;CHEMOTHERAPY;CANCER;DISEASE;PREGNANCY;LYMPHOMA;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;POPULATION;ADVERSE EFFECT;BIOPSY;MULTIPLE MYELOMA;TRANSPLANTATION;COHORT;INCIDENCE (GEOMETRY);ANTIFUNGAL;ASYMPTOMATIC;CLINICAL TRIAL;CONFOUNDING;CONTEXT (ARCHAEOLOGY);CYST;CYTOLOGY;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;INTENSIVE CARE;KIDNEY DISEASE;LEUKEMIA;MECHANICAL VENTILATION;NEONATAL INTENSIVE CARE UNIT;OBSTRUCTIVE SLEEP APNEA;ODDS RATIO;PSYCHOLOGICAL INTERVENTION;REGIMEN;RESPIRATORY DISTRESS;TOXICITY;VENTILATION (ARCHITECTURE)","13;11;10;10;10;7;7;6;5;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","AMYOTROPHIC LATERAL SCLEROSIS;BREAST CANCER;GESTATIONAL AGE;MUTATION;RITUXIMAB;ALLELE;DEMENTIA;FOLLICULAR LYMPHOMA;PHASES OF CLINICAL RESEARCH;BIRTH WEIGHT;CYCLOPHOSPHAMIDE;DIFFUSE LARGE B-CELL LYMPHOMA;LENALIDOMIDE;NEUTROPENIA;OVARIAN CANCER;RNA;CHEMOTHERAPY REGIMEN;CLINICAL ENDPOINT;CONTINUOUS POSITIVE AIRWAY PRESSURE;EPIDERMAL GROWTH FACTOR RECEPTOR;FETUS;FLUCONAZOLE;GENE EXPRESSION;HAZARD RATIO;LOW BIRTH WEIGHT;MITOXANTRONE;MUTANT;PEDIGREE CHART;TOLERABILITY","5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","FRONTOTEMPORAL DEMENTIA;TRINUCLEOTIDE REPEAT EXPANSION;BRONCHOPULMONARY DYSPLASIA;ERLOTINIB;SOD1;ALTERNATIVE SPLICING;ANTHRACYCLINE;ASCUS (BRYOZOA);BENDAMUSTINE;BONE MARROW TRANSPLANT;CENTRAL VENOUS PRESSURE;CHEMOIMMUNOTHERAPY;CHROMOSOME INSTABILITY;COLPOSCOPY;COMPOUND HETEROZYGOSITY;DNA METHYLATION;ECHINOCANDIN;FEBRILE NEUTROPENIA;FLUDARABINE;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;GEFITINIB;GENE EXPRESSION PROFILING;GENOME INSTABILITY;GERMLINE MUTATION;GLOMERULOSCLEROSIS;HERPESVIRIDAE;HETEROPLASMY;HIPPOCAMPAL SCLEROSIS;INTRAUTERINE GROWTH RESTRICTION;INTRAVENTRICULAR HEMORRHAGE;INVASIVE CANDIDIASIS;LATENT TUBERCULOSIS;LONG NON-CODING RNA;MEVALONATE PATHWAY;MICROARRAY;MISSENSE MUTATION;MORPHOLINO;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;NICOTINIC ACETYLCHOLINE RECEPTOR;OVARIAN CARCINOMA;PLACENTAL GROWTH FACTOR;POLYCYSTIC OVARY;PROSTATE BIOPSY;PROSTATECTOMY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETICULOCYTE;RETINOPATHY OF PREMATURITY;RNA SPLICING;SENTINEL LYMPH NODE;SENTINEL NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL FOR GESTATIONAL AGE;TAXANE;THIOTEPA;TRASTUZUMAB;TRUEBEAM;UMBILICAL ARTERY;VINCRISTINE;ZEAXANTHIN","4;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;ADULT;ITALY;INFANT, NEWBORN;MIDDLE AGED;INFANT, PREMATURE, DISEASES;AGED;AMYOTROPHIC LATERAL SCLEROSIS;BREAST NEOPLASMS;MUTATION;ADOLESCENT;RETROSPECTIVE STUDIES;ANTIFUNGAL AGENTS;CHILD, PRESCHOOL;INFANT;NEOPLASM RECURRENCE, LOCAL;RESPIRATORY THERAPY","46;32;21;19;18;18;17;15;13;12;12;11;10;9;9;8;8;8;8;8","AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;LYMPHOID NEOPLASMS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;BREASTFEEDING: EPIDEMIOLOGY, MECHANISMS, AND HEALTH OUTCOMES;CHOLINESTERASE INHIBITORS IN NEURODEGENERATIVE DISEASES;CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS AND CRISPR-ASSOCIATED PROTEINS;DENTAL ANXIETY AND ANESTHETIC MANAGEMENT IN DENTISTRY;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;DIAGNOSIS AND MANAGEMENT OF URTICARIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND TREATMENT OF PATENT DUCTUS ARTERIOSUS;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;DIAGNOSIS AND TREATMENT OF RETINOPATHY OF PREMATURITY;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES","5;5;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","C9ORF72;FOLLICULAR LYMPHOMA;NEURODEGENERATION;TREATMENT OUTCOMES;B-CELL RECEPTOR SIGNALING;BREAST CANCER;BRONCHOPULMONARY DYSPLASIA;CHEMOTHERAPY REGIMEN;CLINICAL ENDPOINT;LYMPHOMA;MANTLE CELL LYMPHOMA;MITOXANTRONE;ONCOGENE ADDICTION;PEDIGREE CHART;PRENATAL DIAGNOSIS;PRETERM INFANTS;PULMONARY VALVE REPLACEMENT;REGIMEN;TARDBP;TOLERABILITY","5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;FONDAZIONE ITALIANA;ITALIANA LINFOMI;LINFOMI FIL;B-CELL LYMPHOMA;FINAL RESULTS;INTENSIVE CARE;PHASE II;PHASE III;AMYOTROPHIC LATERAL;CARE UNITS;CELL TRANSPLANTATION;CHRONIC KIDNEY;CLINICAL CHARACTERISTICS;DISEASE PROGRESSION;DOSE-DENSE CHEMOTHERAPY;EORTC-GCG STUDY;ERLOTINIB VERSUS;FIRST-LINE PLATIN-BASED;FOLLICULAR LYMPHOMA;HEXANUCLEOTIDE REPEAT;III STUDY;ITALIAN SURVEY;KIDNEY DISEASE;LATERAL SCLEROSIS;LYMPHOMA DLBCL;MULTICENTER STUDY;NEONATAL INTENSIVE;NEONATAL RESPIRATORY;NEWLY DIAGNOSED","4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;KIDNEY DISEASE;CHRONIC KIDNEY;AMYOTROPHIC LATERAL;MED -CROSSREF;SERUM LEVELS;CKD PATIENTS;GESTATIONAL AGE;GROWTH FACTOR;OBSTET GYNECOL;LATERAL SCLEROSIS;FAMILIAL AMYOTROPHIC;DIFFERENTIAL DIAGNOSIS;END-STAGE RENAL;LATE-ONSET SEPSIS;NEPHROL -GOOGLE;REPEAT EXPANSION;SIGNIFICANTLY INCREASED;SOC NEPHROL;ALAN AUTOMATED;AUTOMATED METHOD;DISEASEN ENGL;ENDOTHELIAL GROWTH;GLOMERULAR FILTRATION;GYNECOL -CROSSREF;HEXANUCLEOTIDE REPEAT;INTENSIVE CARE;IRGENS LM;LM LEIVESTAD","38;28;19;14;13;12;12;11;11;11;11;10;9;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6",5,0.08,7,4,1,0,0,0,2,0,1.75,4,0,0,3,0,0,1,0,2,1.75,0,0,58,59,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,6.2,1441,14.56,9,0.6,110.8,0,0,5,0,6,0,0,4,0,13,2,0,0,0,0,0,0,14,1,0,15,0,0,0,0,0,0,0,0,0,"United States;Germany;Italy","7;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;39 EDUCATION;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","14;7;5;5;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;DIGESTIVE DISEASES;LYMPHOMA;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEPATITIS;LIVER DISEASE;BRAIN DISORDERS;CARDIOVASCULAR;HEART DISEASE;NEUROSCIENCES;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;BIOENGINEERING;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN CANCER","14;13;8;7;6;4;4;3;3;3;2;2;2;2;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;ORAL AND GASTROINTESTINAL;STROKE","4;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.7 PHYSICAL","11;3;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BRAIN TUMOR;BREAST CANCER;COLON AND RECTAL CANCER;LIVER CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER","3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","6;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2013,178,11.5730337078652,3.06179775280899,0.376404494382022,0.314606741573034,0.646067415730337,1.52058823529412,1.06349206349206,1.43589743589744,1.13861386138614,0.50561797752809,2,104,27,25,8,0.58,0.15,0.14,0.04,28.67,0.821623161844394,4.7427652733119,0.303370786516854,0.853932584269663,0.412,0.353,0.411,0.372,"UMBERTO VITOLO;MARIO BOCCADORO;FIORENZO GAÏTA;PAOLO MANZONI;ANGELO MICHELE CARELLA;CLAUDIO MORETTI;GIANLUCA GAÏDANO;ANNALISA CHIAPPELLA;GABRIELLA RESTAGNO;DAVIDE ROSSI;STEFANO LUMINARI;FABRIZIO D’ASCENZO;FRANCESCO NOVELLI;PELLEGRINO MUSTO;PAOLA CAPPELLO;ANTONIO PALUMBO;BERNARDINO ALLIONE;STEFANO D’ARDÌA;PAOLO SOLIDORO;LUCA BALDINI","15;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5","UMBERTO VITOLO;RICCARDO SOFFIETTI;FRANCESCO NOVELLI;PAOLA CAPPELLO;A PALMO;PAOLO MANZONI;MARIO BOCCADORO;FIORENZO GAÏTA;PAOLO SOLIDORO;ANTONIO PALUMBO;CLAUDIO MORETTI;FABRIZIO D’ASCENZO;ANNALISA CHIAPPELLA;GABRIELLA RESTAGNO;DANIEL K. BENJAMIN;RICCARDO FERRACINI;ILARIA ROATO;SEBASTIANO MARRA;MARIA AGNESE LATINO;DANIELA DE MARIA","1.37;1.27;1.03;1.03;1;0.91;0.82;0.78;0.75;0.74;0.69;0.69;0.67;0.67;0.6;0.58;0.58;0.58;0.56;0.53","UMBERTO VITOLO;MARIO BOCCADORO;FIORENZO GAÏTA;CLAUDIO MORETTI;ANNALISA CHIAPPELLA;GABRIELLA RESTAGNO;FABRIZIO D’ASCENZO;FRANCESCO NOVELLI;PAOLA CAPPELLO;ANTONIO PALUMBO;BERNARDINO ALLIONE;STEFANO D’ARDÌA;PAOLO SOLIDORO;ADRIANO CHIÒ;CHIARA FRAIRIA;PAOLA OMEDÈ;MASSIMO BOFFINI;ANDREA EVANGELISTA;MARTA COSCIA;CLARA PECORARO","15;9;8;7;7;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4","UMBERTO VITOLO;RICCARDO SOFFIETTI;FRANCESCO NOVELLI;PAOLA CAPPELLO;A PALMO;MARIO BOCCADORO;FIORENZO GAÏTA;PAOLO SOLIDORO;ANTONIO PALUMBO;CLAUDIO MORETTI;FABRIZIO D’ASCENZO;ANNALISA CHIAPPELLA;GABRIELLA RESTAGNO;RICCARDO FERRACINI;ILARIA ROATO;SEBASTIANO MARRA;PIERLUIGI SBARRA;PAOLO GONTERO;CHIARA FIORITO;CASTAGNO","1.37;1.27;1.03;1.03;1;0.82;0.78;0.75;0.74;0.69;0.69;0.67;0.67;0.58;0.58;0.58;0.5;0.5;0.5;0.5","UMBERTO VITOLO;FRANCESCO NOVELLI;PAOLA CAPPELLO;PELLEGRINO MUSTO;MARIO MORINO;ALEX VENDRAME;ANDREA BORASI;ANTONIO PONTI;CAMILLE MAZZA;DONATELLA SCAGLIONE;FABRIZIO REBECCHI;G R FRONDA;L. LOCATELLI;LORENZO CAPUSSOTTI;LUCA VIGANÒ;M GARINO;MARIANO TOMATIS;MAURIZIO DEGIULI;MITSURU SASAKO;PAOLO MELLO TEGGIA","453;351;351;310;304;293;293;293;293;293;293;293;293;293;293;293;293;293;293;293","UMBERTO VITOLO;PAOLA CAPPELLO;ALEX VENDRAME;ANDREA BORASI;CAMILLE MAZZA;G R FRONDA;MAURIZIO DEGIULI;FABIO MALAVASI;FRANCESCO NOVELLI;ANTONIO PALUMBO;ANNALISA CHIAPPELLA;MIRELLA GIOVARELLI;ALBERTO L. HORENSTEIN;CAROLA BOCCOMINI;MARIO BOCCADORO;TULLIA TODROS;ADRIANO CHIÒ;VITO FANELLI;PAOLA OMEDÈ;VALERIA MAGAROTTO","453;351;293;293;293;293;293;271;268;247;241;233;224;224;211;194;189;180;169;167","UMBERTO VITOLO;ANNALISA CHIAPPELLA;CLAUDIO MORETTI;FIORENZO GAÏTA;PAOLA CAPPELLO;BERNARDINO ALLIONE;FABRIZIO D’ASCENZO;PAOLO SOLIDORO;ANTONIO PALUMBO;MARIO BOCCADORO;STEFANO D’ARDÌA;FRANCESCO NOVELLI;MARTA COSCIA;MAURO RINALDI;SEBASTIANO MARRA;CHIARA FRAIRIA;CLARA PECORARO;ERNESTA AUDISIO;FILIPPO MARMONT;ADRIANO CHIÒ","15;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;MATHEMATICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;SOCIOLOGY;PSYCHOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE;BUSINESS;PHILOSOPHY","164;66;18;13;11;10;7;5;4;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;IMMUNOLOGY;GASTROENTEROLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;INTENSIVE CARE MEDICINE;PEDIATRICS;BIOCHEMISTRY;CARDIOLOGY;PSYCHIATRY;ENDOCRINOLOGY;RADIOLOGY;CELL BIOLOGY;PALEONTOLOGY;OPTICS;STATISTICS","133;47;41;36;32;30;29;21;19;17;17;16;13;13;12;12;10;10;9;9","CANCER;CHEMOTHERAPY;GENE;DISEASE;POPULATION;LYMPHOMA;CONFIDENCE INTERVAL;BONE MARROW;MULTIPLE MYELOMA;MULTIVARIATE ANALYSIS;PREGNANCY;COHORT;INCIDENCE (GEOMETRY);STAGE (STRATIGRAPHY);BIOPSY;IMMUNE SYSTEM;OBSERVATIONAL STUDY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION","31;26;25;24;20;19;16;12;12;10;10;9;9;9;8;8;8;8;8;8;8","RITUXIMAB;BREAST CANCER;CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;HAZARD RATIO;CYCLOPHOSPHAMIDE;LENALIDOMIDE;CUMULATIVE INCIDENCE;GENOTYPE;METASTASIS;NEUTROPENIA;CISPLATIN;GESTATIONAL AGE;MUTATION;UNIVARIATE ANALYSIS;CHRONIC LYMPHOCYTIC LEUKEMIA;FETUS;GENE EXPRESSION;MYELODYSPLASTIC SYNDROMES;PANCREATIC CANCER;PHENOTYPE","13;12;10;10;9;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4","CARBOPLATIN;FEBRILE NEUTROPENIA;FLUDARABINE;INTERNATIONAL PROGNOSTIC INDEX;OBINUTUZUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;AA AMYLOIDOSIS;AGGRESSIVE LYMPHOMA;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;AXILLA;BRONCHOPULMONARY DYSPLASIA;CANCER IMMUNOTHERAPY;CASPOFUNGIN;CD38;DNA METHYLATION;EPIRUBICIN;EXOME SEQUENCING;FRONTOTEMPORAL DEMENTIA;HERPESVIRIDAE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;NEOADJUVANT THERAPY;POSACONAZOLE;PRIMARY TUMOR;SENTINEL LYMPH NODE;TRASTUZUMAB;VINCRISTINE","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;;MALE;MIDDLE AGED;ADULT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;MULTIPLE MYELOMA;TREATMENT OUTCOME;BREAST NEOPLASMS;AGED, 80 AND OVER;PROGNOSIS;RETROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS;YOUNG ADULT;FOLLOW-UP STUDIES;BRAIN NEOPLASMS;NEOPLASMS","108;77;69;68;48;47;40;33;28;22;22;19;18;18;18;17;16;15;14;14","LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ACUTE MYELOID LEUKEMIA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLIOMAS;MANAGEMENT OF VALVULAR HEART DISEASE;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ATRIAL FIBRILLATION;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CANCER STEM CELLS AND TUMOR METASTASIS;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;HER2 SIGNALING IN BREAST CANCER TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MELANOMA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;PANCREATIC CANCER RESEARCH AND TREATMENT","11;7;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;INTERNATIONAL MYELOMA WORKING GROUP;CUMULATIVE INCIDENCE;HEMATOLOGY;CARBOPLATIN;REGIMEN;TREATMENT;UNIVARIATE ANALYSIS;BREAST CANCER;CONCOMITANT;RADIOTHERAPY;REFRACTORY (PLANETARY SCIENCE);DISCONTINUATION;FETAL DNA ANALYSIS;HIV INFECTION;INTERNATIONAL PROGNOSTIC INDEX;MANTLE CELL LYMPHOMA;MINIMAL RESIDUAL DISEASE;NEOADJUVANT THERAPY","10;10;7;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3","MULTIPLE MYELOMA;PHASE II;BREAST CANCER;FONDAZIONE ITALIANA;ITALIANA LINFOMI;OVARIAN CANCER;FOLLICULAR LYMPHOMA;II STUDY;RETROSPECTIVE STUDY;ACUTE MYELOID;B-CELL LYMPHOMA;CELL TRANSPLANTATION;CHRONIC LYMPHOCYTIC;EMERGENCY DEPARTMENT;LYMPHOCYTIC LEUKEMIA;MULTICENTER PHASE;MYELOID LEUKAEMIA;OBSERVATIONAL STUDY;PANCREATIC CANCER;PATIENTS AFFECTED;PHASE III;STEM CELL;AA AMYLOIDOSIS;ACUTE CORONARY;ADVANCED OVARIAN;ALLOGENEIC STEM;AMYOTROPHIC LATERAL;AORTIC DISSECTION;AORTIC VALVE;B-CELL LYMPHOMAS","7;7;6;6;6;6;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","BONE MARROW;RISK FACTORS;CONFIDENCE INTERVAL;PROGRESSION-FREE SURVIVAL;RISK SCORE;ALERT Q-PCR;BREAST CANCER;ECONOMIC BURDEN;HORMONAL CONTRACEPTION;HR CI;MAXIMUM ERROR;PATIENTS UNDERGOING;PROGENITOR CELLS;SIGNIFICANT DIFFERENCE;SURVIVAL OS;XPERT CT;ADULT PATIENTS;B-CELL LYMPHOMA;BISPHOSPHONATE TREATMENT;CBF AML;CD CD;CELL VIABILITY;ENDOTHELIAL PROGENITOR;FUNGAL INFECTIONS;IMMUNE RESPONSES;INTENSIVE CARE;MEDIAN FOLLOW-UP;MULTIVARIATE ANALYSIS;PANCREATIC CANCER;PREGNANT WOMEN","9;8;7;7;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5",48,0.27,6,4,1,1,0,1,2,1,1,5.25,0,1,4,0,1.75,1.25,1.25,2,2,0,0,87.5,87.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5.68,975.76,7.93,14,0.54,52.5,2,1,6,2,5,0,1,9,0,17,8,0,0,0,0,0,0,24,1,1,25,1,0,0,0,0,0,0,0,0,"United States;Germany;Italy","8;3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3213 PAEDIATRICS","26;16;10;10;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LYMPHOMA;ORPHAN DRUG;PATIENT SAFETY;AGING;BREAST CANCER;STEM CELL RESEARCH;TRANSPLANTATION;CARDIOVASCULAR;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;HEART DISEASE;INFECTIOUS DISEASES;LIVER DISEASE;PREVENTION;BIOTECHNOLOGY","23;20;18;14;12;8;6;4;3;3;3;3;2;2;2;2;2;2;2;1","CANCER;CARDIOVASCULAR;BLOOD;INFECTION;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","14;3;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","17;3;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BREAST CANCER;LIVER CANCER;MYELOMA;HODGKIN'S DISEASE;LUNG CANCER;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER;THYROID CANCER","9;7;3;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","14;3;1;1;1",2,3245753,263535.28,5,15,10.5,1,53,157512.805555556,1.13006684994395,"AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;AMGEN (SWITZERLAND);AMSTERDAM UMC LOCATION VUMC;AUTONOMOUS UNIVERSITY OF MADRID;BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS;DANISH CANCER SOCIETY;DUBLIN CITY UNIVERSITY;DÉLÉGATION PARIS 11;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;INSTITUT CATALÀ D'ONCOLOGIA;INSTITUT SCIENTIFIQUE DE SANTÉ PUBLIQUE;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;KAROLINSKA INSTITUTET;KING'S COLLEGE LONDON;MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH;MEDICAL UNIVERSITY OF VIENNA;QUEEN MARY UNIVERSITY OF LONDON;SORBONNE UNIVERSITY;TAMPERE UNIVERSITY;UNIVERSITY MEDICAL CENTER FREIBURG","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2013-INNOVATION-1 (CALL FOR PROPOSAL);CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);CSA-SA - SUPPORT ACTIONS (FUNDING SCHEME)","2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;1;1;1;1","CANCER;CERVICAL CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;COST EFFECTIVENESS RESEARCH;HEALTH SERVICES;HPV AND/OR CERVICAL CANCER VACCINES;IMMUNIZATION;INFECTIOUS DISEASES;KIDNEY DISEASE;PREVENTION;SEXUALLY TRANSMITTED INFECTIONS;VACCINE RELATED","1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;RENAL AND UROGENITAL","1;1;1","3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;3.4 VACCINES;4.4 POPULATION SCREENING","1;1;1","CERVICAL CANCER","1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","1;1","A01 CLINICAL MEDICINE;A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1;1",NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;1","CANCER;DIGESTIVE DISEASES;RARE DISEASES","1;1;1",NA,NA,NA,NA,NA,NA,"BASIC SCIENCE","1",NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2014,292,14.2671232876712,3.24315068493151,0.308219178082192,0.291095890410959,0.469178082191781,1.64937388193202,1.09756097560976,1.34920634920635,1.14166666666667,0.517123287671233,0,184,58,17,11,0.63,0.2,0.06,0.04,52.43,1.38729087875205,4.71610169491525,0.318493150684932,0.88013698630137,0.433,0.395,0.455,0.408,"UMBERTO VITOLO;MARIO BOCCADORO;ADRIANO CHIÒ;ANDREA CALVO;FIORENZO GAÏTA;BENEDETTO BRUNO;ANNA SAPINO;ANTONIO CANOSA;ANDREA EVANGELISTA;ANTONIO PALUMBO;UMBERTO RICARDI;CRISTINA MOGLIA;PAOLA OMEDÈ;GABRIELLA RESTAGNO;GIOVANNINO CICCONE;FLAVIA SALVI;MAURA BRUNETTI;PAOLO MANZONI;GIANLUCA GAÏDANO;LEONARDO LOPIANO","17;16;15;14;12;12;12;11;11;11;11;11;10;10;9;9;9;8;8;8","FIORENZO GAÏTA;MARIO BOCCADORO;BENEDETTO BRUNO;UMBERTO VITOLO;UMBERTO RICARDI;ADRIANO CHIÒ;ANDREA CALVO;LORENZO PINESSI;L SAVI;CECILIA CONDELLO;ANNA SAPINO;PAOLO SOLIDORO;CRISTINA MOGLIA;ANTONELLA VARETTO;ANDREA EVANGELISTA;ANTONIO CANOSA;LEONARDO LOPIANO;PAOLO MANZONI;G. GRASSI;ANTONIO PALUMBO","1.32;1.31;1.28;1.19;1.05;1.05;1.03;1.01;1;1;0.99;0.84;0.8;0.79;0.79;0.78;0.78;0.74;0.73;0.7","UMBERTO VITOLO;MARIO BOCCADORO;ADRIANO CHIÒ;ANDREA CALVO;FIORENZO GAÏTA;BENEDETTO BRUNO;ANNA SAPINO;ANTONIO CANOSA;ANDREA EVANGELISTA;ANTONIO PALUMBO;PAOLA OMEDÈ;GABRIELLA RESTAGNO;GIOVANNINO CICCONE;MAURA BRUNETTI;LEONARDO LOPIANO;ALESSANDRO RAMBALDI;MARCO LADETTO;ROBERTO PASSERA;FABRIZIO D’ASCENZO;MAURO SALIZZONI","17;16;15;14;12;12;12;11;11;11;10;10;9;9;8;8;8;8;7;7","FIORENZO GAÏTA;MARIO BOCCADORO;BENEDETTO BRUNO;UMBERTO VITOLO;ADRIANO CHIÒ;ANDREA CALVO;LORENZO PINESSI;L SAVI;CECILIA CONDELLO;ANNA SAPINO;PAOLO SOLIDORO;ANTONELLA VARETTO;ANDREA EVANGELISTA;ANTONIO CANOSA;LEONARDO LOPIANO;G. GRASSI;ANTONIO PALUMBO;GABRIELLA RESTAGNO;MAURA BRUNETTI;PAOLA OMEDÈ","1.32;1.31;1.28;1.19;1.05;1.03;1.01;1;1;0.99;0.84;0.79;0.79;0.78;0.78;0.73;0.7;0.7;0.65;0.64","ANTONIO PALUMBO;MICHÈLE CAVO;ELENA ZAMAGNI;SONJA ZWEEGMAN;ANGELA DISPENZIERI;BRENDAN M. WEISS;BRIAN G.M. DURIE;BRUNO PAIVA;EFSTATHIOS KASTRITIS;EVANGELOS TERPOS;GIAMPAOLO MERLINI;HANS ERIK JOHNSEN;HARTMUT GOLDSCHMIDT;JENS HILLENGAß;JESÚS F. SAN MIGUEL;JO CAERS;JOAN BLADÉ;JUAN JOSÉ LAHUERTA;KENNETH C. ANDERSON;LAURA ROSIÑOL","5115;4776;4694;3992;3930;3930;3930;3930;3930;3930;3930;3930;3930;3930;3930;3930;3930;3930;3930;3930","ANTONIO PALUMBO;GIOVANNINO CICCONE;ANDREA EVANGELISTA;ROSELLA SPADI;ANDREA CALVO;GABRIELLA RESTAGNO;FIORENZO GAÏTA;ADRIANO CHIÒ;MAURA BRUNETTI;FRANCA FAGIOLI;UMBERTO VITOLO;ELISA RUBINO;INNOCENZO RAINERO;LORENZO PINESSI;DIONYSSIOS KATSAROS;SEBASTIAN DORIN ASAFTEI;A PULLARA;LEONARDO LOPIANO;MARIO BOCCADORO;PAOLA OMEDÈ","4301;1254;1192;985;803;495;476;440;430;376;357;351;351;351;350;300;298;277;276;273","UMBERTO VITOLO;ANDREA EVANGELISTA;FIORENZO GAÏTA;GIOVANNINO CICCONE;ANNA SAPINO;MARIO BOCCADORO;ANTONIO PALUMBO;GABRIELLA RESTAGNO;PAOLA OMEDÈ;MAURA BRUNETTI;ANDREA CALVO;MARIO AIROLDI;ALFREDO BRUSCO;FERNANDO MUÑOZ;ANNALISA CHIAPPELLA;BENEDETTO BRUNO;BERNARDINO ALLIONE;DONATELLA PACCHIONI;MARCO BARBERIS;MAURO SALIZZONI","15;10;10;9;8;8;8;8;8;7;6;6;5;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;ECONOMICS;PHILOSOPHY;MATERIALS SCIENCE;SOCIOLOGY;HISTORY;POLITICAL SCIENCE;BUSINESS;GEOLOGY;ART;GEOGRAPHY","276;95;21;20;15;10;10;9;7;6;5;4;3;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PEDIATRICS;CARDIOLOGY;ENDOCRINOLOGY;CANCER RESEARCH;PSYCHIATRY;OPTICS;ANESTHESIA;CELL BIOLOGY;NUCLEAR MEDICINE;NURSING","210;99;63;52;51;49;39;32;29;28;26;24;22;22;20;20;14;11;11;11;11","CANCER;CHEMOTHERAPY;GENE;DISEASE;TRANSPLANTATION;LYMPHOMA;POPULATION;MULTIPLE MYELOMA;CONFIDENCE INTERVAL;CLINICAL TRIAL;COHORT;RADIATION THERAPY;BONE MARROW;INCIDENCE (GEOMETRY);PREGNANCY;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;DIABETES MELLITUS;ALTERNATIVE MEDICINE;BIOPSY;PROSPECTIVE COHORT STUDY","49;44;42;33;33;31;28;22;21;19;19;18;17;15;15;14;13;13;12;11;11;11","RITUXIMAB;BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;HAZARD RATIO;AMYOTROPHIC LATERAL SCLEROSIS;CYCLOPHOSPHAMIDE;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CHROMOSOME;FOLLICULAR LYMPHOMA;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;DIFFUSE LARGE B-CELL LYMPHOMA;LENALIDOMIDE;LIVER TRANSPLANTATION;PROSTATE CANCER;UNIVARIATE ANALYSIS;BORTEZOMIB;CUMULATIVE INCIDENCE;GENOTYPE;PLACEBO;SALVAGE THERAPY;TOLERABILITY","15;13;12;12;11;10;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6","KARYOTYPE;AFLIBERCEPT;BENDAMUSTINE;ELISPOT;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;FRONTOTEMPORAL DEMENTIA;OXALIPLATIN;SENTINEL LYMPH NODE;SOD1;CD38;COLONOSCOPY;DNA METHYLATION;EXECUTIVE DYSFUNCTION;HAPLOTYPE;INTERNATIONAL PROGNOSTIC INDEX;MISSENSE MUTATION;MONOCLONAL;TRINUCLEOTIDE REPEAT EXPANSION;VINCRISTINE","5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;MULTIPLE MYELOMA;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;AMYOTROPHIC LATERAL SCLEROSIS;TREATMENT OUTCOME;YOUNG ADULT;ADOLESCENT;PROSPECTIVE STUDIES;PROGNOSIS;BREAST NEOPLASMS;RISK FACTORS","171;137;125;119;102;86;81;58;43;38;35;33;33;32;27;21;21;20;19;19","LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT OF VALVULAR HEART DISEASE;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;GLIOMAS;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;MELANOMA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MOLECULAR RESEARCH ON BREAST CANCER","18;14;13;6;6;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;TREATMENT;NEURODEGENERATION;REGIMEN;AUTOLOGOUS STEM-CELL TRANSPLANTATION;FOLLICULAR LYMPHOMA;UNIVARIATE ANALYSIS;CUMULATIVE INCIDENCE;INTERNATIONAL MYELOMA WORKING GROUP;PROSTHETIC VALVES EVALUATION;RADIOTHERAPY;SALVAGE THERAPY;STROKE (ENGINE);TOLERABILITY;TREATMENT OUTCOMES;B-CELL RECEPTOR SIGNALING;C9ORF72;CONCOMITANT;CONTINUOUS GLUCOSE MONITORING;DIABETES","12;10;9;9;8;8;7;6;6;6;6;6;6;6;6;5;5;5;5;5","MULTIPLE MYELOMA;CELL TRANSPLANTATION;STEM CELL;AMYOTROPHIC LATERAL;LATERAL SCLEROSIS;ALLOGENEIC STEM;B-CELL LYMPHOMA;CANCER PATIENTS;MYELOMA PATIENTS;NEWLY DIAGNOSED;ELDERLY PATIENTS;FOLLICULAR LYMPHOMA;FONDAZIONE ITALIANA;ITALIANA LINFOMI;LIVER TRANSPLANTATION;PHASE II;AFLIBERCEPT SAFETY;BREAST CANCER;COHORT STUDY;COLORECTAL CANCER;DIABETIC PATIENTS;DIAGNOSED MULTIPLE;GLOBAL AFLIBERCEPT;OVARIAN CANCER;PATIENTS RECEIVING;PHASE III;PHASE STUDY;PROSPECTIVE STUDY;RETROSPECTIVE STUDY;AORTIC VALVE","12;10;10;7;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3","CELL LINES;MULTIPLE MYELOMA;AMYOTROPHIC LATERAL;BONE MARROW;CHEMICAL-SHIFT RATIO;LATERAL SCLEROSIS;SIGNAL INTENSITY;CSR CHEMICAL-SHIFT;INTENSITY INDEX;PATIENTS TREATED;RSV INFECTION;CELL TRANSPLANTATION;HR CI;MEDIAN FOLLOW-UP;SII SIGNAL;CLINICAL TRIALS;CONFIDENCE INTERVAL;INCREASED RISK;PATIENTS RECEIVED;PATIENTS UNDERGOING;STEM CELL;CLINICAL FEATURES;COGNITIVE IMPAIRMENT;LOGISTIC REGRESSION;CANCER PATIENTS;DIFFERENCE CI;MULTIVARIATE ANALYSIS;NESTED PCR;PATIENTS UNDERWENT;REFRACTORY DISEASE","15;15;13;13;13;13;13;12;12;12;12;11;11;11;11;10;10;10;10;10;10;9;9;9;8;8;8;8;8;8",104,0.36,6,6.25,2,1.25,1,6.25,2,1,1.75,7,0,1,5.25,3,3,2,3,3.25,2,0,0,95.25,95.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,5.25,738.28,5.94,13,0.45,54.03,1,1,5,3,6,0,1,12,0,18,11,0,0,0,0,0,0,28,0,1,29,0,0,0,0,0,0,0,0,0,"United States;Italy;United Kingdom;Japan;Netherlands;Sweden","8;3;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3210 NUTRITION AND DIETETICS;3215 REPRODUCTIVE MEDICINE","27;13;9;8;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY;TRANSPLANTATION;ORPHAN DRUG;PREVENTION;STEM CELL RESEARCH;BRAIN DISORDERS;CARDIOVASCULAR;HEART DISEASE;INFECTIOUS DISEASES;NEUROSCIENCES;PEDIATRIC;AGING;CHILDHOOD LEUKEMIA;CHRONIC LIVER DISEASE AND CIRRHOSIS","27;17;16;14;13;8;6;6;5;5;4;3;3;3;3;3;3;2;2;2","CANCER;BLOOD;CARDIOVASCULAR;INFECTION;ORAL AND GASTROINTESTINAL;RESPIRATORY;METABOLIC AND ENDOCRINE;NEUROLOGICAL;RENAL AND UROGENITAL;STROKE","10;2;2;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;3.3 NUTRITION AND CHEMOPREVENTION;6.4 SURGERY;6.7 PHYSICAL","16;12;3;2;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BLOOD CANCER;HODGKIN'S DISEASE;BRAIN TUMOR;LIVER CANCER;LUNG CANCER;MELANOMA;MYELOMA;NOT SITE-SPECIFIC CANCER","7;6;3;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.2 SURVEILLANCE;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","15;4;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,"PUBLIC LIBRARY OF SCIENCE","3","42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;44 HUMAN SOCIETY;32 BIOMEDICAL AND CLINICAL SCIENCES;4202 EPIDEMIOLOGY;4403 DEMOGRAPHY","3;2;2;2;1;1;1","AGING;DIABETES;GENETICS;PREVENTION;NUTRITION;OBESITY","2;2;2;2;1;1","METABOLIC AND ENDOCRINE","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING","1;1;1","POPULATION & SOCIETY","1","PUBLIC HEALTH","1",NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2015,351,14.5356125356125,3.15099715099715,0.267806267806268,0.267806267806268,0.47008547008547,1.64535768645358,1.14634146341463,1.49206349206349,1.23134328358209,0.538461538461538,5,218,64,25,29,0.62,0.18,0.07,0.08,33.23,0.891665339585145,5.2751572327044,0.321937321937322,0.888888888888889,0.424,0.404,0.446,0.417,"UMBERTO VITOLO;MARIO BOCCADORO;GIOVANNINO CICCONE;ANDREA EVANGELISTA;ANNALISA CHIAPPELLA;MARCO LADETTO;ADRIANO CHIÒ;FRANCESCO NOVELLI;ALFREDO BRUSCO;ENRICO FUSARO;PAOLA OMEDÈ;GIULIA BENEVOLO;ANDREA CALVO;ANTONIO PALUMBO;MICHÈLE CAVO;GABRIELLA RESTAGNO;GABRIELE MORA;FIORENZO GAÏTA;TULLIA TODROS;GIANLUCA GAÏDANO","21;14;12;11;11;11;11;10;10;10;9;9;9;9;9;9;8;8;8;8","UMBERTO RICARDI;SIMONE PARISI;UMBERTO VITOLO;FRANCESCA GAY;ANDREA ROSSI ZADRA;ANNALISA CHIAPPELLA;ALESSIA CIANCIO;ENZA CARUSO;A BARACCO;TULLIA TODROS;FRANCESCO NOVELLI;ENRICO FUSARO;MARIO AIROLDI;MARIO BOCCADORO;PAOLA OMEDÈ;GIOVANNINO CICCONE;FIORENZO GAÏTA;ANTONINA SMEDILE;ALFREDO BRUSCO;SEBASTIANO MARRA","1.55;1.53;1.38;1.34;1.33;1.15;1;1;1;0.99;0.94;0.93;0.84;0.83;0.79;0.78;0.78;0.77;0.76;0.73","UMBERTO VITOLO;MARIO BOCCADORO;GIOVANNINO CICCONE;ANDREA EVANGELISTA;ANNALISA CHIAPPELLA;MARCO LADETTO;ADRIANO CHIÒ;FRANCESCO NOVELLI;ALFREDO BRUSCO;ENRICO FUSARO;PAOLA OMEDÈ;GIULIA BENEVOLO;ANDREA CALVO;ANTONIO PALUMBO;MICHÈLE CAVO;GABRIELLA RESTAGNO;FIORENZO GAÏTA;TULLIA TODROS;GIANLUCA GAÏDANO;PATRIZIA PREGNO","21;14;12;11;11;11;11;10;10;10;9;9;9;9;9;9;8;8;8;8","SIMONE PARISI;UMBERTO VITOLO;FRANCESCA GAY;ANDREA ROSSI ZADRA;ANNALISA CHIAPPELLA;ALESSIA CIANCIO;A BARACCO;TULLIA TODROS;FRANCESCO NOVELLI;ENRICO FUSARO;MARIO AIROLDI;MARIO BOCCADORO;PAOLA OMEDÈ;GIOVANNINO CICCONE;FIORENZO GAÏTA;ANTONINA SMEDILE;ALFREDO BRUSCO;SEBASTIANO MARRA;E. GALLIO;CLAUDIO MORETTI","1.53;1.38;1.34;1.33;1.15;1;1;0.99;0.94;0.93;0.84;0.83;0.79;0.78;0.78;0.77;0.76;0.73;0.7;0.67","ZHONGYI HU;MARCO LADETTO;TIMOTHY R. REBBECK;UMBERTO VITOLO;PETER JOHNSON;TULLIA TODROS;MARÍA GOMES DA SILVA;ANDREW JACK;ARMANDO LÓPEZ‐GUILLERMO;HERVÉ TILLY;JAN WALEWSKI;M. ANDRÉ;MICHAEL PFREUNDSCHUH;MICHEL MEIGNAN;MARIO BOCCADORO;DIONYSSIOS KATSAROS;ANTONIO PALUMBO;FRANCESCO NOVELLI;ANIL K. SOOD;CHAO-XING YUAN","1232;1075;1042;993;923;819;786;775;775;775;775;775;775;775;762;729;718;681;616;616","UMBERTO VITOLO;TULLIA TODROS;DIONYSSIOS KATSAROS;FRANCESCO NOVELLI;PAOLA CAPPELLO;MARIO BOCCADORO;ANTONIO PALUMBO;PAOLA OMEDÈ;FRANCESCA GAY;FRANCESCA VIGNOLO-LUTATI;GIOVANNINO CICCONE;PAOLO GONTERO;CARLO SENORE;ANDREA EVANGELISTA;ALESSANDRA MALFITANO;STEFANIA OLIVA;STEFANO SPADA;VALERIA MAGAROTTO;ADRIANO CHIÒ;ANNA CASTIGLIONE","993;782;703;660;577;572;528;467;458;426;379;337;305;302;290;290;290;290;274;269","UMBERTO VITOLO;ANNALISA CHIAPPELLA;GIOVANNINO CICCONE;MARIO BOCCADORO;FRANCESCO NOVELLI;ENRICO FUSARO;ANDREA EVANGELISTA;PATRIZIA PREGNO;MARIO AIROLDI;TULLIA TODROS;SIMONE PARISI;CARLO SENORE;CLAUDIO MORETTI;GIULIA BENEVOLO;VINCENZO CANTALUPPI;ALFREDO BRUSCO;ANTONIO PALUMBO;BARBARA BOTTO;GABRIELLA RESTAGNO;MARCO BARBERIS","20;11;10;10;9;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;MATHEMATICS;ECONOMICS;SOCIOLOGY;BUSINESS;HISTORY;POLITICAL SCIENCE;ART;PHILOSOPHY;GEOGRAPHY;ENVIRONMENTAL SCIENCE;GEOLOGY;MATERIALS SCIENCE","329;115;38;24;21;14;14;12;9;9;7;6;6;4;4;3;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;PATHOLOGY;CANCER RESEARCH;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;CARDIOLOGY;RADIOLOGY;PSYCHIATRY;OPTICS;PALEONTOLOGY;ENDOCRINOLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;OBSTETRICS;GYNECOLOGY","267;86;71;62;62;55;54;39;38;33;32;31;22;21;20;19;19;17;17;15","CANCER;DISEASE;GENE;CHEMOTHERAPY;POPULATION;LYMPHOMA;COHORT;CLINICAL TRIAL;TRANSPLANTATION;INCIDENCE (GEOMETRY);ANTIBODY;PREGNANCY;CONFIDENCE INTERVAL;MULTIPLE MYELOMA;RANDOMIZED CONTROLLED TRIAL;IMMUNE SYSTEM;REGIMEN;ALTERNATIVE MEDICINE;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY;VIRUS","79;42;42;41;35;32;28;22;21;20;19;19;18;18;18;17;12;11;11;11;11;11","BREAST CANCER;COLORECTAL CANCER;RITUXIMAB;CYCLOPHOSPHAMIDE;HAZARD RATIO;CLINICAL ENDPOINT;DIFFUSE LARGE B-CELL LYMPHOMA;FETUS;FOLLICULAR LYMPHOMA;NEUTROPENIA;AMYOTROPHIC LATERAL SCLEROSIS;IMATINIB;PHENOTYPE;UNIVARIATE ANALYSIS;ALLELE;AUTOLOGOUS STEM-CELL TRANSPLANTATION;MUTATION;PLACEBO;B CELL;CD34;CUMULATIVE INCIDENCE;GENE EXPRESSION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;LENALIDOMIDE;T CELL","27;21;17;13;12;11;11;9;9;9;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6","BENDAMUSTINE;IMATINIB MESYLATE;MAMMOGRAPHY;COLONOSCOPY;DASATINIB;EPIRUBICIN;GERMINAL CENTER;HERPESVIRIDAE;PRENATAL DIAGNOSIS;RIBAVIRIN;TRINUCLEOTIDE REPEAT EXPANSION;VINCRISTINE;CARBOPLATIN;CETUXIMAB;COLPOSCOPY;DNA METHYLATION;FEBRILE NEUTROPENIA;FLUDARABINE;MYELOPROLIFERATIVE NEOPLASM;ACROMEGALY;AFLIBERCEPT;ALTERNATIVE SPLICING;ANTIVIRAL THERAPY;CD38;CERVICAL SCREENING;CHEMOIMMUNOTHERAPY;DNA EXTRACTION;DNA FRAGMENTATION;ERLOTINIB;EXOME SEQUENCING;GEFITINIB;GENE EXPRESSION PROFILING;GLYCEMIC INDEX;GONADOTROPIN-RELEASING HORMONE;INDUCED PLURIPOTENT STEM CELL;KRAS;LACTOBACILLUS REUTERI;MONOCLONAL;MYELOID-DERIVED SUPPRESSOR CELL;NILOTINIB;OXALIPLATIN;PARADOXICAL EMBOLISM;PERIPHERAL T-CELL LYMPHOMA;PROSTATECTOMY;RNA SPLICING;RUXOLITINIB;SENTINEL LYMPH NODE;SOD1;STEATOHEPATITIS;THYMIDYLATE SYNTHASE","7;7;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;AGED, 80 AND OVER;BIOMARKERS, TUMOR;PANCREATIC NEOPLASMS;ADOLESCENT;PROSPECTIVE STUDIES;COLORECTAL NEOPLASMS;FOLLOW-UP STUDIES;HODGKIN DISEASE","191;157;141;122;102;83;83;71;55;46;30;30;29;27;25;24;24;23;22;22","LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEPATITIS C INFECTION AND TREATMENT;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ADVANCEMENTS IN LUNG CANCER RESEARCH;BREAST CANCER SCREENING TECHNOLOGY;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;MANAGEMENT OF VALVULAR HEART DISEASE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;RHEUMATOID ARTHRITIS;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;","29;11;11;8;8;8;6;5;5;5;5;4;4;4;4;4;4;4;4;3","REGIMEN;CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;MANTLE CELL LYMPHOMA;BREAST CANCER SCREENING;TREATMENT;UNIVARIATE ANALYSIS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BENDAMUSTINE;IMATINIB MESYLATE;BREAST CANCER;CUMULATIVE INCIDENCE;RADIOTHERAPY;TRANSCATHETER AORTIC-VALVE REPLACEMENT;TUMOR MICROENVIRONMENT;CANCER SCREENING;CONCOMITANT;INTERNATIONAL MYELOMA WORKING GROUP;MUTATION;PROGRESSION-FREE SURVIVAL","12;11;9;9;8;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5","BREAST CANCER;CANCER PATIENTS;FONDAZIONE ITALIANA;ITALIANA LINFOMI;COLORECTAL CANCER;MULTIPLE MYELOMA;PHASE III;FOLLICULAR LYMPHOMA;LINFOMI FIL;MULTICENTER STUDY;B-CELL LYMPHOMA;CANCER SCREENING;ELDERLY PATIENTS;METASTATIC COLORECTAL;NEWLY DIAGNOSED;CELL LYMPHOMA;HEPATOCELLULAR CARCINOMA;LONG-TERM OUTCOME;PRELIMINARY DATA;AMYOTROPHIC LATERAL;CONTROLLED TRIAL;LATERAL SCLEROSIS;MANTLE CELL;PANCREATIC CANCER;RHEUMATOID ARTHRITIS;STEM CELL;CELL TRANSPLANTATION;CLINICAL TRIALS;COHORT STUDY;HODGKIN LYMPHOMA","16;14;13;13;11;11;10;8;8;8;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4","PUBMED SCOPUS;CROSSREF PUBMED;HR CI;BREAST CANCER;B-CELL LYMPHOMA;RESIDUAL DISEASE;MINIMAL RESIDUAL;COLORECTAL CANCER;CD CD;CLINICAL TRIALS;ALCOHOL ABUSE;CELL LYMPHOMA;STEM CELL;TUMOR CELLS;CELL LINES;HEART FAILURE;MANTLE CELL;NEWLY DIAGNOSED;ADVERSE EVENTS;OVARIAN FUNCTION;PATIENTS TREATED;CLIN ONCOL;PROGRESSION-FREE SURVIVAL;CANCER PATIENTS;DIGITAL PCR;MEDIAN AGE;MRD DETECTION;ODDS RATIO;REAL-TIME QUANTITATIVE;SURVIVAL OS","78;56;38;32;31;26;24;20;19;18;16;16;16;16;15;15;15;15;14;14;14;13;13;12;12;12;12;12;12;12",117,0.33,10.75,8,2,1,1,5,2.75,1,1,9,1,1,7,1.5,1,2,2,6,3.75,0,0,102,101,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,5.42,391.53,6,17,0.5,57.79,2,1,8,0,9,0,0,14,0,24,10,0,0,0,0,0,0,30,2,2,34,0,0,0,0,0,0,0,0,0,"United States;Italy;Belgium;Germany;Japan;Switzerland","8;7;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;40 ENGINEERING;3207 MEDICAL MICROBIOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4003 BIOMEDICAL ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","33;16;14;3;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;LUNG;PEDIATRIC;LUNG CANCER;ORPHAN DRUG;BIOENGINEERING;CARDIOVASCULAR;HEART DISEASE;LYMPHOMA;PEDIATRIC CANCER;PREVENTION;BRAIN CANCER;BRAIN DISORDERS;DIGESTIVE DISEASES;GENETICS","30;22;18;12;7;7;6;6;5;5;4;4;4;4;4;4;3;3;3;3","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;SKIN","15;3;1;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.3 MEDICAL DEVICES","18;4;2;1;1","LUNG CANCER;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;MYELOMA;PROSTATE CANCER","5;3;3;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.3 CHEMOPREVENTION;6.2 SURVEILLANCE;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","13;4;2;1;1;1;1",1,2995683,499280.5,6,6,6,1,25,173373.222222222,2.0245340976019,"AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;CANCER SOCIETY OF FINLAND;ERASMUS MC;INSTITUTE OF ONCOLOGY LJUBLJANA;LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE;NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT","1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-PHC-2014-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","1;1;1;1","BREAST CANCER;CANCER;CERVICAL CANCER;CLINICAL RESEARCH;COLO-RECTAL CANCER;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;HEALTH SERVICES;PREVENTION","1;1;1;1;1;1;1;1;1","CANCER","1","4.4 POPULATION SCREENING","1","BREAST CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER","1;1;1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","1;1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2016,424,15.3443396226415,2.80896226415094,0.254716981132075,0.235849056603774,0.417452830188679,1.87019230769231,1.25581395348837,1.44927536231884,1.37209302325581,0.476415094339623,1,273,76,26,22,0.64,0.18,0.06,0.05,26.48,0.815302844899433,5.41556886227545,0.344339622641509,0.917452830188679,0.457,0.501,0.53,0.485,"UMBERTO VITOLO;ANTONIO PALUMBO;MARIO BOCCADORO;GIOVANNINO CICCONE;ENRICO FUSARO;SIMONE PARISI;ANNALISA CHIAPPELLA;UMBERTO RICARDI;PATRIZIA RACCA;FABRIZIO D’ASCENZO;PAOLA CASSONI;RICCARDO RAGONA;FIORENZO GAÏTA;ANDREA EVANGELISTA;BENEDETTO BRUNO;PELLEGRINO MUSTO;F.R. GIGLIOLI;ANGELO MICHELE CARELLA;CLAUDIO MORETTI;MARTA COSCIA","29;22;19;17;17;15;15;15;15;14;14;14;13;13;12;12;11;11;11;11","UMBERTO VITOLO;ANTONIO PALUMBO;ENRICO FUSARO;RICCARDO RAGONA;C. FIANDRA;F.R. GIGLIOLI;FIORENZO GAÏTA;UMBERTO RICARDI;MARIO BOCCADORO;ANNALISA CHIAPPELLA;SIMONE PARISI;PAOLA CASSONI;FABRIZIO D’ASCENZO;GIOVANNINO CICCONE;PATRIZIA RACCA;R. ROPOLO;E. GALLIO;CARLO TOMASINI;PAOLO MANZONI;ANNA SAPINO","2.07;1.96;1.63;1.59;1.32;1.31;1.29;1.27;1.22;1.22;1.21;1.19;1.18;1.13;1.09;1.08;1.07;1.03;0.99;0.87","UMBERTO VITOLO;ANTONIO PALUMBO;MARIO BOCCADORO;GIOVANNINO CICCONE;ENRICO FUSARO;SIMONE PARISI;ANNALISA CHIAPPELLA;UMBERTO RICARDI;PATRIZIA RACCA;FABRIZIO D’ASCENZO;PAOLA CASSONI;FIORENZO GAÏTA;ANDREA EVANGELISTA;BENEDETTO BRUNO;F.R. GIGLIOLI;CLAUDIO MORETTI;MARTA COSCIA;C. FIANDRA;ANNA SAPINO;PAOLA OMEDÈ","29;22;19;17;17;15;15;15;15;14;14;13;13;12;11;11;11;10;10;9","UMBERTO VITOLO;ANTONIO PALUMBO;ENRICO FUSARO;C. FIANDRA;F.R. GIGLIOLI;FIORENZO GAÏTA;UMBERTO RICARDI;MARIO BOCCADORO;ANNALISA CHIAPPELLA;SIMONE PARISI;PAOLA CASSONI;FABRIZIO D’ASCENZO;GIOVANNINO CICCONE;PATRIZIA RACCA;R. ROPOLO;E. GALLIO;CARLO TOMASINI;PAOLO MANZONI;ANNA SAPINO;BENEDETTO BRUNO","2.07;1.96;1.63;1.32;1.31;1.29;1.27;1.22;1.22;1.21;1.19;1.18;1.13;1.09;1.08;1.07;1.03;0.99;0.87;0.86","VALTER TORRI;ANTONIO PALUMBO;PATRIZIA RACCA;EMANUELE ZUCCA;DANIELE REGGE;LIVIO TRUSOLINO;FORTUNATO CIARDIELLO;ANDREA SARTORE‐BIANCHI;COSIMO MARTINO;FRANCESCO LEONE;SALVATORE SIENA;SARA LONARDI;SILVIA MARSONI;VITTORINA ZAGONEL;ALBERTO BARDELLI;ALESSIO AMATU;PAOLO M. COMOGLIO;GIULIA SIRAVEGNA;EMANUELE VALTORTA;ANGELO VANZULLI","1361;1169;1070;1032;904;900;898;897;897;897;897;897;897;897;892;892;882;879;874;872","ANTONIO PALUMBO;PATRIZIA RACCA;UMBERTO VITOLO;ROBERTA RUDÀ;GIOVANNINO CICCONE;VALERIA MAGAROTTO;LAURENT ORSI;GIULIA BENEVOLO;FRANCESCO NOVELLI;FABRIZIO D’ASCENZO;ANDREA EVANGELISTA;SARA TÙNESI;EMANUELE PIVETTA;PAOLA CAPPELLO;ANNALISA CHIAPPELLA;MARIO BOCCADORO;ENRICO FUSARO;FIORENZO GAÏTA;MICHELA DONADIO;CLAUDIO MORETTI","1166;957;815;508;481;473;461;386;373;350;345;340;284;278;274;265;250;245;243;239","UMBERTO VITOLO;ANTONIO PALUMBO;ENRICO FUSARO;ANNALISA CHIAPPELLA;GIOVANNINO CICCONE;SIMONE PARISI;ANDREA EVANGELISTA;FIORENZO GAÏTA;FABRIZIO D’ASCENZO;MARIO BOCCADORO;MARTA COSCIA;PATRIZIA RACCA;F.R. GIGLIOLI;CLAUDIO MORETTI;MASSIMO MASSAIA;R. ROPOLO;E. GALLIO;GIULIA BENEVOLO;MARIO AIROLDI;MARIO IANNACCONE","29;21;16;15;15;14;13;13;13;12;11;11;11;9;7;7;7;7;7;7","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;ECONOMICS;POLITICAL SCIENCE;ENGINEERING;MATERIALS SCIENCE;SOCIOLOGY;BUSINESS;PHILOSOPHY;ART;GEOLOGY;HISTORY","403;120;41;29;26;17;17;14;11;10;9;7;5;5;3;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;CARDIOLOGY;NUCLEAR MEDICINE;CANCER RESEARCH;PEDIATRICS;PSYCHIATRY;MEDICAL PHYSICS;PALEONTOLOGY;GYNECOLOGY;UROLOGY;INTENSIVE CARE MEDICINE","323;118;114;71;60;59;48;47;42;39;38;37;33;28;24;23;23;19;19;18","CANCER;CHEMOTHERAPY;GENE;LYMPHOMA;TRANSPLANTATION;DISEASE;CLINICAL TRIAL;POPULATION;MULTIPLE MYELOMA;COHORT;CONFIDENCE INTERVAL;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;ANTIBODY;REGIMEN;PREGNANCY;RETROSPECTIVE COHORT STUDY;BONE MARROW;LEUKEMIA;ADVERSE EFFECT;PROPORTIONAL HAZARDS MODEL","87;74;49;43;43;39;38;37;35;30;30;30;24;21;21;19;19;18;18;15;15","CLINICAL ENDPOINT;COLORECTAL CANCER;RITUXIMAB;BREAST CANCER;CYCLOPHOSPHAMIDE;HAZARD RATIO;LENALIDOMIDE;BORTEZOMIB;CHRONIC LYMPHOCYTIC LEUKEMIA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;PHASES OF CLINICAL RESEARCH;MELPHALAN;NEUTROPENIA;PERCUTANEOUS CORONARY INTERVENTION;PROGRESSION-FREE SURVIVAL;DIFFUSE LARGE B-CELL LYMPHOMA;PROSTATE CANCER;TOLERABILITY","33;23;23;22;22;20;20;17;16;14;14;14;13;12;12;12;11;10;10;10","IBRUTINIB;KRAS;BENDAMUSTINE;CETUXIMAB;FEBRILE NEUTROPENIA;MACE;RIBAVIRIN;TRASTUZUMAB;CARBOPLATIN;COLONOSCOPY;ELECTROCHEMOTHERAPY;EXOME SEQUENCING;FLUDARABINE;IGHV@;CHEMOIMMUNOTHERAPY;ESTROGEN RECEPTOR;GOLIMUMAB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;METASTATIC BREAST CANCER;RUXOLITINIB;VINCRISTINE","7;7;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;MULTIPLE MYELOMA;LUNG NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;PROSPECTIVE STUDIES;YOUNG ADULT;BIOMARKERS, TUMOR;FOLLOW-UP STUDIES;BREAST NEOPLASMS","216;203;155;153;117;113;82;68;66;48;44;42;41;32;32;32;31;30;29;26","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;LYMPHOID NEOPLASMS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;RADIOTHERAPY PHYSICS AND TECHNOLOGY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;HEPATITIS C INFECTION AND TREATMENT;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;TREATMENT AND MANAGEMENT OF ANAL CANCER;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EFFICACY AND RESISTANCE IN CML TREATMENT;GLIOMAS;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;MOLECULAR RESEARCH ON BREAST CANCER","27;24;15;11;9;8;8;7;7;6;5;5;5;5;4;4;4;4;4;4","CLINICAL ENDPOINT;REGIMEN;AUTOLOGOUS STEM-CELL TRANSPLANTATION;TREATMENT;RADIOTHERAPY;INTERNATIONAL MYELOMA WORKING GROUP;MELPHALAN;PROGRESSION-FREE SURVIVAL;REFRACTORY (PLANETARY SCIENCE);METASTATIC COLORECTAL CANCER;TOLERABILITY;BREAST CANCER;MANTLE CELL LYMPHOMA;TRANSCATHETER AORTIC-VALVE REPLACEMENT;DISCONTINUATION;HEMATOLOGY;PROSTHETIC VALVES EVALUATION;RITUXIMAB;SALVAGE THERAPY;AUTOLOGOUS TRANSPLANTATION","33;21;14;14;13;12;12;11;11;10;10;9;9;8;7;7;7;7;7;6","MULTIPLE MYELOMA;COLORECTAL CANCER;NEWLY DIAGNOSED;CELL TRANSPLANTATION;STEM CELL;CANCER PATIENTS;B-CELL LYMPHOMA;BREAST CANCER;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;PHASE STUDY;AUTOLOGOUS STEM;CLINICAL PRACTICE;PHASE III;REAL LIFE;ELDERLY PATIENTS;FONDAZIONE ITALIANA;MYELOMA PATIENTS;PROSTATE CANCER;RANDOMIZED PHASE;RETROSPECTIVE STUDY;VALVE IMPLANTATION;DIAGNOSED MULTIPLE;HODGKIN LYMPHOMA;ITALIANA LINFOMI;LUNG CANCER;METASTATIC COLORECTAL;PATIENTS PTS;ACUTE CORONARY;AMYOTROPHIC LATERAL","23;16;15;14;14;11;10;10;10;9;9;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;5;5","FOLLICULAR LYMPHOMA;SPEAKERS BUREAU;RESEARCH FUNDING;CONSULTANCY HONORARIA;HR CI;ONCOL -GOOGLE;SR SA;TORINO ITALY;RISK FACTORS;CANCER PATIENTS;CLIN ONCOL;ITALY DEPARTMENT;ITALY HEMATOLOGY;ADVISORY COMMITTEES;COLORECTAL CANCER;ENTITYS BOARD;MEDIAN AGE;STEM CELL;HONORARIA RESEARCH;CELL TRANSPLANTATION;CLINICAL PRACTICE;CONFIDENCE INTERVAL;HEMATOLOGY UNIT;BREAST CANCER;CITTÀ DELLA;DELLA SALUTE;MEDIAN FOLLOW-UP;RESPONSE RATE;INTERVAL CI;PROGRESSION-FREE SURVIVAL","44;41;38;33;33;26;25;25;24;23;22;20;20;19;19;19;19;19;18;17;17;17;17;16;16;16;16;16;15;15",150,0.35,9.88,8,2,1,1,2,2,0,1,8.75,1,1,7,2,1,2,3,5,3,0,0,80.75,81.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,3.82,676.7,4.96,11,0.39,42.04,0,1,6,0,5,0,0,16,0,17,11,0,0,0,0,0,0,27,1,0,26,0,0,2,0,0,0,0,0,0,"Italy;United States;Japan;United Kingdom","6;5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4205 NURSING;4208 TRADITIONAL, COMPLEMENTARY AND INTEGRATIVE MEDICINE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","25;14;11;7;5;4;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY;PREVENTION;BIOENGINEERING;CARDIOVASCULAR;HEART DISEASE;ASSISTIVE TECHNOLOGY;HEART DISEASE - CORONARY HEART DISEASE;INFECTIOUS DISEASES;NEUROSCIENCES;ORPHAN DRUG;PEDIATRIC;ATHEROSCLEROSIS;BIOMEDICAL IMAGING;EMERGING INFECTIOUS DISEASES","25;19;18;13;11;7;6;5;4;4;4;3;3;3;3;3;3;2;2;2","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","14;4;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;2.4 SURVEILLANCE AND DISTRIBUTION;4.4 POPULATION SCREENING;5.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;8.1 ORGANISATION AND DELIVERY OF SERVICES","14;4;2;2;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;MELANOMA;MYELOMA;NOT SITE-SPECIFIC CANCER;BRAIN TUMOR;BREAST CANCER;CERVICAL CANCER;LUNG CANCER;SARCOMA","7;4;3;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","11;4;2;1;1;1",1,8130000,280344.83,6,29,10,1,149,220097.360153257,1.92642019742883,"AMSTERDAM UMC LOCATION VUMC;AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE LILLE;DÉLÉGATION PARIS 11;ELI LILLY (UNITED KINGDOM);FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;IMPERIAL COLLEGE LONDON;JANSSEN (BELGIUM);LEIDEN UNIVERSITY MEDICAL CENTER;LIPOTYPE (GERMANY);LUND UNIVERSITY;NOVO NORDISK (DENMARK);SANOFI (GERMANY);SCIPROM (SWITZERLAND);SERVIER (FRANCE);SWISS INSTITUTE OF BIOINFORMATICS;TU DRESDEN;UNIVERSITY MEDICAL CENTER GRONINGEN;UNIVERSITY OF COPENHAGEN;UNIVERSITY OF DUNDEE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2015-03-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","31 BIOLOGICAL SCIENCES;3105 GENETICS","1;1","CLINICAL RESEARCH;DIABETES;GENETICS;PREVENTION","1;1;1;1","GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1;1",NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2017,422,16.414691943128,2.49526066350711,0.253554502369668,0.213270142180095,0.289099526066351,1.82010582010582,1.1505376344086,1.47540983606557,1.18446601941748,0.549763033175355,3,237,88,41,25,0.56,0.21,0.1,0.06,21.21,0.71962276413147,5.72348484848484,0.409952606635071,0.928909952606635,0.457,0.417,0.501,0.439,"UMBERTO VITOLO;FIORENZO GAÏTA;FABRIZIO D’ASCENZO;MARIO BOCCADORO;ANDREA EVANGELISTA;BENEDETTO BRUNO;PAOLA CASSONI;GIANLUCA GAÏDANO;MICHÈLE CAVO;ENRICO FUSARO;GIOVANNINO CICCONE;ELISABETTA ABRUZZESE;MASSIMO BRECCIA;ORNELLA GARRONE;MARIO TIRIBELLI;PAOLO CORRADINI;ENRICO CERRATO;MASSIMILIANO BONIFACIO;BRUNO MARTINO;MONICA CRUGNOLA","34;24;17;16;15;15;15;14;14;14;12;12;12;11;11;11;10;10;10;9","UMBERTO VITOLO;FIORENZO GAÏTA;SIMONE PARISI;ENRICO FUSARO;PAOLA CASSONI;MASSIMO IMAZIO;PAOLO SOLIDORO;FABRIZIO D’ASCENZO;IRENE DOGLIOTTI;ANDREA EVANGELISTA;MARIO BOCCADORO;FRANCESCO NOVELLI;GIOVANNINO CICCONE;BENEDETTO BRUNO;UMBERTO RICARDI;VALENTINA TESIO;FILIPPO PATRUCCO;ANTONELLA VARETTO;DANIELA ACQUADRO MARAN;ANNA SAPINO","2.14;1.99;1.72;1.62;1.5;1.47;1.32;1.22;1.08;0.98;0.96;0.87;0.86;0.85;0.8;0.79;0.78;0.75;0.75;0.74","UMBERTO VITOLO;FIORENZO GAÏTA;FABRIZIO D’ASCENZO;MARIO BOCCADORO;ANDREA EVANGELISTA;BENEDETTO BRUNO;PAOLA CASSONI;ENRICO FUSARO;GIOVANNINO CICCONE;MARCO PAVANI;PAOLO SOLIDORO;PATRIZIA PREGNO;MARIO AIROLDI;UMBERTO RICARDI;ANNA SAPINO;CLAUDIO MORETTI;SIMONE PARISI;ALESSANDRO BUSCA;LUISA GIACCONE;MAURIZIO D’AMICO","34;24;17;16;15;15;15;14;12;9;9;9;9;9;9;8;8;8;8;8","UMBERTO VITOLO;FIORENZO GAÏTA;SIMONE PARISI;ENRICO FUSARO;PAOLA CASSONI;MASSIMO IMAZIO;PAOLO SOLIDORO;FABRIZIO D’ASCENZO;IRENE DOGLIOTTI;ANDREA EVANGELISTA;MARIO BOCCADORO;FRANCESCO NOVELLI;GIOVANNINO CICCONE;BENEDETTO BRUNO;UMBERTO RICARDI;FILIPPO PATRUCCO;ANTONELLA VARETTO;ANNA SAPINO;RENATO ROMAGNOLI;C. CASATO","2.14;1.99;1.72;1.62;1.5;1.47;1.32;1.22;1.08;0.98;0.96;0.87;0.86;0.85;0.8;0.78;0.75;0.74;0.72;0.71","UMBERTO VITOLO;KIM LINTON;GIULIA BENEVOLO;MONICA BALZAROTTI;ALESSANDRA TUCCI;ALESSANDRO RAMBALDI;MICHÈLE CAVO;FRANCESCA PALANDRI;FRANCESCO ALBANO;SIMONA SICA;ALESSANDRO LEVIS;FRANCESCO NOVELLI;ANDRÉS J.M. FERRERI;EMANUELE ZUCCA;JÜRGEN FINKE;VALTER TORRI;PETER JOHNSON;ALICE BERTAINA;ANTONIO PALUMBO;FRANCESCO PISANI","565;526;461;413;411;409;399;391;384;372;361;334;329;326;321;321;320;316;313;311","UMBERTO VITOLO;GIULIA BENEVOLO;ANTONIO PALUMBO;LORELLA ORSUCCI;ALESSANDRO BUSCA;FRANCESCO NOVELLI;ANDREA EVANGELISTA;PAOLA CAPPELLO;FABRIZIO D’ASCENZO;LUCA BRAZZI;ROSETTA LOBREGLIO;GIOVANNINO CICCONE;ADRIANO CHIÒ;ENRICO FUSARO;FIORENZO GAÏTA;MARIO AIROLDI;FEDERICO DE MARCO;CATERINA MARCHIÒ;MAURIZIO D’AMICO;CARLOTTA SACERDOTE","565;461;305;304;295;275;271;265;243;243;243;232;221;200;194;193;161;148;146;145","UMBERTO VITOLO;FIORENZO GAÏTA;FABRIZIO D’ASCENZO;ANDREA EVANGELISTA;ENRICO FUSARO;GIOVANNINO CICCONE;BENEDETTO BRUNO;MARIO AIROLDI;MARCO PAVANI;ALESSANDRO BUSCA;PATRIZIA PREGNO;SIMONE PARISI;PAOLO SOLIDORO;MAURIZIO D’AMICO;ALESSANDRA BEANO;FEDERICO DE MARCO;MORENO FESTUCCIA;PIERLUIGI OMEDÈ;GIULIA BENEVOLO;CLAUDIO MORETTI","34;21;16;14;13;11;10;9;9;8;8;8;8;7;7;7;7;7;7;7","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;CHEMISTRY;MATHEMATICS;SOCIOLOGY;ENGINEERING;POLITICAL SCIENCE;HISTORY;PHILOSOPHY;MATERIALS SCIENCE;GEOGRAPHY;ART;GEOLOGY","394;125;36;33;20;19;15;13;13;9;9;6;6;5;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;GENETICS;PATHOLOGY;IMMUNOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;CANCER RESEARCH;PEDIATRICS;PALEONTOLOGY;BIOCHEMISTRY;PSYCHIATRY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;ENDOCRINOLOGY;FAMILY MEDICINE;NURSING","328;109;104;66;62;59;52;47;36;36;34;32;29;28;28;23;22;21;19;19","CANCER;CHEMOTHERAPY;GENE;LYMPHOMA;DISEASE;TRANSPLANTATION;POPULATION;CLINICAL TRIAL;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;COHORT;ADVERSE EFFECT;STAGE (STRATIGRAPHY);BONE MARROW;MYOCARDIAL INFARCTION;PREGNANCY;MULTIPLE MYELOMA;LEUKEMIA;INCIDENCE (GEOMETRY);PROPORTIONAL HAZARDS MODEL;RETROSPECTIVE COHORT STUDY;VIRUS","86;47;47;47;40;35;34;32;26;26;25;20;20;19;19;19;18;17;15;15;15;15","CLINICAL ENDPOINT;BREAST CANCER;RITUXIMAB;HAZARD RATIO;FOLLICULAR LYMPHOMA;DIFFUSE LARGE B-CELL LYMPHOMA;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;PROGRESSION-FREE SURVIVAL;FETUS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;PHASES OF CLINICAL RESEARCH;NEUTROPENIA;PERCUTANEOUS CORONARY INTERVENTION;LENALIDOMIDE;CHRONIC LYMPHOCYTIC LEUKEMIA;GENOTYPE;HEPATITIS C VIRUS;IMATINIB;LIVER TRANSPLANTATION;MYELODYSPLASTIC SYNDROMES;MYELOFIBROSIS;PHENOTYPE;UNIVARIATE ANALYSIS","28;27;25;16;14;12;11;11;11;10;10;10;10;9;9;8;7;7;7;7;7;7;7;7;7","METASTATIC BREAST CANCER;RIBAVIRIN;BENDAMUSTINE;CHEMOIMMUNOTHERAPY;DASATINIB;DNA METHYLATION;OBINUTUZUMAB;RUXOLITINIB;DRUG-ELUTING STENT;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MACE;NILOTINIB;PLACENTA;SENTINEL LYMPH NODE;TRASTUZUMAB;AGGRESSIVE LYMPHOMA;ARTERY DISSECTION;BRENTUXIMAB VEDOTIN;FLUDARABINE;FRONTOTEMPORAL DEMENTIA;IBRUTINIB;IRINOTECAN;KRAS;MASTECTOMY;NIVOLUMAB;PERIPHERAL T-CELL LYMPHOMA;PRENATAL DIAGNOSIS","8;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;YOUNG ADULT;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADOLESCENT;FOLLOW-UP STUDIES;BREAST NEOPLASMS;REGISTRIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROGNOSIS;SKIN NEOPLASMS;BIOMARKERS","217;203;176;154;123;117;106;69;43;42;41;41;36;32;27;27;26;25;25;24","LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;MELANOMA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;HEPATITIS C INFECTION AND TREATMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;RHEUMATOID ARTHRITIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HEMATOPOIETIC STEM CELL BIOLOGY;INTEROCEPTION AND SOMATIC SYMPTOMS;MOLECULAR RESEARCH ON BREAST CANCER;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MANAGEMENT OF CARDIOVASCULAR DISEASES DURING PREGNANCY;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;TREATMENT AND MANAGEMENT OF ANAL CANCER","29;13;12;8;8;7;7;7;7;6;6;5;5;5;5;4;4;4;4;4","CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;REGIMEN;TREATMENT;MANTLE CELL LYMPHOMA;DISCONTINUATION;PROGRESSION-FREE SURVIVAL;REFRACTORY (PLANETARY SCIENCE);BREAST CANCER;INTERNATIONAL MYELOMA WORKING GROUP;MELANOMA;MINIMAL RESIDUAL DISEASE;PET IMAGING;UNIVARIATE ANALYSIS;CHEMOTHERAPY REGIMEN;CUMULATIVE INCIDENCE;HEMATOPOIETIC CELL TRANSPLANTATION;HEPATITIS C;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BENDAMUSTINE","28;14;14;14;13;12;11;10;8;8;8;7;7;7;6;6;6;6;5;5","BREAST CANCER;MULTIPLE MYELOMA;FOLLICULAR LYMPHOMA;MYELOID LEUKEMIA;CANCER PATIENTS;PHASE III;STEM CELL;CELL TRANSPLANTATION;LEFT MAIN;NEWLY DIAGNOSED;PATIENTS PTS;RHEUMATOID ARTHRITIS;B-CELL LYMPHOMA;CHRONIC MYELOID;CLINICAL TRIALS;CHRONIC LYMPHOCYTIC;COHORT STUDY;OBSERVATIONAL STUDY;PATIENTS UNDERGOING;PHASE II;RISK FACTORS;ACUTE CORONARY;ACUTE LEUKEMIA;BONE MARROW;COLORECTAL CANCER;CORONARY ARTERY;HODGKIN LYMPHOMA;ITALIAN PATIENTS;LONG-TERM FOLLOW-UP;LYMPHOCYTIC LEUKEMIA","14;12;11;10;9;9;9;8;8;8;8;8;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","GASTRIC ACIDITY;BREAST CANCER;MEDIAN FOLLOW-UP;MULTIVARIATE ANALYSIS;ADVERSE EVENTS;HAZARD RATIO;HR CI;MGKG ATLG;PATIENTS TREATED;GLOBAL HEALTH;HEALTH ORGANIZATION;TURIN ITALY;WORLD HEALTH;CLINICAL PRACTICE;CLINICAL TRIAL;CONSULTANCY HONORARIA;DISEASE ACTIVITY;MEDIAN AGE;RISK FACTORS;SURVIVAL OS;BONE MARROW;CONFIDENCE INTERVAL;FOLLICULAR LYMPHOMA;GROWTH STANDARDS;LOGISTIC REGRESSION;PATIENTS UNDERGOING;PROGRESSION-FREE SURVIVAL;LYMPH NODE;POSITIVE PATIENTS;PSYCHOLOGICAL DISTRESS","22;18;18;18;17;17;16;16;15;14;14;14;14;13;13;13;13;13;13;13;12;12;12;12;12;12;12;11;11;11",153,0.36,7,7,2,1,1,4.75,3,1,1,8,0,1,7,1,5.75,2,3,5,2,0,0,83,83,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,4.3,511.8,9.09,20,0.43,59.54,1,2,10,0,13,0,2,18,0,32,14,0,0,0,0,0,0,45,0,1,45,0,0,1,0,0,0,0,0,0,"United States;Italy;Japan;Australia;Belgium;France;Germany","13;3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;36 CREATIVE ARTS AND WRITING;3603 MUSIC;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;4012 FLUID MECHANICS AND THERMAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","41;17;15;13;10;6;4;2;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;LYMPHOMA;AGING;HEALTH SERVICES;PEDIATRIC;PREVENTION;TRANSPLANTATION;BIOENGINEERING;CARDIOVASCULAR;NEUROSCIENCES;BIOMEDICAL IMAGING;BRAIN DISORDERS;DIGESTIVE DISEASES;GENETICS;HEART DISEASE","40;27;22;22;19;13;7;5;5;5;5;5;4;4;4;3;3;3;3;3","CANCER;INFECTION;CARDIOVASCULAR;NEUROLOGICAL;BLOOD;EYE;GENERIC HEALTH RELEVANCE;MENTAL HEALTH;RENAL AND UROGENITAL","13;3;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS;5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT);6.4 SURGERY;6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION);7.1 INDIVIDUAL CARE NEEDS;7.2 END OF LIFE CARE;7.3 MANAGEMENT AND DECISION MAKING;8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","30;6;3;1;1;1;1;1;1;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;MYELOMA;LEUKEMIA / LEUKAEMIA;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;BLOOD CANCER;HEAD AND NECK CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER","11;8;7;4;3;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.6 END-OF-LIFE CARE","19;3;1;1;1;1;1",1,5998800,299940,7,20,7,1,101,256001.792692939,1.64842595655635,"ACADEMIC MEDICAL CENTER;ALFASIGMA (ITALY);ALTA (ITALY);ANAXOMICS (SPAIN);ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;AZIENDA OSPEDALIERA DI PADOVA;EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK - ERIC;EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE;GOETHE UNIVERSITY FRANKFURT;HOSPITAL CLÍNIC DE BARCELONA;POMPEU FABRA UNIVERSITY;UNIVERSITY COLLEGE LONDON;UNIVERSITY HOSPITAL BONN;UNIVERSITY OF BOLOGNA;UNIVERSITY OF PADUA;UNIVERSITY OF ZURICH;VALL D'HEBRON HOSPITAL UNIVERSITARI;WITTEN/HERDECKE UNIVERSITY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;LIVER DISEASE","1;1;1;1;1","ORAL AND GASTROINTESTINAL","1","6.1 PHARMACEUTICALS","1","LIVER CANCER","1",NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,5,"PUBLIC LIBRARY OF SCIENCE","5","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY","3;3;2;1",NA,NA,NA,NA,"1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1;1","BIOMEDICAL","1","BASIC SCIENCE","1","NOT SITE-SPECIFIC CANCER","1",NA,NA
"AOU_CITTADELLASCIENZA",2018,475,16.6989473684211,2.6821052631579,0.275789473684211,0.233684210526316,0.503157894736842,1.86865671641791,1.21296296296296,1.3875,1.42261904761905,0.568421052631579,7,271,105,31,38,0.57,0.22,0.07,0.08,22.89,0.750306002706756,5.51689708141323,0.423157894736842,0.922105263157895,0.456,0.456,0.503,0.457,"UMBERTO VITOLO;GIANLUCA GAÏDANO;FABRIZIO D’ASCENZO;ANNALISA CHIAPPELLA;GIULIA BENEVOLO;BENEDETTO BRUNO;ALESSANDRA IURLO;ANDREA EVANGELISTA;MASSIMILIANO BONIFACIO;MICHÈLE CAVO;GIOVANNINO CICCONE;UMBERTO RICARDI;ELISABETTA ABRUZZESE;MASSIMO BRECCIA;PATRIZIA PREGNO;MONICA CRUGNOLA;MARIO BOCCADORO;MICAELA BERGAMASCHI;FRANCESCA PALANDRI;ROBIN FOÀ","29;18;17;17;16;16;15;15;15;15;14;14;14;14;13;12;12;12;11;11","UMBERTO VITOLO;MASSIMO IMAZIO;ANNALISA CHIAPPELLA;UMBERTO RICARDI;FRANCESCO GUERRERA;CARLO SENORE;OSVALDO RAMPADO;FABRIZIO D’ASCENZO;MAURO RINALDI;MATTEO MARRO;ANDREA EVANGELISTA;C. FIANDRA;MICHELA DONADIO;GIAN PIERO SANCIPRIANO;L. MONGE;ELEONORA PILLONI;GIOVANNINO CICCONE;BENEDETTO BRUNO;PAOLO GONTERO;MARCO FALCONE","2.01;1.76;1.46;1.38;1.37;1.3;1.23;1.23;1.18;1.1;1.08;1.06;1.03;1;1;1;0.98;0.94;0.88;0.87","UMBERTO VITOLO;FABRIZIO D’ASCENZO;ANNALISA CHIAPPELLA;GIULIA BENEVOLO;BENEDETTO BRUNO;ANDREA EVANGELISTA;GIOVANNINO CICCONE;UMBERTO RICARDI;PATRIZIA PREGNO;MARIO BOCCADORO;PAOLO GONTERO;ALESSANDRO BUSCA;FRANCESCO GUERRERA;SIMONE FERRERO;C. FIANDRA;MAURO RINALDI;CARLO SENORE;ENRICO FUSARO;SARA GALIMBERTI;ALFREDO BRUSCO","29;17;17;16;16;15;14;14;13;12;11;11;10;10;10;10;10;10;9;9","UMBERTO VITOLO;MASSIMO IMAZIO;ANNALISA CHIAPPELLA;UMBERTO RICARDI;FRANCESCO GUERRERA;CARLO SENORE;OSVALDO RAMPADO;FABRIZIO D’ASCENZO;MAURO RINALDI;MATTEO MARRO;ANDREA EVANGELISTA;C. FIANDRA;MICHELA DONADIO;L. MONGE;GIOVANNINO CICCONE;BENEDETTO BRUNO;PAOLO GONTERO;MARCO FALCONE;DAVIDE RICCI;ANTONELLA VARETTO","2.01;1.76;1.46;1.38;1.37;1.3;1.23;1.23;1.18;1.1;1.08;1.06;1.03;1;0.98;0.94;0.88;0.87;0.84;0.83","ANGELA BUONADONNA;GIOVANNI GRIGNANI;ANGELO PAOLO DEI TOS;PIERO PICCI;RAIMONDO PIANA;SILVIA STACCHIOTTI;A. BASSIM HASSAN;AKMAL SAFWAT;ALESSANDRO GRONCHI;ALHO HANNU;ANDREA FERRARI;ANNA MARIA FREZZA;ANTONIO LÓPEZ–POUSA;AXEL LE CESNE;BERND KASPER;DAGMAR ADÁMKOVÁ KRÁKOROVÁ;ENRIQUE DE ÁLAVA;EVA WARDELMANN;FRITS VAN COEVORDEN;HANS GELDERBLOM","2267;2139;2127;2127;2127;2127;2059;2059;2059;2059;2059;2059;2059;2059;2059;2059;2059;2059;2059;2059","RAIMONDO PIANA;CARLOTTA SACERDOTE;LORELLA ORSUCCI;UMBERTO VITOLO;BENEDETTO BRUNO;ANNALISA CHIAPPELLA;GIULIA BENEVOLO;CARLO SENORE;PATRIZIA RACCA;MARIO BOCCADORO;PAOLA OMEDÈ;ALESSANDRO BUSCA;GIOVANNINO CICCONE;ADRIANO CHIÒ;NEREO SEGNAN;PATRIZIA PREGNO;LIDIA SACCHETTO;PAOLO BROGANELLI;ROBERTO ZANETTI;STEFANO ROSSO","2127;624;388;361;311;262;260;224;217;210;201;182;179;178;177;176;171;171;171;171","UMBERTO VITOLO;ANNALISA CHIAPPELLA;GIULIA BENEVOLO;FABRIZIO D’ASCENZO;PATRIZIA PREGNO;BENEDETTO BRUNO;ANDREA EVANGELISTA;GIOVANNINO CICCONE;MARIO BOCCADORO;ENRICO FUSARO;CARLO SENORE;MAURO RINALDI;ALESSANDRO BUSCA;ALFREDO BRUSCO;FRANCESCO GUERRERA;PAOLA OMEDÈ;PAOLO GONTERO;SIMONE PARISI;MAURIZIO D’AMICO;F.R. GIGLIOLI","29;17;16;14;13;12;12;11;11;10;10;10;9;9;8;8;7;7;7;6","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;ENGINEERING;POLITICAL SCIENCE;SOCIOLOGY;ECONOMICS;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;ART;GEOGRAPHY;HISTORY","455;134;41;33;26;21;15;14;14;14;13;5;3;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;PATHOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;CARDIOLOGY;RADIOLOGY;PEDIATRICS;CANCER RESEARCH;PSYCHIATRY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;NURSING;OPTICS;PHYSICAL THERAPY;ENDOCRINOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY","377;127;126;84;76;69;57;50;48;42;36;33;28;27;24;23;20;19;18;18;18","CANCER;CHEMOTHERAPY;DISEASE;GENE;POPULATION;COHORT;LYMPHOMA;TRANSPLANTATION;CLINICAL TRIAL;CONFIDENCE INTERVAL;BONE MARROW;MULTIPLE MYELOMA;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;LEUKEMIA;MYELOID LEUKEMIA;PREGNANCY;PROPORTIONAL HAZARDS MODEL;ALTERNATIVE MEDICINE;INCIDENCE (GEOMETRY)","85;54;50;50;46;39;39;38;29;29;27;27;24;23;23;22;22;20;19;19","BREAST CANCER;COLORECTAL CANCER;RITUXIMAB;CLINICAL ENDPOINT;HAZARD RATIO;MUTATION;LENALIDOMIDE;MYELOFIBROSIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;DEMENTIA;CHRONIC LYMPHOCYTIC LEUKEMIA;DIFFUSE LARGE B-CELL LYMPHOMA;NEUTROPENIA;AMYOTROPHIC LATERAL SCLEROSIS;CYCLOPHOSPHAMIDE;IMATINIB;PROGRESSION-FREE SURVIVAL;PHASES OF CLINICAL RESEARCH;CONVENTIONAL PCI;GENE EXPRESSION;GESTATION;PHENOTYPE;UNIVARIATE ANALYSIS","26;26;24;19;19;17;15;15;14;13;11;11;11;10;10;10;10;9;8;8;8;8;8","KRAS;RUXOLITINIB;COLONOSCOPY;IBRUTINIB;BENDAMUSTINE;IMATINIB MESYLATE;DASATINIB;INTERNATIONAL PROGNOSTIC INDEX;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MAMMOGRAPHY;OBINUTUZUMAB;OXALIPLATIN;TRASTUZUMAB;CAREGIVER BURDEN;CARFILZOMIB;CETUXIMAB;DNA METHYLATION;METASTATIC BREAST CANCER;MISSENSE MUTATION;NILOTINIB","9;9;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TREATMENT OUTCOME;AGED, 80 AND OVER;PROGNOSIS;BREAST NEOPLASMS;RISK FACTORS;YOUNG ADULT;PROSPECTIVE STUDIES;FOLLOW-UP STUDIES;LUNG NEOPLASMS;ADOLESCENT","242;231;182;168;136;121;101;78;60;57;51;42;40;37;34;34;31;29;28;26","LYMPHOID NEOPLASMS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;HEMATOPOIETIC STEM CELL BIOLOGY;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;ACUTE MYELOID LEUKEMIA;HER2 SIGNALING IN BREAST CANCER TREATMENT;RADIOTHERAPY PHYSICS AND TECHNOLOGY;RHEUMATOID ARTHRITIS;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS","22;16;12;12;11;9;8;7;7;7;6;6;6;6;5;5;5;4;4;4","CLINICAL ENDPOINT;HEMATOLOGY;HEMATOPOIETIC CELL TRANSPLANTATION;DISCONTINUATION;REFRACTORY (PLANETARY SCIENCE);MYELOFIBROSIS;REGIMEN;MANTLE CELL LYMPHOMA;PROGRESSION-FREE SURVIVAL;TREATMENT;INTERNATIONAL MYELOMA WORKING GROUP;RUXOLITINIB;RUXOLITINIB THERAPY;BREAST CANCER;NEURODEGENERATION;TREATMENT OUTCOMES;UNIVARIATE ANALYSIS;CONCOMITANT;ACUTE MYELOID LEUKEMIA;B-CELL RECEPTOR SIGNALING","19;15;15;14;13;11;11;10;10;10;9;9;9;8;8;8;8;7;6;6","PATIENTS TREATED;MYELOID LEUKEMIA;CANCER PATIENTS;STEM CELL;CELL TRANSPLANTATION;COLORECTAL CANCER;BREAST CANCER;CHRONIC MYELOID;LEUKEMIA PATIENTS;MULTICENTER STUDY;PHASE III;B-CELL LYMPHOMA;FONDAZIONE ITALIANA;ITALIANA LINFOMI;ACUTE LEUKEMIA;MULTIPLE MYELOMA;OBSERVATIONAL STUDY;RETROSPECTIVE STUDY;RHEUMATOID ARTHRITIS;ACUTE CORONARY;ACUTE MYELOID;CANCER SCREENING;CHRONIC LYMPHOCYTIC;CLINICAL PRACTICE;COHORT STUDY;ELDERLY PATIENTS;HEMATOPOIETIC STEM;ITALIAN EXPERIENCE;LYMPHOCYTIC LEUKEMIA;METASTATIC COLORECTAL","19;16;15;15;14;14;13;10;10;10;9;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;RESEARCH FUNDING;ADVISORY BOARD;PUBMED SCOPUS;CONSULTANCY HONORARIA;PATIENTS TREATED;HR CI;COMMITTEES SPEAKERS;FUNDING SPEAKERS;BOARD SPEAKERS;CROSSREF PUBMED;LECTURE FEES;GASTROINTESTINAL STROMAL;HONORARIA RESEARCH;CELGENE HONORARIA;COMMITTEES RESEARCH;ADVERSE EVENTS;BONE MARROW;HONORARIA SPEAKERS;SURVIVAL OS;MEDIAN AGE;MULTIVARIATE ANALYSIS;NOVARTIS CONSULTANCY;STEM CELL;BUREAU JANSSEN;JANSSEN HONORARIA;CLINICAL PRACTICE","247;247;229;130;121;86;54;53;50;48;44;37;36;36;34;33;33;32;32;31;30;29;29;28;27;26;26;25;23;22",169,0.36,7.5,7,2,4,1,1,3,0,1,8,1,1,7,9,1.75,2,4,6,3,0,0,64,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,3.82,742.55,6.5,13,0.34,86.21,0,0,5,0,14,0,2,17,0,24,14,0,0,0,0,0,0,37,1,0,38,0,0,0,0,0,0,0,0,0,"Italy;United Kingdom;Japan;United States;Belgium;Canada;Finland;Germany;Netherlands","5;4;3;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;5202 BIOLOGICAL PSYCHOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES","36;21;11;5;4;4;3;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;DIGESTIVE DISEASES;HEMATOLOGY;RARE DISEASES;AUTOIMMUNE DISEASE;BRAIN DISORDERS;PEDIATRIC;INFLAMMATORY BOWEL DISEASE;TRANSPLANTATION;CARDIOVASCULAR;HEART DISEASE;LIVER DISEASE;NUTRITION;ORGAN TRANSPLANTATION;PEDIATRIC CANCER;PREVENTION;ATHEROSCLEROSIS","35;20;12;10;9;7;7;5;5;5;4;4;3;3;3;3;3;3;3;2","CANCER;ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;BLOOD;NEUROLOGICAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","9;5;4;3;2;1;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;6.4 SURGERY;8.1 ORGANISATION AND DELIVERY OF SERVICES;4.4 POPULATION SCREENING","22;3;3;3;2;2;2;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;COLON AND RECTAL CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;LUNG CANCER;MYELOMA;PANCREATIC CANCER;STOMACH CANCER","4;2;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","9;2;1;1;1",1,12436859,540733,9,23,8,1,8,316083.237137384,1.50276871466469,"AIX-MARSEILLE UNIVERSITY;ASSUTA MEDICAL CENTER;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA;CENTRE GEORGES FRANÇOIS LECLERC;CLAUDE BERNARD UNIVERSITY LYON 1;ERASMUS MC;FONDATION ARC POUR LA RECHERCHE SUR LE CANCER;FONDATION JEAN DAUSSET-CEPH;INSTITUT GUSTAVE ROUSSY;INSTITUT JULES BORDET;ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI;LOUGHBOROUGH UNIVERSITY;PARC DE SALUT;PARIS 13 UNIVERSITY;QUEEN MARY UNIVERSITY OF LONDON;SANTÉ PUBLIQUE FRANCE;UNICANCER GROUP;UNIVERSITY OF CALIFORNIA SYSTEM","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","AGING;BREAST CANCER;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;GENETICS;HEALTH SERVICES;PREVENTION","1;1;1;1;1;1;1;1;1","CANCER","1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;6.1 PHARMACEUTICALS","1;1;1","BREAST CANCER","1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","1;1;1","A01 CLINICAL MEDICINE","1",NA,NA,5,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS","4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;2;2;1","AGING;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CLINICAL RESEARCH;MENTAL HEALTH;NEURODEGENERATIVE;NEUROSCIENCES;PARKINSON'S DISEASE","1;1;1;1;1;1;1;1;1","MENTAL HEALTH;NEUROLOGICAL","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","1;1;1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","2",NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2019,549,17.7814207650273,2.49544626593807,0.247723132969035,0.213114754098361,0.298724954462659,2.00591715976331,1.28301886792453,1.6027397260274,1.25190839694656,0.597449908925319,5,269,135,35,37,0.49,0.25,0.06,0.07,17.78,0.731087724764295,5.64664981036662,0.398907103825137,0.939890710382514,0.472,0.492,0.493,0.487,"UMBERTO VITOLO;MARIO BOCCADORO;MASSIMILIANO BONIFACIO;ALESSANDRA IURLO;MICHÈLE CAVO;ANDREA EVANGELISTA;GIULIA BENEVOLO;MASSIMO BRECCIA;ALESSANDRA LAROCCA;PAOLO CORRADINI;ELISABETTA ABRUZZESE;SARA GALIMBERTI;MONICA CRUGNOLA;ROBIN FOÀ;FABRIZIO D’ASCENZO;ANNALISA CHIAPPELLA;UMBERTO RICARDI;GIANNI BINOTTO;DANIELE CATTANEO;ROSSANA CAVALLO","29;25;23;22;22;18;17;17;16;16;16;14;14;14;14;14;14;14;14;13","UMBERTO VITOLO;LUCIA TATTOLI;GIANCARLO DI VELLA;ROSSANA CAVALLO;MARIA ANTONELLA RUFFINO;ENRICO FUSARO;UMBERTO RICARDI;ALESSANDRA LAROCCA;MARIO BOCCADORO;LUDOVICA VENEZIA;PABLO CORTEGOSO VALDIVIA;CRISTINA COSTA;M PAPOTTI;DORICO RIGHI;EMRE BAKIRCIOĞLU;ALESSANDRO PIOVESAN;GIULIA PETRINI;ANDREA EVANGELISTA;GIORGIO MARIA SARACCO;PAOLO FONIO","2.88;1.83;1.62;1.58;1.57;1.39;1.38;1.26;1.25;1.16;1.16;1.09;1.09;1.03;1;1;1;0.98;0.97;0.91","UMBERTO VITOLO;MARIO BOCCADORO;ANDREA EVANGELISTA;GIULIA BENEVOLO;ALESSANDRA LAROCCA;PAOLO CORRADINI;FABRIZIO D’ASCENZO;ANNALISA CHIAPPELLA;UMBERTO RICARDI;ROSSANA CAVALLO;PATRIZIA PREGNO;MARIA ANTONELLA RUFFINO;SARA BRINGHEN;ENRICO FUSARO;SIMONE FERRERO;PAOLA OMEDÈ;FEDERICA CAVALLO;FRANCESCA GAY;GIOVANNINO CICCONE;MAURO RINALDI","29;25;18;17;16;16;14;14;14;13;13;13;13;13;12;11;11;10;10;10","UMBERTO VITOLO;LUCIA TATTOLI;ROSSANA CAVALLO;MARIA ANTONELLA RUFFINO;ENRICO FUSARO;UMBERTO RICARDI;ALESSANDRA LAROCCA;MARIO BOCCADORO;LUDOVICA VENEZIA;PABLO CORTEGOSO VALDIVIA;CRISTINA COSTA;M PAPOTTI;DORICO RIGHI;EMRE BAKIRCIOĞLU;ALESSANDRO PIOVESAN;GIULIA PETRINI;ANDREA EVANGELISTA;GIORGIO MARIA SARACCO;PAOLO FONIO;SARA BRINGHEN","2.88;1.83;1.58;1.57;1.39;1.38;1.26;1.25;1.16;1.16;1.09;1.09;1.03;1;1;1;0.98;0.97;0.91;0.91","ALESSANDRA IURLO;PASCAL AMÉDRO;HARTMUT GOLDSCHMIDT;PAULA RODRÍGUEZ‐OTERO;KENSHI SUZUKI;MASSIMILIANO BONIFACIO;MARÍA‐VICTORIA MATEOS;SAAD Z. USMANI;DIONYSSIOS KATSAROS;FREDRIK SCHJESVOLD;GAETANO MARIA DE FERRARI;EMANUELE PIVETTA;ANUPKUMAR GEORGE;ASHER CHANAN‐KHAN;DANIEL W. SHERBENOU;DAVID SIMPSON;HILARY BLACKLOCK;IRIT AVIVI;MORIO MATSUMOTO;NOAM BENYAMINI","520;514;460;451;444;441;428;425;417;416;415;413;408;408;408;408;408;408;408;408","GAETANO MARIA DE FERRARI;UMBERTO VITOLO;PAOLA SARACCO;ALESSANDRA LAROCCA;SERGIO GRIBAUDO;PATRIZIA PREGNO;EMANUELE PIVETTA;ANDREA EVANGELISTA;FEDERICA CAVALLO;ENRICO FUSARO;PAOLA GIORDANO;PATRIZIA RACCA;MASSIMO IMAZIO;GIULIA BENEVOLO;CARLA GIUSTETTO;MAURO RINALDI;SARA BRINGHEN;MARIO BOCCADORO;SIMONE PARISI;ENRICO LUPIA","415;403;400;389;364;362;355;317;306;301;285;280;262;251;249;246;244;234;214;212","UMBERTO VITOLO;MARIO BOCCADORO;ANDREA EVANGELISTA;GIULIA BENEVOLO;ALESSANDRA LAROCCA;ANNALISA CHIAPPELLA;ENRICO FUSARO;FABRIZIO D’ASCENZO;SARA BRINGHEN;MARIA ANTONELLA RUFFINO;PATRIZIA PREGNO;FEDERICA CAVALLO;MASSIMO IMAZIO;ROSSANA CAVALLO;GIOVANNINO CICCONE;MARIO AIROLDI;PAOLA OMEDÈ;SIMONE PARISI;DORICO RIGHI;GAETANO MARIA DE FERRARI","29;21;18;17;16;14;13;13;13;13;13;12;10;10;10;9;9;9;9;9","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;SOCIOLOGY;ECONOMICS;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOLOGY;HISTORY;POLITICAL SCIENCE;ART;GEOGRAPHY;ENVIRONMENTAL SCIENCE","526;133;52;30;26;25;25;22;22;20;11;8;5;4;4;4;3;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;ENVIRONMENTAL HEALTH;CARDIOLOGY;RADIOLOGY;PEDIATRICS;PSYCHIATRY;CANCER RESEARCH;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;NURSING;ENDOCRINOLOGY;ASTROBIOLOGY;PALEONTOLOGY;ANESTHESIA;OPTICS","429;164;160;81;73;67;60;58;53;47;46;38;35;34;31;29;23;22;21;20;20","CANCER;CHEMOTHERAPY;LYMPHOMA;DISEASE;POPULATION;MULTIPLE MYELOMA;GENE;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;LEUKEMIA;REFRACTORY (PLANETARY SCIENCE);PROSPECTIVE COHORT STUDY;ANTIBODY;PROPORTIONAL HAZARDS MODEL","106;76;56;55;52;47;46;45;45;41;36;33;31;31;27;26;24;23;22;20","CLINICAL ENDPOINT;RITUXIMAB;LENALIDOMIDE;DIFFUSE LARGE B-CELL LYMPHOMA;HAZARD RATIO;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;BREAST CANCER;PROGRESSION-FREE SURVIVAL;PERCUTANEOUS CORONARY INTERVENTION;PHASES OF CLINICAL RESEARCH;CHRONIC LYMPHOCYTIC LEUKEMIA;IMATINIB;MUTATION;MYELOFIBROSIS;PLACEBO;SALVAGE THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BORTEZOMIB;CHOP;GENE EXPRESSION;IMMUNOTHERAPY;INFLAMMATORY BOWEL DISEASE","37;30;27;25;25;23;23;19;16;15;15;14;12;12;10;10;10;9;9;9;9;9;9","CARFILZOMIB;DARATUMUMAB;VINCRISTINE;POMALIDOMIDE;DASATINIB;IBRUTINIB;MACE;CHEMOIMMUNOTHERAPY;NILOTINIB;OXALIPLATIN;RUXOLITINIB;ANTHRACYCLINE;BENDAMUSTINE;DNA METHYLATION;KRAS;FLUDARABINE;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC INDEX;IRINOTECAN;MYELOPROLIFERATIVE NEOPLASM;OBINUTUZUMAB;RIVAROXABAN;TARGET LESION;TRASTUZUMAB","12;12;12;9;8;8;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;YOUNG ADULT;PROSPECTIVE STUDIES;ADOLESCENT;PROGNOSIS;FOLLOW-UP STUDIES;MULTIPLE MYELOMA;RISK FACTORS;LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE","286;261;190;185;132;118;99;86;60;56;53;51;42;37;36;34;33;32;31;29","LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ACUTE MYELOID LEUKEMIA;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;PANCREATIC CANCER RESEARCH AND TREATMENT;ASTHMA;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY","42;32;15;13;12;8;8;7;7;7;6;6;5;5;5;5;5;4;4;4","CLINICAL ENDPOINT;REFRACTORY (PLANETARY SCIENCE);INTERNATIONAL MYELOMA WORKING GROUP;MANTLE CELL LYMPHOMA;TREATMENT;PROGRESSION-FREE SURVIVAL;DISCONTINUATION;DARATUMUMAB;REGIMEN;HEMATOLOGY;SALVAGE THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;INTERQUARTILE RANGE;PET IMAGING;POMALIDOMIDE;STROKE (ENGINE);TREATMENT OUTCOMES;B-CELL RECEPTOR SIGNALING;BREAST CANCER;CHEMOTHERAPY REGIMEN","37;24;23;20;18;16;14;12;12;11;10;9;9;9;9;9;9;8;8;8","MULTIPLE MYELOMA;PATIENTS TREATED;CANCER PATIENTS;B-CELL LYMPHOMA;MYELOID LEUKEMIA;CHRONIC MYELOID;COLORECTAL CANCER;PHASE III;FONDAZIONE ITALIANA;ITALIANA LINFOMI;BOWEL DISEASE;BREAST CANCER;INFLAMMATORY BOWEL;MYELOMA RRMM;PHASE II;RELAPSEDREFRACTORY MULTIPLE;CONTROLLED TRIAL;LYMPHOMA DLBCL;POOLED ANALYSIS;PRELIMINARY RESULTS;CELL TRANSPLANTATION;CHRONIC LYMPHOCYTIC;DISEASE PATIENTS;FOLLICULAR LYMPHOMA;LEUKEMIA PATIENTS;LYMPHOCYTIC LEUKEMIA;METASTATIC COLORECTAL;MULTICENTER ITALIAN;MULTICENTER STUDY;NEWLY DIAGNOSED","34;21;17;15;13;12;12;12;11;11;10;10;10;9;9;9;8;8;8;8;7;7;7;7;7;7;7;7;7;7","ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;SPEAKERS BUREAU;CONSULTANCY HONORARIA;HONORARIA MEMBERSHIP;COMMITTEES SPEAKERS;HONORARIA RESEARCH;COMMITTEES RESEARCH;CONSULTANCY MEMBERSHIP;BRISTOL-MYERS SQUIBB;CONSULTANCY RESEARCH;ADVISORY CONSULTANCY;NOVARTIS HONORARIA;EQUITY OWNERSHIP;HR CI;JANSSEN CONSULTANCY;AMGEN HONORARIA;PATIENTS TREATED;ADVERSE EVENTS;CELGENE HONORARIA;MEDIAN AGE;CELGENE CONSULTANCY;CLINICAL TRIAL;FUNDING CELGENE;EMPLOYMENT EQUITY;JANSSEN HONORARIA;ADVISORY BOARD;HONORARIA SPEAKERS;PROGRESSION-FREE SURVIVAL","663;663;651;357;347;234;152;123;102;99;70;68;66;61;60;58;56;55;53;52;52;52;51;50;50;49;49;47;47;44",224,0.41,9.26,8,1,1,0,3,1,1,1,9,1,1,9.25,1,1.5,2,4,7,4,0,0,56.5,56,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,47,4.21,825.34,7.78,22,0.47,78.85,0,1,8,1,12,0,0,25,0,32,15,0,0,0,0,0,0,43,2,2,47,0,0,0,0,0,0,0,0,0,"United States;Italy;Belgium;Netherlands;United Kingdom;Finland;Ireland;Japan;Switzerland","15;11;3;3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;5203 CLINICAL AND HEALTH PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3207 MEDICAL MICROBIOLOGY","43;19;16;9;8;7;5;4;4;2;2;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;ORPHAN DRUG;CARDIOVASCULAR;LYMPHOMA;PREVENTION;BRAIN DISORDERS;NEUROSCIENCES;AGING;DIGESTIVE DISEASES;HEART DISEASE;NEURODEGENERATIVE;PEDIATRIC;TRANSPLANTATION;ALS;ATHEROSCLEROSIS","45;33;23;23;17;16;7;6;6;6;5;5;4;4;4;4;4;4;3;3","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;INFECTION;BLOOD;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;SKIN;STROKE","16;6;3;3;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;8.1 ORGANISATION AND DELIVERY OF SERVICES","24;6;5;5;4;2;2;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;HODGKIN'S DISEASE;MYELOMA;COLON AND RECTAL CANCER;PANCREATIC CANCER;SKIN CANCER;BLOOD CANCER;BREAST CANCER;GASTROINTESTINAL TRACT;GENITAL SYSTEM, FEMALE;LUNG CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PROSTATE CANCER","9;6;3;3;2;2;2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.2 SURVEILLANCE;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","12;8;1;1;1;1;1;1;1;1",1,12774825,798426.56,4,16,8,1,59,432474.211095717,1.2694398554056,"ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;BARCELONA SUPERCOMPUTING CENTER;CENTER FOR ADVANCED STUDIES RESEARCH AND DEVELOPMENT IN SARDINIA;FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA;KAROLINSKA INSTITUTET;NATIONAL RESEARCH COUNCIL;OTTO-VON-GUERICKE UNIVERSITY MAGDEBURG;PHILIPS (NETHERLANDS);STOCKHOLM REGIONAL COUNCIL;UNIVERSITAT POLITÈCNICA DE VALÈNCIA;UNIVERSITY HOSPITAL OF LAUSANNE;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF TURIN;WINGS ICT SOLUTIONS (GREECE);ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - LEADERSHIP IN ENABLING AND INDUSTRIAL TECHNOLOGIES - INFORMATION AND COMMUNICATION TECHNOLOGIES (ICT) (PROGRAMME);IA - INNOVATION ACTION (FUNDING SCHEME)","1;1","46 INFORMATION AND COMPUTING SCIENCES;4606 DISTRIBUTED COMPUTING AND SYSTEMS SOFTWARE","1;1","BRAIN DISORDERS;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD)","1;1","GENERIC HEALTH RELEVANCE","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1",NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2020,595,17.5260504201681,2.76134453781513,0.260504201680672,0.278991596638655,0.287394957983193,1.99633251833741,1.25,1.67676767676768,1.26666666666667,0.6,0,296,140,48,30,0.5,0.24,0.08,0.05,23.61,0.936761302579121,6.88666666666667,0.351260504201681,0.922689075630252,0.475,0.412,0.465,0.474,"GAETANO MARIA DE FERRARI;MICHÈLE CAVO;ROSSANA CAVALLO;ADRIANO CHIÒ;ALESSANDRA LAROCCA;MARÍA‐VICTORIA MATEOS;FABRIZIO D’ASCENZO;PAUL G. RICHARDSON;ANDREA CALVO;ENRICO FUSARO;SARA GALIMBERTI;BENEDETTO BRUNO;ALBERT ORIOL;CRISTINA MOGLIA;SIMONE FERRERO;ANTONIO CANOSA;SIMONE PARISI;MAURO RINALDI;PIETRO QUAGLINO;MASSIMILIANO BONIFACIO","33;25;19;18;15;14;14;14;14;14;13;13;13;13;12;12;12;12;12;12","GAETANO MARIA DE FERRARI;ROSSANA CAVALLO;MARCO FALCONE;ADRIANO CHIÒ;ENRICO FUSARO;MASSIMO IMAZIO;CRISTINA COSTA;PIETRO QUAGLINO;SIMONE RIBERO;MAURO RINALDI;GABRIELE BIANCO;FABRIZIO D’ASCENZO;SILVIA GONELLA;ANDREA CALVO;MARIA ANTONELLA RUFFINO;ALESSANDRO ANDREIS;SIMONE PARISI;FRANCESCO GIUSEPPE DE ROSA;CRISTINA MOGLIA;PAOLO GONTERO","3.32;2.24;1.61;1.48;1.45;1.43;1.39;1.36;1.32;1.3;1.26;1.21;1.17;1.16;1.15;1.14;1.12;1.1;1.1;1.04","GAETANO MARIA DE FERRARI;ROSSANA CAVALLO;ADRIANO CHIÒ;ALESSANDRA LAROCCA;FABRIZIO D’ASCENZO;ANDREA CALVO;ENRICO FUSARO;SARA GALIMBERTI;BENEDETTO BRUNO;CRISTINA MOGLIA;SIMONE FERRERO;ANTONIO CANOSA;SIMONE PARISI;MAURO RINALDI;PIETRO QUAGLINO;ALESSANDRO BUSCA;MARCO FALCONE;SIMONE RIBERO;MARIO BOCCADORO;GIULIA BENEVOLO","33;19;18;15;14;14;14;13;13;13;12;12;12;12;12;11;11;10;10;10","GAETANO MARIA DE FERRARI;ROSSANA CAVALLO;MARCO FALCONE;ADRIANO CHIÒ;ENRICO FUSARO;MASSIMO IMAZIO;CRISTINA COSTA;PIETRO QUAGLINO;SIMONE RIBERO;MAURO RINALDI;GABRIELE BIANCO;FABRIZIO D’ASCENZO;SILVIA GONELLA;ANDREA CALVO;MARIA ANTONELLA RUFFINO;ALESSANDRO ANDREIS;SIMONE PARISI;FRANCESCO GIUSEPPE DE ROSA;CRISTINA MOGLIA;PAOLO GONTERO","3.32;2.24;1.61;1.48;1.45;1.43;1.39;1.36;1.32;1.3;1.26;1.21;1.17;1.16;1.15;1.14;1.12;1.1;1.1;1.04","LUCA BRAZZI;DAVIDE CHIUMELLO;FEDERICA ROMITTI;LUCIANO GATTINONI;LUIGI CAMPOROTA;MATTIA BUSANA;PIETRO CAIRONI;MICHÈLE CAVO;SARA LONARDI;ALBERTO ZANIBONI;GIANLUCA TOMASELLO;SARA GALIMBERTI;FABRIZIO BERT;PELLEGRINO MUSTO;MAURO KRAMPERA;ROBERTA SILIQUINI;FELICETTO FERRARA;ANNA CANDONI;LUCA ARCAINI;MARIA CHIARA TISI","1899;1727;1727;1727;1727;1727;1727;1207;771;691;691;652;650;647;643;641;633;622;622;618","LUCA BRAZZI;FRANCESCA GAY;EZIO GHIGO;SIMONA BO;FABIO BROGLIO;ALESSANDRO BUSCA;FRANCO DE MICHIELI;MARIO BOCCADORO;CARLO SENORE;STEFANIA OLIVA;MASSIMO IMAZIO;GIULIA BENEVOLO;ELISA RUBINO;GERARDO CORTESE;ADRIANO CHIÒ;ROSSELLA TROIA;ALESSANDRA LAROCCA;ROSSANA CAVALLO;GIULIANA RITORTO;SARA BRINGHEN","1897;574;559;559;547;544;523;463;454;396;378;364;355;333;316;300;297;289;268;248","GAETANO MARIA DE FERRARI;ROSSANA CAVALLO;ADRIANO CHIÒ;ALESSANDRA LAROCCA;FABRIZIO D’ASCENZO;ENRICO FUSARO;ANDREA CALVO;CRISTINA MOGLIA;SIMONE PARISI;MARCO FALCONE;MASSIMO IMAZIO;BENEDETTO BRUNO;CRISTINA COSTA;MAURO RINALDI;GIULIA BENEVOLO;ANTONIO CANOSA;MARIO BOCCADORO;GABRIELE BIANCO;C. CERUTI;FRANCESCA GAY","29;19;17;15;14;14;13;12;12;11;10;10;10;10;10;9;9;9;8;8","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;SOCIOLOGY;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;PHILOSOPHY;MATERIALS SCIENCE;GEOGRAPHY;HISTORY;ART;ENVIRONMENTAL SCIENCE;GEOLOGY","579;141;69;39;34;33;26;26;23;16;14;11;11;6;5;5;2;2;2","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;RADIOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;PSYCHIATRY;INTENSIVE CARE MEDICINE;CANCER RESEARCH;BIOCHEMISTRY;FAMILY MEDICINE;OPTICS;PALEONTOLOGY;VIROLOGY;PHYSICAL THERAPY","474;177;111;96;85;79;71;64;63;63;43;43;40;36;31;31;31;30;30;29","DISEASE;CANCER;COHORT;GENE;POPULATION;CHEMOTHERAPY;TRANSPLANTATION;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;MULTIPLE MYELOMA;INCIDENCE (GEOMETRY);MYOCARDIAL INFARCTION;LYMPHOMA;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;LEUKEMIA;OUTBREAK;REFRACTORY (PLANETARY SCIENCE);PROSPECTIVE COHORT STUDY;COHORT STUDY;OBSERVATIONAL STUDY","110;93;60;55;55;47;44;41;39;38;31;31;28;28;27;26;26;26;24;21;21","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;BREAST CANCER;2019-20 CORONAVIRUS OUTBREAK;HAZARD RATIO;COLORECTAL CANCER;AMYOTROPHIC LATERAL SCLEROSIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;LENALIDOMIDE;UNIVARIATE ANALYSIS;BORTEZOMIB;CYCLOPHOSPHAMIDE;CUMULATIVE INCIDENCE;MUTATION;PERCUTANEOUS CORONARY INTERVENTION;CHRONIC LYMPHOCYTIC LEUKEMIA;DEMENTIA;LIVER TRANSPLANTATION;PLACEBO;ACUTE LEUKEMIA;CONVENTIONAL PCI;PROSTATE CANCER","50;28;24;22;22;19;18;17;16;13;12;12;11;11;11;9;9;9;9;8;8;8","CORONAVIRUS DISEASE 2019 (COVID-19);POMALIDOMIDE;COLONOSCOPY;FRONTOTEMPORAL DEMENTIA;KRAS;CARFILZOMIB;DARATUMUMAB;IBRUTINIB;DASATINIB;DIFFUSING CAPACITY;EXOME SEQUENCING;FETAL HEAD;FLUDARABINE;IRINOTECAN;OXALIPLATIN;PROSTATECTOMY;RIVAROXABAN;SENTINEL LYMPH NODE;VINCRISTINE;ANDROGEN DEPRIVATION THERAPY;BENDAMUSTINE;BUSULFAN;ENDOGENOUS RETROVIRUS;HERPESVIRIDAE;HYPERPHENYLALANINEMIA;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KLEBSIELLA PNEUMONIAE;MACE;MAMMOGRAPHY;METASTATIC BREAST CANCER;MONOCLONAL;NILOTINIB;RUXOLITINIB;THIOTEPA;VENETOCLAX","50;8;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ITALY;ADULT;RETROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;TREATMENT OUTCOME;AGED, 80 AND OVER;COVID-19;MULTIPLE MYELOMA;PROSPECTIVE STUDIES;AMYOTROPHIC LATERAL SCLEROSIS;RISK FACTORS;COLORECTAL NEOPLASMS;ADOLESCENT;PROGNOSIS","334;260;154;146;112;96;96;79;55;51;49;38;35;32;32;29;29;27;25;25","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;LYMPHOID NEOPLASMS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ACUTE MYELOID LEUKEMIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CORONAVIRUS DISEASE 2019;HEMATOPOIETIC STEM CELL BIOLOGY;EFFICACY AND RESISTANCE IN CML TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;ATRIAL FIBRILLATION;GLIOMAS;MELANOMA;PANCREATIC CANCER RESEARCH AND TREATMENT","25;17;15;14;13;10;8;8;8;7;6;6;6;6;6;5;5;5;5;5","CLINICAL ENDPOINT;PANDEMIC;REFRACTORY (PLANETARY SCIENCE);2019-20 CORONAVIRUS OUTBREAK;INTERNATIONAL MYELOMA WORKING GROUP;TREATMENT;DISCONTINUATION;REGIMEN;UNIVARIATE ANALYSIS;INTERQUARTILE RANGE;MANTLE CELL LYMPHOMA;CUMULATIVE INCIDENCE;NEURODEGENERATION;STROKE (ENGINE);HEMATOLOGY;HEMATOPOIETIC CELL TRANSPLANTATION;MELANOMA;POMALIDOMIDE;INTERIM ANALYSIS;LIVER DISEASE","29;27;26;23;15;15;14;14;14;12;11;10;9;9;8;8;8;8;7;7","MULTIPLE MYELOMA;AMYOTROPHIC LATERAL;LATERAL SCLEROSIS;BREAST CANCER;MYELOID LEUKEMIA;STEM CELL;CELL TRANSPLANTATION;PATIENTS TREATED;RELAPSEDREFRACTORY MULTIPLE;COLORECTAL CANCER;NEWLY DIAGNOSED;HORIZON OP-;LEUKEMIA PATIENTS;OBSERVATIONAL STUDY;CLINICAL PRACTICE;COHORT STUDY;PATIENTS UNDERGOING;RISK FACTORS;ACUTE LEUKEMIA;ACUTE MYELOID;ALLOGENEIC STEM;CELL LYMPHOMA;CORONAVIRUS DISEASE;DIAGNOSED MULTIPLE;METASTATIC COLORECTAL;OP- MELFLUFEN;PATIENTS PTS;CANCER PATIENTS;COVID- PANDEMIC;DEXAMETHASONE DEX","28;16;16;14;13;13;12;12;12;11;10;9;9;9;8;8;8;8;7;7;7;7;7;7;7;7;7;6;6;6","ENTITYS BOARD;ADVISORY COMMITTEES;SPEAKERS BUREAU;CONSULTANCY HONORARIA;HONORARIA MEMBERSHIP;RESEARCH FUNDING;HONORARIA SPEAKERS;TRAVEL ACCOMMODATIONS;ACCOMMODATIONS EXPENSES;COMMITTEES SPEAKERS;CONSULTANCY MEMBERSHIP;CURRENT EMPLOYMENT;FUNDING SPEAKERS;PATIENTS TREATED;JANSSEN CONSULTANCY;MEDIAN AGE;PUBLICLY-TRADED COMPANY;HR CI;AMGEN CONSULTANCY;AMGEN HONORARIA;CELGENE HONORARIA;EXPENSES RESEARCH;CURRENT EQUITY;EQUITY HOLDER;HONORARIA RESEARCH;ADVERSE EVENTS;JANSSEN HONORARIA;BUREAU JANSSEN;COMMITTEES JANSSEN;BUREAU AMGEN","524;508;384;267;243;181;149;126;125;110;74;61;61;56;55;51;50;49;46;46;45;45;44;44;44;43;41;38;36;34",268,0.45,9.91,9,1,1,0,3,2,1,1,11,1,1,10,1.75,1,2,4,7,4,0,0,53,53.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,3.94,2433.81,7.1,25,0.48,63.62,0,4,9,1,12,0,0,26,0,31,21,0,0,0,0,0,0,48,3,1,51,0,0,1,0,0,0,0,0,0,"Italy;United States;Japan;Belgium;France;Germany;Switzerland;United Kingdom","11;10;3;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;36 CREATIVE ARTS AND WRITING;3602 CREATIVE AND PROFESSIONAL WRITING;37 EARTH SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4205 NURSING;4206 PUBLIC HEALTH","49;30;14;9;7;4;3;2;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;PREVENTION;HEMATOLOGY;LUNG;BRAIN DISORDERS;DIGESTIVE DISEASES;HEALTH SERVICES;NEUROSCIENCES;AGING;LYMPHOMA;CARDIOVASCULAR;GENETICS;INFECTIOUS DISEASES;UROLOGIC DISEASES;BIOMEDICAL IMAGING;BRAIN CANCER","51;28;25;20;14;14;13;7;6;6;6;6;5;5;4;4;4;4;3;3","CANCER;CARDIOVASCULAR;INFECTION;BLOOD;EYE;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;SKIN","15;5;2;1;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;8.1 ORGANISATION AND DELIVERY OF SERVICES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","21;7;5;4;3;2;2;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;BRAIN TUMOR;BLADDER CANCER;COLON AND RECTAL CANCER;MYELOMA;BLOOD CANCER;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PROSTATE CANCER;THYROID CANCER","7;7;4;3;2;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","14;4;2;1;1;1;1;1",3,5896177.5,425981.39,5.33333333333333,11,6,0.666666666666667,53.3333333333333,593775.856550262,1.00206162550436,"AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;AMSTERDAM UMC LOCATION VUMC;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AUGUST PI I SUNYER BIOMEDICAL RESEARCH INSTITUTE;CONCENTRIS (GERMANY);DÉLÉGATION PARIS 11;ERASMUS MC;EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (SWITZERLAND);EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE;EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY;GOETHE UNIVERSITY FRANKFURT;HOSPITAL CLÍNIC DE BARCELONA;INSTITUT CATALÀ D'ONCOLOGIA;INSTITUT CATALÀ DE LA SALUT;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;KAROLINSKA INSTITUTET;MADRID HEALTH SERVICE;NORDIC BIOSCIENCE (DENMARK);PIRKANMAA HOSPITAL DISTRICT","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;ITALIAN ASSOCIATION FOR CANCER RESEARCH","2;1","COALITION S;EC & ERC - EUROPEAN UNION;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP","2;2;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","2;2;1;1;1","CANCER;CLINICAL RESEARCH;DIGESTIVE DISEASES;HEALTH SERVICES;PREVENTION;CERVICAL CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COLO-RECTAL CANCER;HPV AND/OR CERVICAL CANCER VACCINES;IMMUNIZATION;INFECTIOUS DISEASES;LIVER DISEASE;SEXUALLY TRANSMITTED INFECTIONS;VACCINE RELATED","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION;ORAL AND GASTROINTESTINAL","1;1;1","4.4 POPULATION SCREENING;3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","2;1;1;1;1","CERVICAL CANCER;COLON AND RECTAL CANCER","1;1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","2;1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A01 CLINICAL MEDICINE","2;1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CITTADELLASCIENZA",2021,720,19.9958333333333,2.69861111111111,0.227777777777778,0.231944444444444,0.2625,2.2952380952381,1.312,1.89772727272727,1.35,0.683333333333333,2,349,169,60,37,0.48,0.23,0.08,0.05,18.89,1.22508398608379,7.15454545454547,0.388888888888889,0.9375,0.542,0.476,0.472,0.475,"GAETANO MARIA DE FERRARI;ADRIANO CHIÒ;ROSSANA CAVALLO;SIMONE FERRERO;FABRIZIO D’ASCENZO;GIOVANNINO CICCONE;MICHÈLE CAVO;ANDREA CALVO;CRISTINA MOGLIA;ANTONIO CANOSA;UMBERTO MANERA;MONICA TANI;MARIO BOCCADORO;PAOLO GONTERO;MAURO RINALDI;PAOLO CORRADINI;ROSARIO VASTA;CRISTINA COSTA;SARA GALIMBERTI;ALESSANDRO BUSCA","30;27;23;23;23;22;22;21;20;18;17;16;16;16;16;16;16;16;15;15","ADRIANO CHIÒ;GAETANO MARIA DE FERRARI;ROSSANA CAVALLO;ANDREA CALVO;CRISTINA COSTA;CRISTINA MOGLIA;ENRICO FUSARO;FABRIZIO D’ASCENZO;MATTEO BOATTINI;LEONARDO LOPIANO;CARLO ALBERTO ARTUSI;ANTONIO CANOSA;MAURO RINALDI;GABRIELE BIANCO;SIMONE PARISI;SIMONE FERRERO;GIOVANNINO CICCONE;UMBERTO MANERA;MASSIMO IMAZIO;LUCA BRAZZI","3.03;2.43;2.26;1.84;1.77;1.72;1.68;1.61;1.55;1.55;1.55;1.51;1.47;1.45;1.43;1.41;1.35;1.34;1.31;1.31","GAETANO MARIA DE FERRARI;ADRIANO CHIÒ;ROSSANA CAVALLO;SIMONE FERRERO;FABRIZIO D’ASCENZO;GIOVANNINO CICCONE;ANDREA CALVO;CRISTINA MOGLIA;ANTONIO CANOSA;UMBERTO MANERA;MARIO BOCCADORO;PAOLO GONTERO;MAURO RINALDI;ROSARIO VASTA;CRISTINA COSTA;ALESSANDRO BUSCA;ALESSANDRO ANDREIS;MASSIMO IMAZIO;FEDERICA CAVALLO;RENATO ROMAGNOLI","30;27;23;23;23;22;21;20;18;17;16;16;16;16;16;15;15;15;15;14","ADRIANO CHIÒ;GAETANO MARIA DE FERRARI;ROSSANA CAVALLO;ANDREA CALVO;CRISTINA COSTA;CRISTINA MOGLIA;ENRICO FUSARO;FABRIZIO D’ASCENZO;MATTEO BOATTINI;LEONARDO LOPIANO;CARLO ALBERTO ARTUSI;ANTONIO CANOSA;MAURO RINALDI;GABRIELE BIANCO;SIMONE PARISI;SIMONE FERRERO;GIOVANNINO CICCONE;UMBERTO MANERA;MASSIMO IMAZIO;LUCA BRAZZI","3.03;2.43;2.26;1.84;1.77;1.72;1.68;1.61;1.55;1.55;1.55;1.51;1.47;1.45;1.43;1.41;1.35;1.34;1.31;1.31","ROBERTO CASALE;ANA LANGER;ARIS T. PAPAGEORGHIOU;BABAGANA BAKO;BECKY LIU;CARMEN VECCIARELLI;CONSTANZA P. SOTO CONTI;D. ORÓS;EDUARDO ALFREDO DURO;ERNAWATI ERNAWATI;FEDERICO PREFUMO;HADIZA GALADANCI;HELLAS CENA;IRENE CETIN;JOANNA SICHITIU;JORGE ARTURO CARDONA‐PÉREZ;JOSÉ VILLAR;KHOLIN A.M. KHOLIN;LOÏC SENTILHES;M. OBERTO","1214;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202;1202","M. OBERTO;RAIMONDO PIANA;MASSIMO IMAZIO;MARIO BOCCADORO;ALESSANDRO BUSCA;FABRIZIO D’ASCENZO;CARLO SENORE;ELISA RUBINO;GAETANO MARIA DE FERRARI;SILVIA MARTINI;ROSSANA CAVALLO;SILVIA GONELLA;GUGLIELMO GALLONE;ADRIANO CHIÒ;ANNALISA CHIAPPELLA;OVIDIO DE FILIPPO;ANA CALATRAVA;DIANA TURTURICA;FEDERICA CAVALLO;BARBARA BOTTO","1202;1127;1016;923;500;418;391;383;367;335;329;316;310;284;264;263;262;262;260;240","GAETANO MARIA DE FERRARI;ADRIANO CHIÒ;ROSSANA CAVALLO;ANDREA CALVO;FABRIZIO D’ASCENZO;GIOVANNINO CICCONE;CRISTINA MOGLIA;ANTONIO CANOSA;CRISTINA COSTA;MARIO BOCCADORO;ALESSANDRO BUSCA;ALESSANDRO ANDREIS;MAURO RINALDI;GABRIELE BIANCO;ENRICO FUSARO;MATTEO BOATTINI;SIMONE FERRERO;BARBARA BOTTO;GIULIA BENEVOLO;LORELLA ORSUCCI","26;24;19;19;18;18;17;17;16;16;15;14;14;13;13;13;13;13;12;12","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;ENGINEERING;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOLOGY;GEOGRAPHY;HISTORY;ART;ENVIRONMENTAL SCIENCE","689;170;73;49;48;32;31;27;26;23;19;13;10;7;5;4;4;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;IMMUNOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;RADIOLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;OPTICS;BIOCHEMISTRY;FAMILY MEDICINE;VIROLOGY;EMERGENCY MEDICINE;PALEONTOLOGY;NURSING;PHYSICAL THERAPY","565;200;168;118;104;92;78;66;64;64;62;56;50;44;43;38;35;33;30;29;29","DISEASE;CANCER;GENE;CHEMOTHERAPY;COHORT;CONFIDENCE INTERVAL;POPULATION;LYMPHOMA;TRANSPLANTATION;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;INCIDENCE (GEOMETRY);MULTIPLE MYELOMA;CLINICAL TRIAL;PROSPECTIVE COHORT STUDY;OUTBREAK;ADVERSE EFFECT;MYOCARDIAL INFARCTION;BONE MARROW;COHORT STUDY","151;124;80;66;64;61;59;58;50;47;45;43;43;38;37;30;29;28;27;25","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;BREAST CANCER;COLORECTAL CANCER;HAZARD RATIO;RITUXIMAB;2019-20 CORONAVIRUS OUTBREAK;PHENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;AMYOTROPHIC LATERAL SCLEROSIS;LENALIDOMIDE;CUMULATIVE INCIDENCE;IMMUNOTHERAPY;BORTEZOMIB;GENOTYPE;MUTATION;PROGRESSION-FREE SURVIVAL;CHRONIC LYMPHOCYTIC LEUKEMIA;CYCLOPHOSPHAMIDE;LIVER TRANSPLANTATION","70;36;31;31;30;30;27;19;18;17;17;15;14;13;13;13;13;12;12;12","CORONAVIRUS DISEASE 2019 (COVID-19);CARFILZOMIB;BENDAMUSTINE;KLEBSIELLA PNEUMONIAE;POMALIDOMIDE;VINCRISTINE;COLONOSCOPY;DARATUMUMAB;FRONTOTEMPORAL DEMENTIA;IBRUTINIB;MACE;PRENATAL DIAGNOSIS;RUXOLITINIB;CEFTAZIDIME;CYSTECTOMY;DIFFUSING CAPACITY;INTERNATIONAL PROGNOSTIC INDEX;MISSENSE MUTATION;NEOADJUVANT THERAPY;NILOTINIB;NIVOLUMAB;PROBAND;SINGLE-NUCLEOTIDE POLYMORPHISM;VENETOCLAX","70;10;9;8;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",";HUMANS;FEMALE;MALE;MIDDLE AGED;COVID-19;AGED;RETROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADULT;ITALY;TREATMENT OUTCOME;SARS-COV-2;MULTIPLE MYELOMA;PROGNOSIS;PROSPECTIVE STUDIES;AGED, 80 AND OVER;NEOPLASM RECURRENCE, LOCAL;COLORECTAL NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS","369;347;148;140;100;98;96;89;78;69;68;57;49;46;46;40;39;38;36;35","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT OF VALVULAR HEART DISEASE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASES;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HEMATOPOIETIC STEM CELL BIOLOGY;MOLECULAR MECHANISMS OF AMYLOIDOSIS;CORONAVIRUS DISEASE 2019;EFFICACY AND RESISTANCE IN CML TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CHOLANGIOCARCINOMA","37;30;21;18;14;11;10;10;9;9;8;7;7;7;7;7;6;6;6;5","CLINICAL ENDPOINT;PANDEMIC;INTERNATIONAL MYELOMA WORKING GROUP;2019-20 CORONAVIRUS OUTBREAK;MANTLE CELL LYMPHOMA;REGIMEN;REFRACTORY (PLANETARY SCIENCE);CUMULATIVE INCIDENCE;TREATMENT;HEMATOLOGY;PROGRESSION-FREE SURVIVAL;DISCONTINUATION;CLINICAL PRACTICE;UNIVARIATE ANALYSIS;BENDAMUSTINE;CARDIAC IMAGING;CONCOMITANT;FOLLICULAR LYMPHOMA;HEMATOPOIETIC CELL TRANSPLANTATION;MINIMAL RESIDUAL DISEASE","37;31;24;21;20;20;19;16;14;13;13;12;10;10;9;9;9;9;9;9","MULTIPLE MYELOMA;CANCER PATIENTS;COLORECTAL CANCER;FONDAZIONE ITALIANA;ITALIANA LINFOMI;AMYOTROPHIC LATERAL;COVID- PANDEMIC;LATERAL SCLEROSIS;MYELOID LEUKEMIA;BREAST CANCER;CLINICAL PRACTICE;COHORT STUDY;PHASE II;CELL TRANSPLANTATION;RELAPSEDREFRACTORY MULTIPLE;LINFOMI FIL;PATIENTS TREATED;PROSPECTIVE STUDY;RISK FACTORS;SARS-COV- INFECTION;ACUTE MYELOID;CELL LYMPHOMA;FOLLICULAR LYMPHOMA;METASTATIC COLORECTAL;NEWLY DIAGNOSED;PATIENTS UNDERGOING;STEM CELL;BLADDER CANCER;CANCER SCREENING;COVID- INFECTION","31;19;18;17;17;14;14;14;13;12;12;12;12;10;10;9;9;9;9;9;8;8;8;8;8;8;8;7;7;7","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;RESEARCH FUNDING;CONSULTANCY HONORARIA;HR CI;HONORARIA MEMBERSHIP;COMMITTEES SPEAKERS;PUBMED SCOPUS;MEDIAN AGE;RISK FACTORS;PATIENTS TREATED;MULTIPLE MYELOMA;MEDIAN FOLLOW-UP;ADVERSE EVENTS;HONORARIA RESEARCH;SURVIVAL OS;CROSSREF PUBMED;ADVISORY ROLE;NEWLY DIAGNOSED;STEM CELL;CLINICAL PRACTICE;CLINICAL TRIALS;CONFIDENCE INTERVAL;PROGRESSION-FREE SURVIVAL;COMMITTEES RESEARCH;COVID- PANDEMIC;JANSSEN CONSULTANCY;SARS-COV- INFECTION;PRIMARY ENDPOINT","374;374;270;202;141;95;93;89;81;59;57;54;53;50;48;47;45;43;39;39;37;35;35;34;34;33;33;33;33;32",354,0.49,10.25,9.75,1,1,0,2,1,1,2,11,2.25,1,9,4,1,2,6,7,5,0,0,39,39,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,3.79,822.08,5.26,22,0.56,92.31,0,1,7,1,16,0,2,12,0,32,7,0,0,0,0,0,0,38,1,0,39,0,0,0,0,0,0,0,0,0,"United States;Italy;United Kingdom;Belgium;Ireland;Netherlands","9;8;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;4003 BIOMEDICAL ENGINEERING;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;4012 FLUID MECHANICS AND THERMAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","38;13;13;8;4;4;4;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;PATIENT SAFETY;CARDIOVASCULAR;LYMPHOMA;HEART DISEASE;BRAIN DISORDERS;NEUROSCIENCES;AGING;AUTOIMMUNE DISEASE;BIOENGINEERING;NEURODEGENERATIVE;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH;TRANSPLANTATION;ALS","37;28;20;14;11;9;7;7;6;4;4;3;3;3;3;3;3;3;3;2","CANCER;CARDIOVASCULAR;NEUROLOGICAL;MUSCULOSKELETAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;SKIN","10;6;3;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;5.3 MEDICAL DEVICES;7.1 INDIVIDUAL CARE NEEDS","24;9;4;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;MYELOMA;MELANOMA;BRAIN TUMOR;BREAST CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HODGKIN'S DISEASE;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;STOMACH CANCER","9;6;3;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","13;3;1;1;1;1",1,3117336,779334,6,4,4,1,2,640451.439883596,1.1242070126829,"AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;ERASMUS MC;INSTITUTE OF ONCOLOGY LJUBLJANA;INSTITUTE OF ONCOLOGY PROF. DR. ION CHIRICUTA","1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","1;1;1;1","BREAST CANCER;CANCER;CERVICAL CANCER;CLINICAL RESEARCH;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEALTH SERVICES;PREVENTION","1;1;1;1;1;1;1;1","CANCER","1","4.4 POPULATION SCREENING","1","BREAST CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER","1;1;1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","1;1;1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1",NA,NA,6,"FRONTIERS;ZENODO;TAYLOR & FRANCIS GROUP","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;5202 BIOLOGICAL PSYCHOLOGY","12;4;2;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;BRAIN DISORDERS;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEURODEGENERATIVE;NEUROSCIENCES;AGING;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;MULTIPLE SCLEROSIS;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;DEMENTIA;DEPRESSION;DIGESTIVE DISEASES;GENETICS;HEMATOLOGY","6;4;3;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;NEUROLOGICAL","3;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;1;1","CLINICAL","3","CLINICAL MEDICINE AND SCIENCE","4","BLOOD CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER","1;1;1;1;1;1",NA,NA
"AOU_CITTADELLASCIENZA",2022,688,21.1395348837209,2.69331395348837,0.228197674418605,0.25,0.274709302325581,2.05128205128205,1.27642276422764,1.68627450980392,1.29452054794521,0.731104651162791,1,292,137,63,38,0.42,0.2,0.09,0.06,8.01,0.896828243222128,6.7017857142857,0.427325581395349,0.96656976744186,0.516,0.468,0.499,0.481,"GAETANO MARIA DE FERRARI;LUCA BRAZZI;MICHÈLE CAVO;ADRIANO CHIÒ;ROSSANA CAVALLO;SIMONE FREA;CARLOTTA SACERDOTE;ALESSANDRO BUSCA;ANDREA CALVO;RENATO ROMAGNOLI;BENEDETTO BRUNO;FRANCESCO GIUSEPPE DE ROSA;ENRICO FUSARO;CRISTINA MOGLIA;GABRIELE BIANCO;ANTONIO CANOSA;PAOLO GONTERO;CRISTINA COSTA;SILVIA CORCIONE;GIOVANNINO CICCONE","30;22;21;21;20;18;18;17;17;16;16;16;16;16;15;15;15;15;14;14","GAETANO MARIA DE FERRARI;LUCA BRAZZI;ROSSANA CAVALLO;GABRIELE BIANCO;CRISTINA COSTA;SIMONE FREA;GIANCARLO DI VELLA;MATTEO BOATTINI;RENATO ROMAGNOLI;SARA COMINI;ADRIANO CHIÒ;SILVIA CORCIONE;FRANCESCO GIUSEPPE DE ROSA;M. SACCO;CRISTINA MOGLIA;GIOVANNINO CICCONE;MARCO IANNACCONE;GIORGIA MONTRUCCHIO;ANDREA CALVO;C.G. DE ANGELIS","2.66;2.62;2.31;1.88;1.87;1.84;1.71;1.46;1.42;1.39;1.25;1.24;1.22;1.18;1.16;1.16;1.08;1.04;1.04;1.03","GAETANO MARIA DE FERRARI;LUCA BRAZZI;ADRIANO CHIÒ;ROSSANA CAVALLO;SIMONE FREA;CARLOTTA SACERDOTE;ALESSANDRO BUSCA;ANDREA CALVO;RENATO ROMAGNOLI;BENEDETTO BRUNO;FRANCESCO GIUSEPPE DE ROSA;ENRICO FUSARO;CRISTINA MOGLIA;GABRIELE BIANCO;ANTONIO CANOSA;PAOLO GONTERO;CRISTINA COSTA;SILVIA CORCIONE;GIOVANNINO CICCONE;ANDREA EVANGELISTA","30;22;21;20;18;18;17;17;16;16;16;16;16;15;15;15;15;14;14;13","GAETANO MARIA DE FERRARI;LUCA BRAZZI;ROSSANA CAVALLO;GABRIELE BIANCO;CRISTINA COSTA;SIMONE FREA;GIANCARLO DI VELLA;MATTEO BOATTINI;RENATO ROMAGNOLI;SARA COMINI;ADRIANO CHIÒ;SILVIA CORCIONE;FRANCESCO GIUSEPPE DE ROSA;M. SACCO;CRISTINA MOGLIA;GIOVANNINO CICCONE;MARCO IANNACCONE;GIORGIA MONTRUCCHIO;ANDREA CALVO;C.G. DE ANGELIS","2.66;2.62;2.31;1.88;1.87;1.84;1.71;1.46;1.42;1.39;1.25;1.24;1.22;1.18;1.16;1.16;1.08;1.04;1.04;1.03","MICHÈLE CAVO;FRANCESCA GAY;MARIO BOCCADORO;ALESSANDRA LAROCCA;ANDRÉA CAPRA;MARÍA‐VICTORIA MATEOS;HARTMUT GOLDSCHMIDT;ADRIANO CHIÒ;ELENA ZAMAGNI;PIETER SONNEVELD;CARLOTTA SACERDOTE;SONJA ZWEEGMAN;BRONNO VAN DER HOLT;HANS SALWENDER;NIELS W.C.J. VAN DE DONK;GORDON COOK;ROSSANA CAVALLO;SARA LONARDI;FEDERICA MORANO;FILIPPO PIETRANTONIO","388;361;331;322;295;286;279;265;265;258;243;242;229;229;229;228;228;226;225;225","FRANCESCA GAY;ALESSANDRA LAROCCA;MARIO BOCCADORO;ANDRÉA CAPRA;ADRIANO CHIÒ;FRANCESCA BONELLO;MATTIA D’AGOSTINO;ROSSANA CAVALLO;CARLOTTA SACERDOTE;CRISTINA COSTA;GABRIELE BIANCO;ANDREA CALVO;LORELLA ORSUCCI;MATTEO BOATTINI;GIULIANA RITORTO;CRISTINA MOGLIA;CARLO SENORE;LUCA BRAZZI;PIER LUIGI CALVO;ALESSANDRO BUSCA","361;322;293;253;229;223;208;190;183;175;167;155;146;143;140;132;128;127;119;113","GAETANO MARIA DE FERRARI;ROSSANA CAVALLO;SIMONE FREA;LUCA BRAZZI;ENRICO FUSARO;CARLOTTA SACERDOTE;ADRIANO CHIÒ;GABRIELE BIANCO;CRISTINA COSTA;ALESSANDRO BUSCA;ANDREA CALVO;RENATO ROMAGNOLI;CRISTINA MOGLIA;GIOVANNINO CICCONE;ANDREA EVANGELISTA;BENEDETTO BRUNO;M. SACCO;MATTEO BOATTINI;FABRIZIO D’ASCENZO;FRANCESCA GAY","26;18;18;17;16;15;15;14;14;14;14;13;13;13;12;11;11;11;10;10","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;MATHEMATICS;MATERIALS SCIENCE;GEOGRAPHY;ART;GEOLOGY;HISTORY;ENVIRONMENTAL SCIENCE","657;188;69;45;44;43;33;30;25;21;17;16;15;6;5;3;3;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;CARDIOLOGY;RADIOLOGY;BIOCHEMISTRY;PSYCHIATRY;PEDIATRICS;INTENSIVE CARE MEDICINE;OPTICS;PALEONTOLOGY;NURSING;ANESTHESIA;FAMILY MEDICINE;MICROBIOLOGY","508;182;123;104;103;85;80;79;70;65;55;54;50;45;42;34;33;31;31;29","DISEASE;CANCER;GENE;COHORT;POPULATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;TRANSPLANTATION;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;INCIDENCE (GEOMETRY);LYMPHOMA;ADVERSE EFFECT;LEUKEMIA;MULTIPLE MYELOMA;PROSPECTIVE COHORT STUDY;HEART FAILURE;RANDOMIZED CONTROLLED TRIAL;COHORT STUDY;MYOCARDIAL INFARCTION","118;103;77;72;69;61;54;53;49;47;41;35;33;33;33;33;32;30;27;27","INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;CLINICAL ENDPOINT;BREAST CANCER;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;LENALIDOMIDE;CUMULATIVE INCIDENCE;EJECTION FRACTION;RITUXIMAB;2019-20 CORONAVIRUS OUTBREAK;AMYOTROPHIC LATERAL SCLEROSIS;CHRONIC LYMPHOCYTIC LEUKEMIA;LIVER TRANSPLANTATION;PROSTATE CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;UNIVARIATE ANALYSIS;CONVENTIONAL PCI;MYELOFIBROSIS;PERCUTANEOUS CORONARY INTERVENTION;PSEUDOMONAS AERUGINOSA;TOLERABILITY","57;31;29;22;22;22;21;18;18;18;17;15;15;14;14;12;12;11;11;11;11;11","CORONAVIRUS DISEASE 2019 (COVID-19);DNA METHYLATION;FLUDARABINE;COLONOSCOPY;DARATUMUMAB;IBRUTINIB;KLEBSIELLA PNEUMONIAE;PROSTATECTOMY;BROTH MICRODILUTION;FRONTOTEMPORAL DEMENTIA;IGHV@;MACE;MACHINE PERFUSION;POMALIDOMIDE;RUXOLITINIB;BUSULFAN;CEFTAZIDIME;CYSTECTOMY;EXOME SEQUENCING;GENOME INSTABILITY;MEROPENEM;SOD1;THIOTEPA","56;8;8;7;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5","HUMANS;;FEMALE;RETROSPECTIVE STUDIES;COVID-19;MALE;ADULT;TREATMENT OUTCOME;PROSPECTIVE STUDIES;ITALY;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MIDDLE AGED;AMYOTROPHIC LATERAL SCLEROSIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MULTIPLE MYELOMA;COLORECTAL NEOPLASMS;BREAST NEOPLASMS;SARS-COV-2;LEUKEMIA, MYELOID, ACUTE","353;323;85;84;75;63;47;45;44;43;40;38;36;33;32;29;27;25;25;24","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;CORONAVIRUS DISEASE 2019;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MANAGEMENT OF VALVULAR HEART DISEASE;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PANCREATIC CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HEMATOPOIETIC STEM CELL BIOLOGY;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;CORONAVIRUS DISEASE 2019 RESEARCH;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE","26;19;16;15;13;12;12;11;10;10;10;9;8;7;7;7;7;6;6;5","CLINICAL ENDPOINT;PANDEMIC;REGIMEN;INTERQUARTILE RANGE;INTERNATIONAL MYELOMA WORKING GROUP;CUMULATIVE INCIDENCE;DISCONTINUATION;TREATMENT;2019-20 CORONAVIRUS OUTBREAK;HEMATOLOGY;STROKE (ENGINE);MANTLE CELL LYMPHOMA;TOLERABILITY;TRANSCATHETER AORTIC-VALVE REPLACEMENT;UNIVARIATE ANALYSIS;HEMATOPOIETIC CELL TRANSPLANTATION;CARDIAC IMAGING;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BREAST CANCER SCREENING;FOLLICULAR LYMPHOMA","30;28;25;22;19;18;18;16;15;14;13;11;11;11;11;10;9;8;8;8","MULTIPLE MYELOMA;COVID- PANDEMIC;MYELOID LEUKEMIA;COHORT STUDY;OBSERVATIONAL STUDY;FONDAZIONE ITALIANA;ACUTE MYELOID;COLORECTAL CANCER;ITALIANA LINFOMI;PROSTATE CANCER;BREAST CANCER;AMYOTROPHIC LATERAL;HEART FAILURE;LATERAL SCLEROSIS;STEM CELL;CANCER PATIENTS;CELL TRANSPLANTATION;PROSPECTIVE OBSERVATIONAL;EUROPEAN PROSPECTIVE;NEWLY DIAGNOSED;PATIENTS UNDERGOING;RISK FACTORS;ACUTE LYMPHOBLASTIC;BLADDER CANCER;CELL LYMPHOMA;CHRONIC LYMPHOCYTIC;CLINICAL PRACTICE;CROSS-SECTIONAL STUDY;FINAL RESULTS;HEPATOCELLULAR CARCINOMA","27;18;17;16;16;13;12;12;12;11;10;9;9;9;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6","MEDIAN AGE;HR CI;PATIENTS TREATED;MEDIAN FOLLOW-UP;PRIMARY ENDPOINT;ADVERSE EVENTS;VIEW LARGEDOWNLOAD;RISK FACTORS;PATIENTS UNDERGOING;PATIENTS RECEIVED;STATISTICALLY SIGNIFICANT;STEM CELL;COVID- PANDEMIC;SURVIVAL OS;PROGRESSION-FREE SURVIVAL;MULTIPLE MYELOMA;CONSECUTIVE PATIENTS;MEDIAN TIME;PATIENTS RECEIVING;CONFIDENCE INTERVAL;CLINICAL TRIALS;HAZARD RATIO;SURVIVAL PFS;BREAST CANCER;CLINICAL PRACTICE;LIVER TRANSPLANTATION;SARS-COV- INFECTION;INTENSIVE CARE;CLINICAL OUTCOMES;HEART FAILURE","78;72;70;60;49;46;46;45;43;41;38;37;36;35;34;33;32;32;32;31;30;29;29;28;28;28;28;27;26;26",342,0.5,7.96,9.75,1,1,0,2,1,1,0,11,1,1,9.25,1,1.25,1,3,6.25,4,0,0,19,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,4,1025.76,3.29,12,0.46,76.08,1,0,7,0,8,0,0,10,0,19,7,0,0,0,0,0,0,26,0,0,26,0,0,0,0,0,0,0,0,0,"Italy;United States;Belgium;Japan;Netherlands","15;9;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","26;14;8;3;3;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;HEMATOLOGY;NEUROSCIENCES;PREVENTION;BRAIN DISORDERS;CARDIOVASCULAR;DIGESTIVE DISEASES;INFECTIOUS DISEASES;BRAIN CANCER;CHRONIC PAIN;EMERGING INFECTIOUS DISEASES;LIVER CANCER;LIVER DISEASE;LUNG;PAIN RESEARCH;PEDIATRIC","23;17;12;12;12;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2","CANCER;INFECTION;BLOOD;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;RESPIRATORY","7;2;1;1;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.7 PHYSICAL","16;2;2;2;1;1;1;1","BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;LIVER CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;BLADDER CANCER;BLOOD CANCER;LUNG CANCER;MELANOMA;PANCREATIC CANCER","2;2;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","8;2;1;1;1;1;1;1",2,1574408.5,221051.69,3,7.5,6.5,1,2,741095.098248858,0.928355890661918,"AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;CANCER SOCIETY OF FINLAND;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;BABEȘ-BOLYAI UNIVERSITY;ERASMUS MC;FRENCH NATIONAL CANCER INSTITUTE;FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA;GERMAN CANCER RESEARCH CENTER;LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY - BIPS;NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY;SCIENSANO (BELGIUM);UNIVERSITÉ CATHOLIQUE DE LOUVAIN","2;2;2;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","EU4HEALTH PROGRAMME (EU4H) (PROGRAMME)","2","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;2","CANCER;BREAST CANCER;CLINICAL RESEARCH;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEALTH SERVICES;PREVENTION","2;1;1;1;1;1;1","CANCER","2","4.4 POPULATION SCREENING","1","BREAST CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER","1;1;1","4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1",NA,NA,8,"FRONTIERS","8","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3210 NUTRITION AND DIETETICS;5202 BIOLOGICAL PSYCHOLOGY","12;5;3;3;2;1;1;1;1","CLINICAL RESEARCH;CANCER;DIGESTIVE DISEASES;RARE DISEASES;COMPARATIVE EFFECTIVENESS RESEARCH;COST EFFECTIVENESS RESEARCH;HEALTH SERVICES;LIVER CANCER;LIVER DISEASE;PREVENTION;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;ALS;AUTOIMMUNE DISEASE;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;DIABETES;GENETICS","7;5;5;4;3;3;3;3;3;3;2;2;2;2;1;1;1;1;1;1","CANCER;MENTAL HEALTH;METABOLIC AND ENDOCRINE;NEUROLOGICAL","5;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;1;1","CLINICAL;BIOMEDICAL","7;1","CLINICAL MEDICINE AND SCIENCE;HEALTH SERVICES RESEARCH;BASIC SCIENCE","4;3;1","LIVER CANCER;COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER","3;2;2",NA,NA
"AOU_CITTADELLASCIENZA",2023,689,21.5573294629898,3.27285921625544,0.288824383164006,0.281567489114659,0.313497822931785,2.21859545004946,1.31788079470199,1.84761904761905,1.30909090909091,0.735849056603774,3,292,132,43,46,0.42,0.19,0.06,0.07,3.86,0.879816293649333,6.35452481349337,0.397677793904209,0.933236574746009,0.543,0.501,0.496,0.517,"GAETANO MARIA DE FERRARI;BENEDETTO BRUNO;GIOVANNINO CICCONE;BARBARA BOTTO;MARCO CERRANO;ALESSANDRO BUSCA;MICHÈLE CAVO;MONICA BOCCHIA;ALESSANDRA IURLO;FRANCESCA GAY;LUCA ARCAINI;FRANCESCO BRUNO;PELLEGRINO MUSTO;MASSIMO BRECCIA;ANDREA EVANGELISTA;PAOLO CORRADINI;C.G. DE ANGELIS;ADRIANO CHIÒ;ROSSANA CAVALLO;SIMONE FERRERO","38;26;25;23;22;21;21;20;20;20;19;19;19;19;18;18;18;18;17;17","GAETANO MARIA DE FERRARI;FRANCESCA GAY;C.G. DE ANGELIS;BENEDETTO BRUNO;ROSSANA CAVALLO;M. SACCO;PAOLO GONTERO;FRANCESCO BRUNO;CRISTINA COSTA;ALESSANDRO BUSCA;LEONARDO LOPIANO;CARLO ALBERTO ARTUSI;ADRIANO CHIÒ;MATTEO ANSELMINO;MARCO CERRANO;M. GESUALDO;OVIDIO DE FILIPPO;GIOVANNINO CICCONE;GABRIELE BIANCO;F. FIMIANO","3.02;1.89;1.81;1.67;1.67;1.65;1.47;1.45;1.44;1.38;1.3;1.3;1.29;1.24;1.21;1.17;1.17;1.14;1.12;1.07","GAETANO MARIA DE FERRARI;BENEDETTO BRUNO;GIOVANNINO CICCONE;BARBARA BOTTO;MARCO CERRANO;ALESSANDRO BUSCA;MICHÈLE CAVO;FRANCESCA GAY;FRANCESCO BRUNO;ANDREA EVANGELISTA;C.G. DE ANGELIS;ADRIANO CHIÒ;ROSSANA CAVALLO;SIMONE FERRERO;MARIO BOCCADORO;GIULIA BENEVOLO;ANDREA CALVO;VALENTINA GIAI;ENRICO FUSARO;SIMONE PARISI","38;26;25;23;22;21;21;20;19;18;18;18;17;17;17;17;17;17;17;16","GAETANO MARIA DE FERRARI;FRANCESCA GAY;C.G. DE ANGELIS;BENEDETTO BRUNO;ROSSANA CAVALLO;M. SACCO;PAOLO GONTERO;FRANCESCO BRUNO;CRISTINA COSTA;ALESSANDRO BUSCA;LEONARDO LOPIANO;CARLO ALBERTO ARTUSI;ADRIANO CHIÒ;MATTEO ANSELMINO;MARCO CERRANO;M. GESUALDO;OVIDIO DE FILIPPO;GIOVANNINO CICCONE;GABRIELE BIANCO;F. FIMIANO","3.02;1.89;1.81;1.67;1.67;1.65;1.47;1.45;1.44;1.38;1.3;1.3;1.29;1.24;1.21;1.17;1.17;1.14;1.12;1.07","MICHÈLE CAVO;FRANCESCA GAY;MARIO BOCCADORO;ROBERTO MINA;GAETANO MARIA DE FERRARI;ANGELO BELOTTI;PIETER SONNEVELD;MELETIOS Α. DIMOPOULOS;EIRINI KATODRITOU;NIELS W.C.J. VAN DE DONK;LAURA ROSIÑOL;ANNEMIEK BROIJL;FREDRIK SCHJESVOLD;PAULA RODRÍGUEZ‐OTERO;ROMAN HÁJEK;WILFRIED ROELOFFZEN;HERMANN EINSELE;ELISABETTA ANTONIOLI;JOAN BLADÉ;CHIARA BENEDETTO","215;211;206;198;197;191;191;175;174;173;171;166;166;166;166;166;165;164;156;154","GAETANO MARIA DE FERRARI;FRANCESCA GAY;ROBERTO MINA;MARIO BOCCADORO;CHIARA BENEDETTO;MAURO PORPIGLIA;ANDREA CALVO;REBECCA PANCONESI;ROSSANA CAVALLO;ADRIANO CHIÒ;ERNESTA AUDISIO;GIULIA BENEVOLO;GABRIELE BIANCO;MATTIA D’AGOSTINO;OVIDIO DE FILIPPO;LUISA GIACCONE;CRISTINA COSTA;PAOLO GONTERO;CARLA GIUSTETTO;ALESSANDRO BUSCA","196;190;188;141;136;133;104;78;78;76;74;74;69;69;67;65;63;56;54;53","GAETANO MARIA DE FERRARI;BARBARA BOTTO;MARCO CERRANO;ERNESTA AUDISIO;GIOVANNINO CICCONE;FRANCESCO BRUNO;C.G. DE ANGELIS;ENRICO FUSARO;ANDREA CALVO;ALESSANDRO BUSCA;CAROLA BOCCOMINI;GIULIA BENEVOLO;VALENTINA GIAI;SIMONE PARISI;ANDREA EVANGELISTA;FRANCESCA GAY;M. SACCO;OVIDIO DE FILIPPO;ROSSANA CAVALLO;ADRIANO CHIÒ","34;23;22;21;19;18;18;17;16;16;16;16;16;16;15;15;15;14;14;13","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;ENGINEERING;MATHEMATICS;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;GEOGRAPHY;BUSINESS;PHILOSOPHY;MATERIALS SCIENCE;ART;HISTORY;GEOLOGY","666;186;66;55;42;29;23;21;18;15;15;8;7;7;4;3;3;2","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;CARDIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;IMMUNOLOGY;RADIOLOGY;PALEONTOLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;BIOCHEMISTRY;NURSING;CANCER RESEARCH;UROLOGY;ENDOCRINOLOGY;OPTICS;PHYSICAL THERAPY","541;217;157;109;104;92;86;77;66;63;55;45;44;41;37;33;25;25;24;23;23","DISEASE;CANCER;COHORT;POPULATION;CHEMOTHERAPY;GENE;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION;RANDOMIZED CONTROLLED TRIAL;MULTIPLE MYELOMA;LYMPHOMA;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;ADVERSE EFFECT;LEUKEMIA;CLINICAL TRIAL;MYELOID LEUKEMIA;DISCONTINUATION;HEART FAILURE;BONE MARROW","105;102;82;73;69;68;66;63;60;51;50;47;38;37;37;35;33;32;32;29","CLINICAL ENDPOINT;LENALIDOMIDE;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;EJECTION FRACTION;RITUXIMAB;LIVER TRANSPLANTATION;CHRONIC LYMPHOCYTIC LEUKEMIA;MINIMAL RESIDUAL DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;AUTOLOGOUS STEM-CELL TRANSPLANTATION;AMYOTROPHIC LATERAL SCLEROSIS;BORTEZOMIB;COLORECTAL CANCER;NEUTROPENIA;GENOTYPE;PERCUTANEOUS CORONARY INTERVENTION;CYCLOPHOSPHAMIDE;IMMUNOTHERAPY;MULTICENTER STUDY;PLACEBO;TOLERABILITY","55;32;31;31;29;26;25;21;20;19;18;16;15;15;15;15;14;14;13;12;12;12;12","CORONAVIRUS DISEASE 2019 (COVID-19);VENETOCLAX;CARFILZOMIB;DARATUMUMAB;DNA METHYLATION;BENDAMUSTINE;RUXOLITINIB;IBRUTINIB;IGHV@;NILOTINIB;FLUDARABINE;POMALIDOMIDE;VINCRISTINE;CHIMERIC ANTIGEN RECEPTOR;COLONOSCOPY;DEEP BRAIN STIMULATION;KLEBSIELLA PNEUMONIAE;LEVODOPA;SINGLE-NUCLEOTIDE POLYMORPHISM;ACUTE LYMPHOCYTIC LEUKEMIA;CEFTAZIDIME;CHEMOIMMUNOTHERAPY;ELTROMBOPAG;EXOME SEQUENCING;FEBRILE NEUTROPENIA;FRONTOTEMPORAL DEMENTIA;INTERNATIONAL PROGNOSTIC INDEX;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MACE;MACHINE PERFUSION;METASTATIC BREAST CANCER;MODIFIED RANKIN SCALE;TAMOXIFEN","31;14;13;13;10;8;8;7;7;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4",";HUMANS;RETROSPECTIVE STUDIES;FEMALE;MALE;ADULT;TREATMENT OUTCOME;MIDDLE AGED;COVID-19;AGED;ITALY;PROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CHILD;AMYOTROPHIC LATERAL SCLEROSIS;BREAST NEOPLASMS;STROKE;NEOPLASM RECURRENCE, LOCAL;NEOPLASMS;ANTI-BACTERIAL AGENTS","397;289;75;71;52;48;45;37;35;34;33;31;30;24;22;22;21;20;20;18","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;EFFICACY AND RESISTANCE IN CML TREATMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;MANAGEMENT OF VALVULAR HEART DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;RHEUMATOID ARTHRITIS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;PANCREATIC CANCER RESEARCH AND TREATMENT;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ATRIAL FIBRILLATION;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA","40;28;24;23;16;14;13;11;10;9;9;9;8;8;8;7;7;6;6;6","CLINICAL ENDPOINT;DISCONTINUATION;REFRACTORY (PLANETARY SCIENCE);MANTLE CELL LYMPHOMA;MINIMAL RESIDUAL DISEASE;REGIMEN;INTERNATIONAL MYELOMA WORKING GROUP;PANDEMIC;STROKE (ENGINE);AUTOLOGOUS STEM-CELL TRANSPLANTATION;HEMATOLOGY;SINGLE CENTER;TREATMENT OUTCOMES;VENETOCLAX;DARATUMUMAB;TOLERABILITY;ACUTE MYELOID LEUKEMIA;CARDIAC IMAGING;CONCOMITANT;ECHOCARDIOGRAPHY","55;32;22;21;21;20;19;18;17;16;15;15;14;14;13;13;12;12;11;11","MULTIPLE MYELOMA;MYELOID LEUKEMIA;ACUTE MYELOID;STEM CELL;NEWLY DIAGNOSED;BREAST CANCER;CELL TRANSPLANTATION;COHORT STUDY;FONDAZIONE ITALIANA;ITALIANA LINFOMI;MULTICENTER STUDY;PATIENTS TREATED;REAL LIFE;LIVER TRANSPLANTATION;PHASE III;CHRONIC LYMPHOCYTIC;CHRONIC MYELOID;COVID- PANDEMIC;HEART FAILURE;LYMPHOCYTIC LEUKEMIA;PHASE II;LYMPHOMA PATIENTS;MYELOMA PATIENTS;OBSERVATIONAL STUDY;RESIDUAL DISEASE;RETROSPECTIVE STUDY;AMYOTROPHIC LATERAL;AUTOLOGOUS STEM;B-CELL LYMPHOMA;CANCER PATIENTS","34;27;21;20;18;17;16;15;15;15;12;12;12;11;11;10;10;10;10;10;10;9;9;9;9;9;8;8;8;8","HR CI;MEDIAN FOLLOW-UP;MEDIAN AGE;PATIENTS TREATED;PRIMARY ENDPOINT;STEM CELL;SURVIVAL OS;ADVERSE EVENTS;NEWLY DIAGNOSED;PATIENTS RECEIVED;PROGRESSION-FREE SURVIVAL;MULTIPLE MYELOMA;SARS-COV- INFECTION;MEDIAN TIME;MYELOID LEUKEMIA;SURVIVAL PFS;MULTIVARIATE ANALYSIS;BONE MARROW;AXIAL POSTURAL;MONTHS CI;CELL TRANSPLANTATION;POSTURAL ABNORMALITIES;RESIDUAL DISEASE;RISK FACTORS;STATISTICALLY SIGNIFICANT;ADVISORY ROLE;ACUTE MYELOID;COVID- PANDEMIC;PATIENTS PTS;DISEASE ACTIVITY","99;89;85;82;60;57;56;52;49;49;46;45;45;44;44;43;42;41;38;37;36;36;36;36;36;35;34;34;33;32",243,0.35,9.75,11,1,1.5,0,2,1,1,0,12,1,1,11,1,1,2,3,9,4.75,0,0,10,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3.12,757.16,2.75,5,0.2,30.24,0,0,5,0,6,0,2,12,0,17,8,0,0,0,0,0,0,24,0,1,25,0,0,0,0,0,0,0,0,0,"Italy;Germany;United States;Belgium;Japan;Switzerland","16;3;3;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3203 DENTISTRY;3204 IMMUNOLOGY","25;13;9;6;4;4;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;PATIENT SAFETY;LYMPHOMA;NEUROSCIENCES;BRAIN DISORDERS;LUNG;BEHAVIORAL AND SOCIAL SCIENCE;CARDIOVASCULAR;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DEPRESSION;GENETICS;HEART DISEASE;MENTAL HEALTH;PREVENTION;SERIOUS MENTAL ILLNESS;AUTOIMMUNE DISEASE","22;17;11;8;8;6;5;5;4;4;3;3;3;3;3;3;3;3;3;2","CANCER;CARDIOVASCULAR;MENTAL HEALTH;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","8;3;3;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;2.4 SURVEILLANCE AND DISTRIBUTION;6.2 CELLULAR AND GENE THERAPIES","14;3;2;2;1;1","NON-HODGKIN'S LYMPHOMA;LUNG CANCER;BLADDER CANCER;BRAIN TUMOR;BREAST CANCER;LIVER CANCER","5;3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;3.3 CHEMOPREVENTION;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;2;2;1;1;1",1,11432044,879388,4,13,10,1,0,761335.457623858,0.90498871831135,"ACCELOPMENT (SWITZERLAND);ASSUTA MEDICAL CENTER;AZIENDA OSPEDALIERA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO;INSTITUT GUSTAVE ROUSSY;SHEBA MEDICAL CENTER;TECHNICAL UNIVERSITY OF MUNICH;TECHNION – ISRAEL INSTITUTE OF TECHNOLOGY;THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER;UNIVERSITY CLINICAL CENTRE MARIBOR;UNIVERSITY COLLEGE CORK;UNIVERSITY HOSPITAL HEIDELBERG;UNIVERSITY MEDICAL CENTER GRONINGEN;VRIJE UNIVERSITEIT BRUSSEL","1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-MISS-2021-CANCER-02 (CALL FOR PROPOSAL);HORIZON-RIA - HORIZON  RESEARCH AND INNOVATION ACTIONS (FUNDING SCHEME);HORIZON.2.1 - HEALTH (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","BIOENGINEERING;BIOMEDICAL IMAGING;BREAST CANCER;CANCER;CLINICAL RESEARCH;HEALTH SERVICES;PREVENTION","1;1;1;1;1;1;1","CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING","1;1;1","BREAST CANCER","1","4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,26,"AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS","24;2","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES","30;27;13;13;1","GENETICS;HEMATOLOGY;HUMAN GENOME;BIOTECHNOLOGY;CLINICAL RESEARCH;RARE DISEASES;ALS;BRAIN DISORDERS;CANCER;DIGESTIVE DISEASES;DIGESTIVE DISEASES - (GALLBLADDER);LIVER DISEASE;NEURODEGENERATIVE;NEUROSCIENCES;ORPHAN DRUG;PREVENTION","5;4;4;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL","11;1","5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS","4;3;1","BIOMEDICAL;CLINICAL","5;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","17;8","MYELOMA;LIVER CANCER","24;1",NA,NA
"AOU_CITTADELLASCIENZA",2024,524,20.293893129771,3.1736641221374,0.269083969465649,0.286259541984733,0.278625954198473,2.071608040201,1.29357798165138,1.70454545454545,1.29203539823009,0.549618320610687,7,254,96,30,29,0.48,0.18,0.06,0.06,0.84,0.87461954666878,5.17759121730708,0.393129770992366,0.937022900763359,0.526,0.447,0.455,0.481,"GAETANO MARIA DE FERRARI;RENATO ROMAGNOLI;SIMONE FREA;FABRIZIO D’ASCENZO;VERONICA DUSI;CRISTINA COSTA;SILVIA MORBELLI;FILIPPO ANGELINI;ANDREA SAGLIETTO;GUGLIELMO GALLONE;DAMIANO PATRONO;OVIDIO DE FILIPPO;MATTEO ANSELMINO;CHIARA BENEDETTO;GIOVANNINO CICCONE;ANDREA CALVO;LEONARDO LOPIANO;ADRIANO CHIÒ;M. SACCO;PIER PAOLO BOCCHINO","41;18;17;16;16;16;15;14;13;13;12;12;12;11;11;11;11;11;10;10","ELEONORA CASTELLANA;GAETANO MARIA DE FERRARI;CRISTINA COSTA;GIOVANNINO CICCONE;MASSIMO DI MAÏO;VERONICA DUSI;RENATO ROMAGNOLI;ANDREA SAGLIETTO;GABRIELE BIANCO;MATTEO BOATTINI;TOMMASO LUPIA;MATTEO ANSELMINO;M. SACCO;DAMIANO PATRONO;SILVIA MORBELLI;SIMONE FREA;CHIARA BENEDETTO;FILIPPO ANGELINI;GUGLIELMO GALLONE;ALESSANDRA BEANO","3.17;3;1.73;1.65;1.6;1.26;1.25;1.18;1.16;1.16;1.14;1.1;1.07;1.05;1.05;1.04;1.03;1.02;1.02;1","GAETANO MARIA DE FERRARI;RENATO ROMAGNOLI;SIMONE FREA;FABRIZIO D’ASCENZO;VERONICA DUSI;CRISTINA COSTA;SILVIA MORBELLI;FILIPPO ANGELINI;ANDREA SAGLIETTO;GUGLIELMO GALLONE;DAMIANO PATRONO;OVIDIO DE FILIPPO;MATTEO ANSELMINO;CHIARA BENEDETTO;GIOVANNINO CICCONE;ANDREA CALVO;LEONARDO LOPIANO;ADRIANO CHIÒ;M. SACCO;PIER PAOLO BOCCHINO","41;18;17;16;16;16;15;14;13;13;12;12;12;11;11;11;11;11;10;10","ELEONORA CASTELLANA;GAETANO MARIA DE FERRARI;CRISTINA COSTA;GIOVANNINO CICCONE;MASSIMO DI MAÏO;VERONICA DUSI;RENATO ROMAGNOLI;ANDREA SAGLIETTO;GABRIELE BIANCO;MATTEO BOATTINI;TOMMASO LUPIA;MATTEO ANSELMINO;M. SACCO;DAMIANO PATRONO;SILVIA MORBELLI;SIMONE FREA;CHIARA BENEDETTO;FILIPPO ANGELINI;GUGLIELMO GALLONE;ALESSANDRA BEANO","3.17;3;1.73;1.65;1.6;1.26;1.25;1.18;1.16;1.16;1.14;1.1;1.07;1.05;1.05;1.04;1.03;1.02;1.02;1","GAETANO MARIA DE FERRARI;SIMONE FREA;GABRIELE BIANCO;MATTEO BOATTINI;ADRIANO CHIÒ;ANTONIO GRIECO;CRISTINA COSTA;ANNA LUDOVICA FRACANZANI;ROSSANA CAVALLO;CHIARA BENEDETTO;SARA COMINI;ALESSANDRO GALLUZZO;ANNOP LEKHAKUL;ATTILA BORBÉLY;AZMEE MOHD GHAZI;CORNELIA ZARA;CYNTHIA PAREDES-PAUCAR;DIANE BARKER;DORIT KNAPPE;FATIH ERDAL","33;29;27;27;26;26;26;24;24;23;23;22;22;22;22;22;22;22;22;22","SIMONE FREA;GABRIELE BIANCO;GAETANO MARIA DE FERRARI;MATTEO BOATTINI;ADRIANO CHIÒ;CRISTINA COSTA;ANDREA SAGLIETTO;FRANCESCA GAY;RENATO ROMAGNOLI;FILIPPO ANGELINI;FABRIZIO D’ASCENZO;SILVIA MARTINI;ROSSANA CAVALLO;ALESSANDRO ANDREIS;EZIO DAVID;FEDERICO GIACOBBE;GIUSEPPE GIANNINO;ANDREA CALVO;ANTONIO CANOSA;CRISTINA MOGLIA","29;27;27;27;26;25;19;17;17;16;15;15;14;13;13;13;13;12;12;12","GAETANO MARIA DE FERRARI;RENATO ROMAGNOLI;SIMONE FREA;FABRIZIO D’ASCENZO;CRISTINA COSTA;SILVIA MORBELLI;FILIPPO ANGELINI;GUGLIELMO GALLONE;ANDREA SAGLIETTO;VERONICA DUSI;DAMIANO PATRONO;OVIDIO DE FILIPPO;ANDREA CALVO;GIOVANNINO CICCONE;MATTEO ANSELMINO;ADRIANO CHIÒ;M. SACCO;PIER PAOLO BOCCHINO;LIVIA GIORDANO;ALESSANDRO BUSCA","36;18;17;16;14;14;14;13;13;13;12;12;11;11;10;10;10;10;9;9","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;CHEMISTRY;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;ECONOMICS;BUSINESS;PHILOSOPHY;GEOGRAPHY;MATERIALS SCIENCE;GEOLOGY;ART;HISTORY","504;113;59;53;44;29;26;23;22;21;19;12;11;8;6;4;3;2","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ONCOLOGY;CARDIOLOGY;GENETICS;INTENSIVE CARE MEDICINE;RADIOLOGY;PSYCHIATRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PEDIATRICS;ANESTHESIA;NURSING;NEUROSCIENCE;GYNECOLOGY;LAW;CANCER RESEARCH;FAMILY MEDICINE;PHARMACOLOGY;UROLOGY","380;122;88;84;79;66;61;50;48;45;42;35;29;28;28;26;22;21;20;20;20;20","DISEASE;CANCER;RANDOMIZED CONTROLLED TRIAL;COHORT;GENE;RETROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;POPULATION;TRANSPLANTATION;CHEMOTHERAPY;CLINICAL TRIAL;HEALTH CARE;ALTERNATIVE MEDICINE;CONFIDENCE INTERVAL;MULTIPLE MYELOMA;HEART FAILURE;PREGNANCY;INCIDENCE (GEOMETRY);NEUROLOGY;OBSERVATIONAL STUDY","83;81;47;42;38;36;33;33;32;28;24;21;20;20;19;18;17;16;15;15","BREAST CANCER;CLINICAL ENDPOINT;LIVER TRANSPLANTATION;HAZARD RATIO;IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PARKINSON'S DISEASE;AMYOTROPHIC LATERAL SCLEROSIS;LENALIDOMIDE;COLORECTAL CANCER;PROSTATE CANCER;CARDIOGENIC SHOCK;ENDOMETRIAL CANCER;MULTICENTER STUDY;MUTATION;NEURORADIOLOGY;OVARIAN CANCER;PSEUDOMONAS AERUGINOSA;2019-20 CORONAVIRUS OUTBREAK;DEMENTIA;GENE EXPRESSION;PERCUTANEOUS CORONARY INTERVENTION;PROSTATE","21;20;19;16;15;14;12;11;11;10;10;9;8;8;8;8;8;8;7;7;7;7;7","CORONAVIRUS DISEASE 2019 (COVID-19);MAMMOGRAPHY;DARATUMUMAB;DNA METHYLATION;PEMBROLIZUMAB;PRENATAL DIAGNOSIS;ACINETOBACTER BAUMANNII;FRONTOTEMPORAL DEMENTIA;ARTERY DISSECTION;CHIMERIC ANTIGEN RECEPTOR;MACHINE PERFUSION;MILAN CRITERIA;NIVOLUMAB;P2Y12;POMALIDOMIDE;PROSTATECTOMY;STENOTROPHOMONAS MALTOPHILIA;TOTAL BODY IRRADIATION;VENETOCLAX;ABSOLUTE NEUTROPHIL COUNT;ACROMEGALY;AORTIC VALVE REPAIR;AUTOIMMUNE ENCEPHALITIS;CARBOPLATIN;CARFILZOMIB;CEFTAZIDIME;COLONOSCOPY;CYSTECTOMY;DEEP BRAIN STIMULATION;DIFFUSING CAPACITY;DRUG-ELUTING STENT;FUNCTIONAL MITRAL REGURGITATION;HERPESVIRIDAE;IBRUTINIB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTRAVENTRICULAR HEMORRHAGE;KLEBSIELLA PNEUMONIAE;LEVODOPA;MODIFIED RANKIN SCALE;OBETICHOLIC ACID;POLY ADP RIBOSE POLYMERASE;PTEN;RETINOPATHY OF PREMATURITY;RUXOLITINIB;SEED DORMANCY;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN;TRANSCRIPTOME;TWIN PREGNANCY","14;6;5;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;PROSPECTIVE STUDIES;ADOLESCENT;RISK FACTORS;CHILD;REGISTRIES;PROGNOSIS;COHORT STUDIES;FOLLOW-UP STUDIES;TIME FACTORS","327;195;122;110;93;83;64;40;35;29;27;21;15;15;14;13;11;10;10;10","AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MANAGEMENT OF VALVULAR HEART DISEASE;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;ACUTE MYELOID LEUKEMIA;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;LYMPHOID NEOPLASMS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;PANCREATIC CANCER RESEARCH AND TREATMENT","12;12;12;10;9;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5","CLINICAL ENDPOINT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIAC IMAGING;LIVER TRANSPLANTATION;STROKE (ENGINE);TREATMENT;LIVING DONOR LIVER TRANSPLANTATION;NEURORADIOLOGY;SURGICAL AORTIC-VALVE REPLACEMENT;2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER SCREENING;CONCOMITANT;HEMATOPOIETIC CELL TRANSPLANTATION;MANTLE CELL LYMPHOMA;PROSTHETIC VALVES EVALUATION;SINGLE CENTER;CARDIOGENIC SHOCK;CARDIOVASCULAR RISK ASSESSMENT;DIAGNOSIS;LIVER DISEASE","22;13;11;11;10;10;9;8;8;7;7;7;7;7;7;7;6;6;6;6","MULTIPLE MYELOMA;LIVER TRANSPLANTATION;CANCER PATIENTS;OBSERVATIONAL STUDY;PARKINSONS DISEASE;COHORT STUDY;PROSTATE CANCER;AMYOTROPHIC LATERAL;BREAST CANCER;CANCER SCREENING;CARDIOGENIC SHOCK;LATERAL SCLEROSIS;CLINICAL OUTCOMES;MULTICENTER STUDY;AORTIC VALVE;CORONARY ARTERY;ENDOMETRIAL CANCER;ITALIAN SOCIETY;NEWLY DIAGNOSED;PHASE TRIAL;RANDOMIZED TRIAL;RETROSPECTIVE MULTICENTER;CLINICAL TRIALS;COLORECTAL CANCER;CONTROLLED TRIAL;CROSS-SECTIONAL STUDY;DELPHI CONSENSUS;GANGLION BLOCK;RHEUMATOID ARTHRITIS;STELLATE GANGLION","15;12;11;10;10;9;9;8;8;8;8;8;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5","CLINICAL PRACTICE;SUPPORTING INFORMATION;HR CI;RISK FACTORS;MULTIPLE MYELOMA;CLINICAL TRIALS;PATIENTS TREATED;HEART FAILURE;MEDIAN AGE;PRIMARY OUTCOME;LIVER TRANSPLANTATION;PATIENTS UNDERGOING;MEDIAN FOLLOW-UP;SIGNIFICANT DIFFERENCES;STEM CELL;BODY COMPOSITION;BREAST CANCER;INCREASED RISK;SURVIVAL OS;AORTIC VALVE;MEDIAN MONTHS;RETROSPECTIVE STUDY;SIGNIFICANT DIFFERENCE;STATISTICALLY SIGNIFICANT;CONFIDENCE INTERVAL;ENDOMETRIAL CANCER;HYPER MUCINOUS;IN-HOSPITAL MORTALITY;INTENSIVE CARE;MECHANICAL VENTILATION","26;26;23;23;22;21;21;20;20;18;17;16;15;15;15;13;13;13;13;12;12;12;12;12;11;11;11;11;11;11",3,0.01,43.08,73,0,0,0,0,0,0,0,77.5,0,0,73,0,0,3.25,16,50,17.25,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,3.5,351,0.27,0,0,40,0,0,1,0,0,0,0,1,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Switzerland","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;DEPRESSION;MENTAL HEALTH;ORPHAN DRUG;PREVENTION;REHABILITATION;STEM CELL RESEARCH;TRANSPLANTATION","2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","1;1;1","NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
